Investigation into mechanisms of metastasis in breast cancer and pancreatic cancer by Moore, Gemma
 Investigation into mechanisms 
of metastasis in breast cancer 
and pancreatic cancer 
 
A thesis submitted for the degree of Ph.D. by 
Gemma Moore, B.Sc. Hons 
 
 
The experimental work described in this thesis was performed under the supervision 
of Dr. Laura Breen and Dr. Fiona O’Neill. 
 
National Institute for Cellular Biotechnology 
School of Biotechnology 
Dublin City University 
July 2017
i 
 
 
 
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of Ph.D. is entirely my own work, that I have exercised 
reasonable care to ensure that the work is original, and does not to the best of my 
knowledge breach any law of copyright, and has not been taken from the work of others 
save and to the extent that such work has been cited and acknowledged within the text of 
my work. 
 
Signed: _________________  ID No.: 57480571 
 
 Date:  
ii 
. 
 
 
 
This thesis is dedicated to my loving family. 
My parents, Joan and Jimmy. 
My sister, Deborah. 
My brother, James.
iii 
Acknowledgements 
 
Firstly, I would like to thank Dr. Laura Breen. Laura coming on board as my supervisor 
was the best thing that happened throughout my PhD. I am so unbelievably grateful to 
you. I always felt like we were a team, in it together. You always made time for me and 
were nothing but supportive. When things went wrong, it was usually you telling me to 
forget about it, go home early and start a fresh tomorrow, which was exactly what I 
needed to hear. I’ll never be able to put into words how much easier everything was 
because I had you there to help me. Thank you so much, I am eternally grateful. 
 
I would like to thank Professor Martin Clynes. If not for the opportunity you gave me I 
would not be where I am today. From the original just 6 weeks of Intra lab experience, 
to the whole Summer, to a PhD, none of this would have happened if you had not given 
me the opportunity, the support and guidance over the years. I am completely grateful. 
The NICB is a special place to train as a scientist which is down to you, the atmosphere 
of learning has been fostered and developed through you. 
 
Fiona, you were such a great addition to my supervisory panel. You always had such 
great enthusiasm which was so refreshing especially in the final year. I appreciate all 
your help, advice and I appreciate that you always made time for me. 
 
Sandra, my unofficial, surrogate supervisor. Over the last couple of years, you have given 
me so much of your time which I am extremely grateful for. Your advice was always 
helpful and you happily listened to me rant and rave. 
 
Overall, I want to say a huge thank you to everyone in the NICB. Over the years, I have 
asked questions and gotten help from virtually every person in the building. The centre 
has such a great attitude towards collaboration and training of young scientists. I am 
grateful to everyone who has helped me along the way. 
 
iv 
To everyone on the top floor over the 5 years and specifically Paul, Shane, Edel, Orla, 
Alan, Kevin and Laura, you guys have been the best part of the PhD process. I wouldn’t 
want to face a PhD without all the fun and laughs we had. I love you all and will miss you 
so much.  
 
To my best friend, Vanessa, I am so lucky to have you. You have listened to me rant, 
rave, moan and cry so patiently over the years. Your support, encouragement and 
enthusiasm was so important to me during the PhD. You were always so encouraging 
and never doubted that I would get there in the end. Our friendship is forever, we are 
sisters, family, and that is never ending.  
 
Finally, to my family, this is our achievement, not mine. I wouldn’t have been able to do 
any of this without you. Everyday of my life I have felt how much you love me and that 
you are proud of me. Your support, understanding and humour have gotten me through 
the tough parts. In return, I offer my unending love, support and knowledge that I am 
proud everyday to be a member of our little family. You are my home, my heart, my 
happiness. 
 
v 
 
 
 
 
 
 
 
Table of Contents
vi 
Table of Contents ..................................................................................................... v 
Table of Figures ...................................................................................................... xii 
Abbreviations ........................................................................................................ xvi 
Abstract .................................................................................................................... 1 
1. Introduction ......................................................................................................... 2 
1.1. Cancer ................................................................................................................. 3 
1.2. Breast Cancer ...................................................................................................... 4 
1.3. Triple Negative Breast Cancer ............................................................................. 5 
1.3.1. Triple Negative Breast Cancer Subtypes ................................................... 7 
1.3.2. TNBC or Basal-like? ................................................................................... 7 
1.3.3. Triple Negative Breast Cancer Subtypes ................................................... 8 
1.3.3.1. Basal-like subtypes ............................................................................ 9 
1.3.3.2. Mesenchymal .................................................................................. 10 
1.3.3.3. Luminal androgen receptor ............................................................. 10 
1.3.4. Other classifications ................................................................................ 11 
1.3.4.1. Claudin-low ..................................................................................... 11 
1.3.4.2. Molecular Apocrine ......................................................................... 11 
1.4. Pancreatic cancer .............................................................................................. 12 
1.4.1. Fibrosis .................................................................................................... 14 
1.4.2. Pancreatic Microenvironment ................................................................ 18 
1.4.3. Pancreatic Stromal Cells ......................................................................... 19 
1.4.3.1. Fibroblasts vs Stellate cells .............................................................. 21 
1.4.3.2. Activated vs Quiescent stromal cells .............................................. 22 
1.5. Metastasis ......................................................................................................... 23 
1.5.1. Anoikis ..................................................................................................... 23 
1.5.1.1. The Intrinsic Pathway ...................................................................... 24 
1.5.1.2. The Extrinsic Pathway ..................................................................... 26 
1.5.1.3. Bcl-2 Family of Proteins ................................................................... 27 
vii 
1.5.1.3.1. Anti-apoptotic proteins ......................................................... 27 
1.5.1.3.2. Multidomain Pro-apoptotic proteins .................................... 27 
1.5.1.3.3. Pro-apoptotic BH3-only proteins .......................................... 27 
1.5.2. Anoikis resistance ................................................................................... 29 
1.5.3. Invasion ................................................................................................... 30 
1.5.3.1. Single-cell invasion .......................................................................... 32 
1.5.3.2. Multi-cellular streaming .................................................................. 33 
1.5.3.3. Collective invasion ........................................................................... 34 
1.5.4. Indirect Co-culture .................................................................................. 35 
1.5.5. miRNA ..................................................................................................... 36 
1.5.5.1. Biogenesis ........................................................................................ 37 
1.5.5.2. Nomenclature ................................................................................. 39 
1.5.5.3. miRNA in cancer .............................................................................. 41 
1.5.5.4. miRNA in Pancreatic Cancer ............................................................ 49 
1.5.5.5. RNAi ................................................................................................. 51 
1.6. Aims ................................................................................................................... 57 
2. Materials and Methods ...................................................................................... 58 
2.1. Cell culture ........................................................................................................ 59 
2.1.1. Cell Lines ................................................................................................. 60 
2.1.2. Monitoring of sterility of cell culture solutions ...................................... 65 
2.1.3. Sub-culturing of adherent cell lines ........................................................ 65 
2.1.4. Assessment of cell number and viability ................................................ 65 
2.1.5. Cryopreservation of cells ........................................................................ 66 
2.1.6. Thawing of cryopreserved cells .............................................................. 67 
2.1.7. Mycoplasma analysis of cell lines ........................................................... 67 
2.2. Anoikis Assay Optimisation ............................................................................... 67 
2.3. Anoikis Assay ..................................................................................................... 69 
2.4. Microarray Profiling .......................................................................................... 71 
viii 
2.4.1. Microarray GeneChip® Human Gene 1.0 ST Array processing and 
hybridization ............................................................................................ 71 
2.4.2. Microarray miRNA 3.0 processing and hybridization ............................. 71 
2.5. Western Blotting ............................................................................................... 72 
2.5.1. Whole cell extract preparation ............................................................... 72 
2.5.2. Protein Quantification ............................................................................ 72 
2.5.3. Immunoblotting ...................................................................................... 73 
2.6. Transfection ...................................................................................................... 74 
2.6.1. siRNA Transfection Optimisation ............................................................ 74 
2.6.2. siRNA Transfection Protocol - 24 well plate format ............................... 74 
2.6.3. Pre/Anti-miR Transfection Protocol ....................................................... 76 
2.6.4. Plasmid Transfection Protocol ................................................................ 77 
2.6.5. Selection of stably transfected cells ....................................................... 77 
2.7. RNA Extraction .................................................................................................. 78 
2.8. RNA quantification using the Nanodrop spectrophotometer .......................... 79 
2.9. Reverse Transcription PCR ................................................................................ 79 
2.9.1. cDNA synthesis ........................................................................................ 79 
2.9.2. miRNA Reverse Transcription ................................................................. 80 
2.10. Quantitative Reverse Transcription PCR ......................................................... 81 
2.10.1. Gene expression Assays ........................................................................ 81 
2.10.2. miRNA expression Assays ..................................................................... 82 
2.11. Proliferation Assay .......................................................................................... 83 
2.12. Invasion assay ................................................................................................. 84 
2.13. 2D Colony Formation ...................................................................................... 85 
2.14. 3D Colony formation – Soft Agar Assay .......................................................... 85 
2.15. Indirect Co-culture .......................................................................................... 86 
2.16. Statistical Analysis ........................................................................................... 87 
3. Results – Microarray Analysis of Anoikis Resistance in Triple Negative Breast 
Cancer ................................................................................................................ 88 
3.1. Aim .................................................................................................................... 89 
3.2. Anoikis in metastasis ......................................................................................... 89 
3.3. Microarray Analysis ........................................................................................... 90 
ix 
3.4. Interrogation of microarray data ...................................................................... 91 
3.4.1. Literature Mining .................................................................................... 93 
3.4.2. Target gene – GRP78 ............................................................................... 96 
3.4.3. Validation of target gene GRP78, expression profile ........................... 102 
3.5. GRP78 Knockdown Optimisation .................................................................... 103 
3.6. Functional effects of GRP78 knockdown ........................................................ 104 
4. Discussion – Microarray Analysis of Anoikis Resistance in Triple Negative Breast 
Cancer .............................................................................................................. 115 
4.1. Microarray Analysis ......................................................................................... 116 
4.2. Investigation of microarray data ..................................................................... 116 
5. Results – Investigation of the Role of the Tumour Microenvironment in Pancreatic 
Cancer .............................................................................................................. 124 
5.1. Aim .................................................................................................................. 125 
5.2. Pancreatic Cancer ........................................................................................... 125 
5.3. Panel of pancreatic cancer cell lines ............................................................... 126 
5.4. Functional effects of 48hr indirect co-culture with stromal cell populations 128 
5.4.1. Functional effects of 48hr indirect co-culture with tumour derived 
fibroblasts (Pt-102) ................................................................................ 129 
5.4.2. Functional effects of conditioned media of Pt-102 .............................. 134 
5.4.3. Functional effects of indirect co-culture with tumour derived fibroblasts 
(Pt-127) .................................................................................................. 139 
5.4.4. Functional effects of indirect co-culture with pancreatic stellate cells 143 
5.5. Time-course experiment ................................................................................. 145 
5.6. In-assay indirect co-culture of Panc-1 cells with stromal cells ....................... 147 
5.7. Determination of the optimum co-culture control ........................................ 150 
5.8. Determination of activation state of tumour derived fibroblasts .................. 154 
5.9. Functional effects of indirect co-culture with tumour derived fibroblasts (Pt-
102) using the optimum control ..................................................................... 157 
6. Discussion - Investigation of the Role of the Tumour Microenvironment in 
Pancreatic Cancer ............................................................................................. 165 
6.1. Investigations of functional effects post 48hr indirect co-culture with multiple 
stromal cell populations ................................................................................. 167 
x 
6.2. Time-course experiment ................................................................................. 173 
6.3. Assessment of in-assay indirect co-culture set up.......................................... 173 
6.4. Determination of the optimum indirect co-culture control ........................... 175 
6.5. Functional effects of indirect co-culture with tumour derived fibroblasts (Pt-
102) using the optimum control ..................................................................... 176 
7. Results – Investigation of the Role of miRNA in Metastatic Phenotypes in 
Pancreatic Cancer ............................................................................................. 180 
7.1. Aim .................................................................................................................. 181 
7.2. Alteration of miRNA expression ...................................................................... 181 
7.2.1. Investigation of transiently altered miRNA expression ........................ 182 
7.2.2. Development of stable cell lines to alter miRNA expression ............... 189 
7.2.3. Generation of stably altered cell lines .................................................. 192 
7.2.3.1. Optimisation of selection agent concentration, Hygromycin B .... 192 
7.2.3.2. Optimisation of transfection reagent concentration, Mirus TransIT 
X2 and vector concentration .......................................................... 192 
7.2.3.3. Confirmation of inducement of Panc-1 cells with miR-505 sponge
 ........................................................................................................ 194 
7.2.4. miRNA target selection and validation of altered miRNA expression .. 195 
7.2.5. Confirmation of altered miRNA expression .......................................... 200 
7.2.6. Functional effects of stable enduring alteration of miRNA expression 204 
8. Discussion – Investigation of the Role of miRNA in Metastatic Phenotypes in 
Pancreatic Cancer ............................................................................................. 216 
8.1. Functional effects of transient alteration of miRNA in Panc-1 cells ............... 217 
8.2. Phenotypic changes of Panc-1 cells with stably altered miRNA expression .. 220 
8.2.1. Functional effects of sponge knockdown of miRNA in Panc-1 cells ..... 220 
8.2.2. Functional effects of stable miRNA overexpression in Panc-1 cells ..... 222 
9. Concluding Discussion ...................................................................................... 227 
9.1. Concluding Discussion ..................................................................................... 228 
10. Conclusions and Future Work ......................................................................... 230 
10.1. Conclusions ................................................................................................... 231 
xi 
10.2. Future Work .................................................................................................. 234 
11. Bibliography................................................................................................... 237 
xii 
 
Table of Figures 
 
Figure 1-1. Anoikis sensitivity and anoikis resistance in metastasis _______________________________ 5 
Figure 1-2. Trends in cancer survival by tumour site 1971-2011 (Pancreatic Cancer Action 2017) _____ 14 
Figure 1-3. Abundance of stroma in pancreatic cancer tumours ________________________________ 15 
Figure 1-4. The fine balance of production and degradation of ECM in the pancreatic microenvironment 
in both healthy and desmoplastic pancreas _______________________________________ 16 
Figure 1-5. The role of ECM in the recovery from injury in a healthy pancreas (information adapted from 
(Phillips 2012)) ______________________________________________________________ 17 
Figure 1-6. Loss of balance in ECM production by stromal cells leads to fibrosis (information adapted 
from (Phillips 2012)) _________________________________________________________ 18 
Figure 1-7. Pancreatic stellate cells in the pancreatic tumour microenvironment __________________ 20 
Figure 1-8. Schematic of the intrinsic and extrinsic pathways __________________________________ 25 
Figure 1-9. Schematic of different forms of invasion _________________________________________ 31 
Figure 1-10. Representative images of two different forms of invasion __________________________ 33 
Figure 1-11. A schematic of the indirect co-culture model used to investigate the pancreatic tumour 
microenvironment ___________________________________________________________ 36 
Figure 1-12. miRNA biogenesis and processing _____________________________________________ 39 
Figure 1-13. Schematic of RNAi methods used to alter miRNA levels ____________________________ 52 
Figure 2-1. Haemocytometer grid layout __________________________________________________ 66 
Figure 2-2. A schematic of the indirect co-culture model used to investigate the pancreatic tumour 
microenvironment ___________________________________________________________ 86 
Figure 3-1. Percentage anoikis across the range of TNBC cell lines ______________________________ 91 
Figure 3-2. Pathway Studios analysis of common priority diseases by effect ______________________ 94 
Figure 3-3. Pathway Studios analysis of common cellular processes _____________________________ 95 
Figure 3-4. Pathway Studios analysis of HSPA5 effect in diseases _______________________________ 99 
Figure 3-5. Pathway Studios analysis of the role of HSPA5 in cellular processes __________________ 100 
Figure 3-6. Kaplan Meier plot showing the relationship of GRP78 expression with survival _________ 101 
Figure 3-7. Level of GRP78 and β-actin protein across a panel of TNBC cell lines __________________ 102 
Figure 3-8. Densitometry analysis of GRP78 protein across a panel of TNBC cell lines ______________ 103 
Figure 3-9. GRP78 knockdown through optimisation of siRNA concentration ____________________ 104 
Figure 3-10. Validation of transfection ___________________________________________________ 105 
Figure 3-11. GRP78 protein knockdown post transfection ____________________________________ 105 
Figure 3-12. Densitometry analysis of GRP78 knockdown ____________________________________ 106 
Figure 3-13. Percentage proliferation at 24hr in both anoikis resistant cell lines post GRP78 knockdown
 _________________________________________________________________________ 107 
xiii 
 
Figure 3-14. Percentage survival of the MDA-MB-231 cell line post GRP78 knockdown ____________ 108 
Figure 3-15. Percentage survival of the MDA-MB-468 cell line post GRP78 knockdown ____________ 108 
Figure 3-16. Percentage invasion post GRP78 knockdown in both anoikis resistant TNBC cell lines ___ 110 
Figure 3-17. Representative images of invasion levels of both MDA-MB-231 and MDA-MB-468 cells post 
GRP78 knockdown __________________________________________________________ 110 
Figure 3-18. Percentage proliferation over 7 days in both anoikis resistant cell lines post GRP78 
knockdown ________________________________________________________________ 111 
Figure 3-19. Percentage 2D colony formation of the MDA-MB-231 cell line post GRP78 knockdown__ 112 
Figure 3-20. Representative image of 2D colony formation of the MDA-MB-231 cell line post GRP78 
knockdown ________________________________________________________________ 113 
Figure 3-21. Percentage 3D colony formation of both anoikis resistant TNBC cell lines post GRP78 
knockdown ________________________________________________________________ 113 
Figure 5-1. Levels of anoikis across a panel of pancreatic cancer cell lines _______________________ 127 
Figure 5-2. Levels of invasion across a panel of pancreatic cancer cell lines ______________________ 127 
Figure 5-3. A schematic of the indirect co-culture model used to investigate the pancreatic tumour 
microenvironment __________________________________________________________ 129 
Figure 5-4. Percentage survival in attached and suspension conditions of Mia PaCa-2 cells post co-
culture ___________________________________________________________________ 130 
Figure 5-5. Percentage survival in attached and suspension conditions of Panc-1 cells post co-culture 130 
Figure 5-6. Percentage proliferation post co-culture across a panel of pancreatic cancer cell lines ___ 131 
Figure 5-7. Percentage invasion post co-culture across a panel of pancreatic cancer cell lines _______ 132 
Figure 5-8. Representative images of invasion post a) mono culture and b) co-culture conditions across a 
panel of pancreatic cancer cell lines ____________________________________________ 133 
Figure 5-9. Percentage survival in attached and suspension conditions of Mia PaCa-2 cells post 
conditioned media treatment _________________________________________________ 135 
Figure 5-10. Percentage survival in attached and suspension conditions of Panc-1 cells post conditioned 
media treatment ___________________________________________________________ 136 
Figure 5-11. Percentage proliferation in Mia PaCa-2 and Panc-1 cells post conditioned media treatment
 _________________________________________________________________________ 137 
Figure 5-12. Percentage invasion of the Panc-1 cell line post treatment with conditioned media ____ 138 
Figure 5-13. Percentage survival in attached and survival conditions of Mia PaCa-2 cells post co-culture 
with Pt-127 ________________________________________________________________ 140 
Figure 5-14. Percentage survival in attached and survival conditions of Panc-1 cells post co-culture with 
Pt-127 ____________________________________________________________________ 140 
Figure 5-15. Percentage proliferation of Mia PaCa-2 and Panc-1 cells post co-culture with Pt-127 ___ 141 
Figure 5-16. Percentage invasion of Mia PaCa-2 and Panc-1 cells post co-culture with Pt-127 _______ 142 
Figure 5-17. Percentage proliferation of Mia PaCa-2 and Panc-1 cells post co-culture with pancreatic 
stellate cells (hPSC24) _______________________________________________________ 143 
xiv 
 
Figure 5-18. Percentage invasion of Mia PaCa-2 and Panc-1 cells post co-culture with pancreatic stellate 
cells (hPSC24) ______________________________________________________________ 144 
Figure 5-19. Cell number of Mia PaCa-2 cells post indirect co-culture with tumour derived fibroblasts (Pt-
102) at a range of time-points _________________________________________________ 145 
Figure 5-20. Invasion levels of Mia PaCa-2 cells post co-culture with tumour derived fibroblasts (Pt-102) 
at a range of time-points _____________________________________________________ 146 
Figure 5-21. Percentage proliferation of Panc-1 cells post in-assay co-culture with Pt-102 and hPSC24 148 
Figure 5-22. Colony formation of Panc-1 cells post in-assay co-culture with Pt-102 _______________ 149 
Figure 5-23. Representative image of colony formation of Panc-1 cells post in-assay co-culture _____ 149 
Figure 5-24. Proliferation of Panc-1 cells using a range of co-culture variants ____________________ 151 
Figure 5-25. Proliferation of Panc-1 cells using volume controls with CM treatment _______________ 152 
Figure 5-26. Proliferation of Panc-1 cells using a range of co-culture variants with an appropriate control
 _________________________________________________________________________ 153 
Figure 5-27. Level of podoplanin protein in patient tumour derived fibroblasts (Pt-102) ___________ 155 
Figure 5-28. Densitometry analysis of podoplanin protein in patient tumour derived fibroblasts (Pt-102)
 _________________________________________________________________________ 156 
Figure 5-29. Schematic of the previous mono culture control and the optimum mono culture control 158 
Figure 5-30. Percentage survival in attached and suspension conditions of Panc-1 cells post co-culture 
with Pt-102 fibroblasts using the optimum control. _______________________________ 158 
Figure 5-31. Percentage survival in attached and suspension conditions of BxPc-3 cells post co-culture 
with Pt-102 fibroblasts using the optimum control. _______________________________ 159 
Figure 5-32. Percentage proliferation of Panc-1 and BxPc-3 cells post co-culture with Pt-102 fibroblasts 
using the optimum control ___________________________________________________ 160 
Figure 5-33. Colony formation of Panc-1 cells post co-culture with Pt-102 fibroblasts using the optimum 
control ___________________________________________________________________ 161 
Figure 5-34. Representative image of colony formation of Panc-1 cells post co-culture with Pt-102 
fibroblasts using the optimum control __________________________________________ 161 
Figure 5-35. Colony formation of BxPc-3 cells post co-culture with Pt-102 fibroblasts using the optimum 
control ___________________________________________________________________ 162 
Figure 5-36. Representative image of colony formation of BxPc-3 cells post co-culture with Pt-102 
fibroblasts using the optimum control __________________________________________ 162 
Figure 5-37. Percentage invasion of Panc-1 and BxPc-3 cells post co-culture with Pt-102 fibroblasts using 
the optimum control ________________________________________________________ 163 
Figure 5-38. Representative images of invasion levels of both Panc-1 and BxPc-3 cells post mono and co-
culture ___________________________________________________________________ 164 
Figure 7-1. Percentage proliferation of Panc-1 cells post transient transfection with a range of Pre-miRs
 _________________________________________________________________________ 185 
xv 
 
Figure 7-2. Percentage proliferation of Panc-1 cells post transient transfection with a range of Anti-miRs
 _________________________________________________________________________ 186 
Figure 7-3. Percentage colony formation of Panc-1 cells post transient transfection with a range of Pre-
miRs _____________________________________________________________________ 187 
Figure 7-4. Representative image of colony formation of Panc-1 cells following transient miRNA 
overexpression _____________________________________________________________ 187 
Figure 7-5. Percentage colony formation of Panc-1 cells post transient transfection with a range of Anti-
miRs _____________________________________________________________________ 188 
Figure 7-6. Representative image of colony formation of Panc-1 cells following transient miRNA 
reduction _________________________________________________________________ 189 
Figure 7-7. Vector map of miRNA sponge knockdown of target miRNA _________________________ 191 
Figure 7-8. Vector map of miRNA overexpression of target miRNA ____________________________ 191 
Figure 7-9. Optimisation of selection agent concentration, Hygromycin B _______________________ 192 
Figure 7-10. Screen of basal miRNA expression across a panel of pancreatic cancer cell lines _______ 196 
Figure 7-11. Relative quantification of miR-378 expression post sponge knockdown ______________ 201 
Figure 7-12. Relative quantification of miR-505 expression post sponge knockdown ______________ 201 
Figure 7-13. Relative quantification of miR-7a overexpression post transfection __________________ 202 
Figure 7-14. Relative quantification of miR-34a overexpression post transfection ________________ 202 
Figure 7-15. Relative quantification of miR-206 overexpression post transfection ________________ 203 
Figure 7-16. Percentage survival of induced and un-induced Panc-1 cells _______________________ 204 
Figure 7-17. Percentage survival of Panc-1 cells post sponge knockdown of miRNA expression ______ 205 
Figure 7-18. Percentage survival of Panc-1 cells post miRNA overexpression _____________________ 205 
Figure 7-19. Percentage proliferation of induced and un-induced Panc-1 cells ___________________ 206 
Figure 7-20. Percentage proliferation of Panc-1 cells post sponge knockdown of miRNA expression __ 207 
Figure 7-21. Percentage proliferation of Panc-1 cells post miRNA overexpression ________________ 207 
Figure 7-22. Percentage colony formation of Panc-1 cells post sponge knockdown of miRNA expression
 _________________________________________________________________________ 208 
Figure 7-23. Representative image of colony formation of Panc-1 post sponge knockdown _________ 209 
Figure 7-24. Percentage colony formation of Panc-1 cells post miRNA overexpression _____________ 209 
Figure 7-25. Representative image of colony formation of Panc-1 cells post miRNA overexpression __ 210 
Figure 7-26. Percentage invasion of induced and un-induced Panc-1 cells _______________________ 211 
Figure 7-27. Percentage invasion of Panc-1 cells post sponge knockdown of miRNA expression _____ 211 
Figure 7-28. Percentage invasion of Panc-1 cells post miRNA overexpression ____________________ 212 
Figure 7-29. Representative images of invasion of Panc-1 cells post miRNA expression alteration ____ 213 
Figure 7-30. Kaplan Meier plot showing the relationship of miR-7 expression with survival _________ 215 
 
xvi 
 
Abbreviations 
2D  - 2-Dimensional 
3D  - 3-Dimensional 
Ago-2  - Argonaute-2 
Apaf  - Apoptotic protease activating factor 
AR  - Androgen Receptor 
Bcl-2  - B-cell Lymphoma 2 
B-CLL  - B cell chronic lymphocytic leukaemia 
BL1  - Basal-like 1 
BL2  - Basal-like 2 
Bmf  - Bcl-2 Modifying Factor 
BSA  - Bovine Serum Albumin 
CAF   - Cancer Associated Fibroblast 
cDNA  - complementary DNA 
cPR  - Complete Pathological Response 
CM  - Conditioned Media 
Ct  - Comparative Threshold 
DDR2  - Discoidin Domain-containing Receptor 2 
DFS  - Disease-Free Survival 
DISC  - Death Inducing Signalling Complex 
DMEM  - Dulbecco’s Minimum Essential Medium 
DMSO  - Dimethyl Sulfoxide 
DNA  - Deoxyribonucleic Acid 
dNTP  - Deoxynucleotide Triphosphate 
ECM  - Extra-Cellular Matrix 
EDTA  - Ethylenediaminetetraacetic Acid  
EMT  - Epithelial to Mesenchymal Transition 
ER  - Estrogen Receptor 
xvii 
 
ER  - Endoplasmic Reticulum 
ERK  - Extracellular Signal-regulated Kinases 
FAK  - Focal Adhesion Kinase 
FADD  - Associated Death Domain 
FAP  - Fibroblast Activation Protein 
FC  - Fold Change 
FCS  - Fetal Calf Serum 
FLIP  - FLICE-inhibitory Protein 
GAPDH - Glyceraldehyde-3-Phosphate Dehydrogenase  
GFP  - Green Fluorescent Protein 
HER2  - Human Epidermal Growth Factor Receptor 2 
HIF  - Hypoxia Inducible Factor 
HMEC  - Human Mammary Epithelial Cell 
hPSC  - human Pancreatic Stellate Cell 
HSC  - Hepatic Stellate Cell 
HuR  - Human Antigen R 
IAP  - Inhibitor of Apoptosis 
IGFBP  - Insulin-like Growth Factor Binding Protein 
IHC  - Immunohistochemistry 
IM  - Immunomodulatory 
IMS  - Industrial Methylated Spirits  
ILK  - Integrin-linked Kinase 
kDa  - Kilo Daltons 
KM  - Kaplan-Meier 
LAR  - Luminal Androgen Receptor 
M  - Mesenchymal 
miR  - microRNA 
miRNA  - microRNA 
xviii 
 
MMP  - Matrix Metalloproteinase 
mRNA  - messenger RNA 
MSL  - Mesenchymal Stem-like 
NC  - Negative control 
No RT  - No Reverse Transcriptase 
NSCLC  - Non-Small Cell Lung Cancer 
OD  - Optical Density 
OMM   - Outer Mitochondrial Membrane 
OS  - Overall Survival 
OV  - Overexpression 
PBS  - Phosphate Saline Buffer 
PCR  - Polymerase Chain Reaction 
PDAC  - Pancreatic Ductal Adenocarcinoma  
PDGFRα - PDGF receptor-α 
PDGFRβ - PDGF receptor-β 
PET  - Pancreatic Endocrine Tumour 
PI3K  - Phosphoinositide 3-kinase 
Pre-miRNA - Preliminary microRNA 
Pri-miRNA - Primary microRNA 
PR  - Progesterone Receptor 
PSC  - Pancreatic Stellate Cell 
q-RT-PCR - quantitative Reverse Transcriptase PCR 
RB1  - Retinoblastoma Protein 1 
RFP  - Red Fluorescent Protein 
RFS  - Relapse Free Survival 
RISC  - RNA-induced Silencing Complex 
RNA  -  Ribonucleic Acid 
RNAi  - RNA interference 
xix 
 
RNase  - Ribonuclease 
RNA pol - RNA Polymerase 
rpm  - Revolutions Per Minute 
RPMI  - Roswell Park Memorial Institute Medium 
shRNA  - short hairpin RNA 
siRNA  - short interfering RNA 
Smac/DIABLO - Second Mitochondrial-derived activator of caspases/direct IAP 
binding protein 
Spg  - Sponge 
TAF  - Tumour-associated Fibroblast 
TIMP  - Tissue Inhibitor of Metalloproteinase 
TNBC  - Triple Negative Breast Cancer 
TNF  - Tumour Necrosis Factor 
TRBP  - TAR Binding Protein 
Un  - Untransfected 
UPR  - Unfolded Protein Response 
UTR  - Untranslated Region 
v/v  - volume/volume 
XIAP  - X-linked Inhibitor of Apoptosis 
 
xx 
 
Conference Presentations 
• Poster presentation. Gemma Moore, Fiona O’Neill, Sinead Aherne, Gerard 
McVey, Michael Moriarty, Laura Breen and Martin Clynes. Investigating the role 
of the tumour microenvironment in the behaviour of pancreatic cancer cells 
using indirect co-culture. Cambridge Pancreatic Cancer Symposium, Cambridge, 
England, 2017.  
• Oral presentation. Gemma Moore, Fiona O’Neill, Sinead Aherne, Gerard McVey, 
Michael Moriarty, Laura Breen and Martin Clynes. Investigating the role of the 
tumour microenvironment in the behaviour of pancreatic cancer cells using 
indirect co-culture. School of Biotechnology 8th Annual Research Day, DCU, 
2016. 
• Flash 5 Oral presentation. Gemma Moore, Fiona O’Neill, Sinead Aherne, Gerard 
McVey, Michael Moriarty, Laura Breen and Martin Clynes. Investigating the role 
of the tumour microenvironment in the behaviour of pancreatic cancer cells 
using indirect co-culture. School of Biotechnology 8th Annual Research Day, DCU, 
2016. 
• Poster presentation. Gemma Moore and Fiona O’Neill*. Investigating the role 
of the tumour microenvironment and its role in radiation therapy in pancreatic 
cancer. AACR, The Function of the Tumor Microenvironment in Cancer 
Progression in San Diego, CA, 2016. *Presenting author 
• Poster presentation. Gemma Moore, Fiona O’Neill, Sinead Aherne, Gerard 
McVey, Michael Moriarty, Laura Breen and Martin Clynes. Investigating the role 
of the tumour microenvironment in the behaviour of pancreatic cancer cells 
using indirect co-culture. Pancreatic Cancer Symposium, Marseille, France, 
2015. 
• Poster presentation. Gemma Moore, Fiona O’Neill, Sinead Aherne, Laura Breen 
and Martin Clynes Investigating the role of the tumour microenvironment in 
the behaviour of pancreatic cancer cells using indirect co-culture. Cambridge 
Pancreatic Cancer Symposium, Cambridge, England, 2015.  
• Annual BioAT Research Day, poster and oral presentations 2012-2015. 
o June 2012 – Poster – Mechanisms of Anoikis Resistance in Human 
Cancer Cells 
o June 2013 – Oral presentation – Mechanisms of Anoikis Resistance in 
Breast Cancer Cells 
o June 2014 – Poster – The effects of pancreatic cancer cell & pancreatic 
stellate cell interactions 
o June 2015 – Oral presentation – Investigating the role of the tumour 
microenvironment in the behaviour of pancreatic cancer cells using 
indirect co-culture. 
1 
 
Abstract 
Investigation into mechanisms of metastasis in breast cancer and pancreatic cancer 
Gemma Moore 
 
The aim of this project was to investigate mechanisms of metastasis in triple negative 
breast cancer (TNBC) and pancreatic cancer. Metastasis is the ability of a cell to spread 
to another location colonising a secondary site, which contributes to approximately 90% 
of cancers fatalities. Both TNBC and pancreatic cancer possess poor prognosis, limited 
therapeutic options and the risk of each becoming metastatic remains a major risk. This 
body of work aimed to investigate unique influences on the metastatic capabilities of 
both TNBC and pancreatic cancer cells. Three critical metastatic phenotypes were 
investigated, specifically anoikis resistance (anchorage independence), colony 
formation, proliferation and invasion. Metastasis was investigated through three 
approaches: i) microarray profiling was used to investigate genes that were differentially 
expressed in anoikis resistant conditions, ii) an indirect co-culture model that mimicked 
the tumour microenvironment was used to assess critical metastatic phenotypes in 
pancreatic cancer and iii) miRNA expression profiling and a range of methods for altering 
miRNA expression in cell culture were deployed to assess the effect of altered miRNA 
expression on the metastatic phenotypes of pancreatic cancer.  
 
Through microarray profiling 26 genes were identified as differentially expressed in 
anoikis resistant conditions. Specifically, GRP78 was identified as a regulator of growth 
in TNBC through proliferation and colony formation, with GRP78 acting as an oncogene. 
The development of an indirect co-culture model allowed insight into the complicated 
role of the tumour microenvironment in pancreatic cancer. This investigation led to the 
observation that the stroma can act to inhibit and restrain the progression of pancreatic 
cancer. Altering miRNA expression led to the identification of a range of tumour 
suppressor miRNA including miR-7a, miR-204 and miR-378. Each induced different 
changes in metastatic phenotypes including a reduction proliferation, colony formation 
and an extreme increase in invasion. A highly novel finding is the validity of using sponge 
knockdown vectors as a valuable research tool in pancreatic cancer. In conclusion, 
anoikis, proliferation, colony formation and invasion were greatly influenced by gene 
expression, the tumour microenvironment and miRNA expression. Using these three 
approaches a greater understanding of metastasis and consequently of how both TNBC 
and pancreatic cancer progress has been gained. With this greater understanding comes 
a greater possibility of developing effective therapies. 
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1. Introduction
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1.1. Cancer 
 
Cancer is the second leading causes of death worldwide, accounting for 8.2 million 
deaths in 2012 (Ferlay et al. 2013). There are over 200 different types of cancer, each 
with different characteristics, prognosis and treatments. Two different cancer types are 
the focus of this investigative project, triple negative breast cancer and pancreatic 
cancer. Both of these malignancies possess poor prognosis and poor treatment options. 
 
Metastasis is a process which contributes to the high mortality rate in cancer (Jiang et 
al. 2015). In fact, without metastasis 90% of cancers would not be fatal (Hu et al. 2016). 
Metastasis is the ability of a cell to spread to another location in the body not only 
surviving in this foreign site, also surviving the journey and establishing further growth 
in this new location (Kozlowski, Kozlowska and Kocki 2015). Gaining a greater 
understanding of metastasis is required to further understand the progression of cancer 
and with this comes a greater possibility of developing effective targeted therapies. 
Metastasis occurs through a cascade of processes, signals and functions. This body of 
work aims to investigate metastasis through several metastatic characteristics, 
specifically anoikis, invasion, miRNA and the tumour microenvironment. Each of these 
aspects of metastasis (which are explained in further detail below) are critical steps in 
the metastatic cascade. 
 
This project aimed to investigate the metastatic process through anoikis, growth and 
invasion in both triple negative breast cancer and pancreatic cancer. The effect of the 
tumour microenvironment and altered miRNA expression on the metastatic phenotypes 
mentioned was assessed in pancreatic cancer. 
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1.2. Breast Cancer 
 
Breast cancer, a cancer of the tissues of the breast, is the second most common cancer 
in women in Ireland, affecting approximately 3,000 women every year (National Cancer 
Registry Ireland 2016). Investigation of the genes expressed in breast cancer cells has 
been performed in recent years using DNA Microarrays; this work has led to 
identification of four main molecular classes of breast cancer (Sotiriou et al. 2003). These 
classes are Luminal A, Luminal B, HER2 and triple negative (Sotiriou, Phil and Pusztai 
2003) and are known as the intrinsic subtypes of breast cancer. These classes differ due 
to the receptors expressed on the cell surface. The receptors include the estrogen 
receptor (ER), the progesterone receptor (PR) and the HER2 receptor. Luminal A and B 
both are ER positive (ER+) with luminal A being HER2 positive and luminal B being HER2 
negative (Carey et al. 2006). Luminal B can in some instances be HER2 positive this is 
associated with high expression of Ki67 (a proliferative marker) which luminal A 
expresses lowly (Voduc et al. 2010).  
 
The HER2 subtype of breast cancer is ER-, PR- and HER2 positive (Hugh et al. 2009). Triple 
negative breast cancer (TNBC) is negative for all these receptors and is also known as 
basal-like breast cancer. Prior to these molecular classifications breast cancer was 
classified based on tumour size, presence of lymph node metastasis and histological 
grade (Reis-Filho and Pusztai 2011). TNBC tumours are generally larger, of higher grade 
than in other forms of breast cancer and TNBCs have lymph node involvement at 
diagnosis (Lehmann et al. 2011). Over the last decade breast cancer has become much 
more treatable with the advances in using hormone and targeted therapies. These 
therapies are applicable to Luminal A, Luminal B and HER2 classes of breast cancer 
(Sotiriou, Phil and Pusztai 2003) as the therapies are effective on the receptors on the 
cell surface. TNBC cannot be treated with these therapies due to the lack of these 
receptors on its cell surface. As a result, triple negative breast cancers have limited 
treatment options (Foulkes, Smith and Reis-Filho 2010) and poor prognosis (Ressler, 
Mlineritsch and Greil 2010). Unfortunately, the risk of TNBC becoming metastatic i.e. 
spreading to other areas of the body, remains a genuine risk and concern. A major factor 
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in the success of metastasis is the ability to resist anoikis. Anoikis is a form of cell death 
due to detachment of a cell from the extra-cellular matrix (ECM) (Frisch and Francis 
1994). This aspect of metastasis in TNBC was investigated through microarray analysis 
in this research. A better understanding of how TNBC spreads through the body may 
lead to development of new and efficient treatment for TNBC. 
 
Figure 1-1. Anoikis sensitivity and anoikis resistance in metastasis 
 
(A) shows anoikis-sensitive cells separating from a primary tumour and undergoing anoikis upon entering 
the blood stream. (B) shows anoikis resistance protecting circulating tumour cells from undergoing 
anoikis, thereby facilitating metastasis (Geiger and Peeper 2005). 
 
1.3. Triple Negative Breast Cancer 
 
Triple negative breast cancer constitutes 10-20% of breast cancer cases (Carey et al. 
2010). This form of breast cancer affects younger people i.e. premenopausal women, 
more frequently and has a higher prevalence in African-American and Hispanic women 
(Carey et al. 2006, Amirikia et al. 2011). TNBC is biologically more aggressive than the 
other breast cancer subtypes; it has a higher rate of early recurrence and metastasis, 
with this metastasis being more often to the central nervous system, specifically the 
brain and the lungs compared to the other subtypes (Elsamany and Abdullah 2014). This 
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higher rate of early metastasis is shown by a study of 1601 breast cancer patients 
between the years of 1987 and 1997 in Toronto. This study showed the median time to 
death of TNBC patients was 4.2 years compared to 6 years for the other breast cancer 
types. Also, all TNBC patients died within 10 years of diagnosis with deaths of patients 
with other breast cancer types occurring over 18 years (Dent et al. 2007). This group also 
observed that there was no correlation between tumour size and nodal status in TNBC 
while a correlation was present in other breast cancer types. In TNBC even small 
tumours had a high rate of positive nodal status with 55% of women with tumours ≤1cm 
possessing at least one positive lymph node (Dent et al. 2007). This observation displays 
how early the metastasis occurs in TNBC, before the tumour has even reached a 
substantial size the cancer has begun to spread. This is confirmed by the observation 
that the mean time to distant recurrence in TNBC was only 2.6 years compared to 5 
years in the other breast cancer patients (Dent et al. 2007). This early recurrence and 
metastasis has been observed by many other studies (Kennecke et al. 2010, Radosa et 
al. 2016, Lai et al. 2016, Chen, Ding and Wang 2015, Kümmel et al. 2015). It is due to this 
startlingly early recurrence and metastasis, that greater understanding of the 
mechanisms of metastasis in TNBC is required. To successfully treat a cancer with such 
early metastasis is near impossible.  
 
TNBC has a compelling association with BRCA mutational status, with the triple negative 
subtype being diagnosed significantly more frequently in women with BRCA mutations 
in comparison with BRCA-negative patients (Pellegrino et al. 2016). Patients carrying 
BRCA mutations carry an 80% lifetime risk of developing breast cancer (Anders and 
Carey 2009). Chemotherapy is the current standard therapy available for TNBC, either 
individually or in combination with surgery and/or radiotherapy. Despite having higher 
rates of initial clinical response to neo adjuvant chemotherapy compared to other 
intrinsic subtypes, most TNBC cases relapse within 3 years (Kleivi Sahlberg et al. 2015). 
This chemotherapy treatment focuses on cytotoxic agents such as anthracyclines and 
taxanes but in recent years an interest has developed in platinum compounds. This 
interest developed due to the association of BRCA mutation and TNBC. Platinum drugs 
produce DNA double-strand breaks, while BRCA mutations cause dysfunction of the DNA 
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repair process (Hastak, Alli and Ford 2010). Therefore, a treatment inducing double-
strand DNA breaks in a BRCA mutated TNBC which has inhibited DNA repair function 
may prove to be highly effective (Staudacher et al. 2011). Several studies and clinical 
trials are investigating this hypothesis currently (Tutt et al. 2015, Karginova et al. 2015). 
Another developing treatment for TNBC, poly (ADP-ribose) polymerase (PARP) inhibitors 
also act to block DNA repair mechanisms and therefore may be a promising treatment 
in BRCA mutated TNBC patients (O'Shaughnessy et al. 2011). There are several PARP 
inhibitors at different stages of clinical development (Audeh 2014) and studies are now 
showing a greater efficacy using PARP inhibitors in combination with chemotherapeutics 
(O'Shaughnessy et al. 2011, Sun et al. 2014).  
 
1.3.1. Triple Negative Breast Cancer Subtypes 
 
TNBC is a diverse heterogenous collection of breast cancers which show a range of 
histological patterns and pathological features. In recent years, the TNBC subtype has 
been analysed using gene expression profiles and has been further divided into subtypes 
within TNBC. There is some ambiguity in the literature on these subtypes as different 
groups have identified different subtypes and some have identified similar subtypes but 
titled them differently. The following sections address this ambiguity, settling on one 
form of classifications and giving some insight into the crossover of other classifications. 
 
1.3.2. TNBC or Basal-like? 
 
There is a crossover in use of the terms of TNBC and Basal-like breast cancer with many 
believing the two are relatively synonymous but just as many believe this to be untrue. 
Basal-like subtype is described as possessing characteristics of normal myoepithelial 
cells of the breast ductal and lobular system, such as expressing keratin 5/6 and 17 (Van 
De Rijn et al. 2002, Perou et al. 2000). The title basal-like comes from the fact that these 
cytokeratins are typically found in the basal epithelium layer of the skin and airways 
(Perou 2010). These tumours are highly proliferative whether measured by Ki-67 
staining, proliferating cell nuclear antigen, immunohistochemistry (IHC) or gene 
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expression (Perou 2010, Cheang et al. 2009, Hugh et al. 2009). This high rate of 
proliferation may be due to a non-functional RB1 protein which is a critical cell cycle 
regulator (Perou 2010). As well as being RB1 deficient these tumours are p53 deficient 
and are associated with BRCA1 mutation (Chiche et al. 2016). Interestingly, the majority 
of BRCA1 mutation carriers who develop breast cancer develop the basal-like form of 
breast cancer (Perou 2010). The relationship between TNBC and basal-like is difficult. 
Some reports show 90% of TNBC to be basal-like (Kreike et al. 2007). More recently gene 
expression analysis identifying subtypes within TNBC observed only 47% of TNBC cases 
to be basal-like (Lehmann et al. 2011). There is still no internationally accepted definition 
or distinction for Basal-like and Triple Negative breast cancer. 
 
1.3.3. Triple Negative Breast Cancer Subtypes 
 
Lehmann et al., performed gene expression profiling on 21 breast cancer data sets which 
identified 587 TNBC cases. Cluster analysis on these TNBC cases resulted in 6 subtypes 
of TNBC but this has recently been refined to just four subtypes (Lehmann et al. 2016). 
The original six subtypes were Basal-like 1 (BL-1), Basal-like 2 (BL-2), Immunomodulatory 
(IM), Mesenchymal (M), Mesenchymal stem-like (MSL) and Luminal androgen receptor 
(LAR). The four refined subtypes and their relative frequencies are: 
• Basal-like 1 (BL-1) – 35% 
• Basal-like 2 (BL-2) – 22% 
• Mesenchymal (M) – 22% 
• Luminal androgen receptor (LAR) – 16% 
 
2% of cases were unclassified with the Immunomodulatory and Mesenchymal stem-like 
subtypes being removed. These subtypes were determined to represent tumours with 
substantial infiltrating lymphocytes and tumour-associated mesenchymal cells 
respectively (Lehmann et al. 2016). These subtypes were identified using publicly 
available gene expression datasets from 587 TNBC tumours with the four subtypes being 
distributed as follows: 35% BL-1, 22% BL-2, 25% M, 16% LAR and 2% unclassified 
(Lehmann et al. 2016). Comparison of the four TNBC subtypes with the intrinsic subtypes 
9 
 
of breast cancer found BL-1, Bl-2 and M subtypes are largely composed of genes 
associated with basal-like breast cancers while the LAR subtype is mainly comprised of 
genes associated with luminal and HER2 subtypes (Lehmann et al. 2016). This finding 
agrees with a study from North Carolina. This study also used DNA microarray profiling 
to subtype TNBC, identifying that each of the four intrinsic breast cancer subtypes are 
present within the TNBC subtype (Perou 2010). The four refined subtypes identified by 
Lehmann et al., as well as some crossover of these subtypes with subtypes identified 
through other studies are detailed below. 
 
1.3.3.1. Basal-like subtypes 
 
These TNBC subtypes are highly proliferative showing high staining (70%) of Ki-67 which 
is a proliferation marker (Elsamany and Abdullah 2014). The basal-like TNBCs are highly 
sensitive to antimitotic chemotherapeutic agents e.g. taxanes, with BL-1 patients 
showing a pathological complete response (pCR) of 41% compared to 18% in BL-2 
patients and 29% in LAR (Lehmann et al. 2016). Tumours in BL-1 patients were found to 
be of the highest grade compared to all other subtypes but interestingly were of the 
lowest clinical stage with only 6% determined as stage 3 (Lehmann et al. 2016). The BL-
2 subtype possessed the highest clinical stage with 30% of BL-2 tumours being stage 3 
(Lehmann et al. 2016). While both Basal-like subtypes share several characteristics, 
there are differences present. The BL-1 class displays high expression of genes 
associated with cell cycle and cell division while the gene expression profile of the BL-2 
class is enriched for genes involved in growth factor signalling, glycolysis and 
gluconeogenesis as well as growth factor receptors (Lehmann et al. 2011). BL-1 patients 
showed a significantly better overall survival compared to all other refined subtypes 
combined (Lehmann et al. 2016). The BL-1 subtype also displayed a better relapse-free 
survival (RFS) with near 60% survival at 10 years (Lehmann et al. 2016). There is some 
cross-over of characteristics and similarities between the BL1 and BL2 subtypes. Both 
classifications show high levels of proliferation and an overall basal-like profile. These 
subtypes are most likely subtypes of each other with BL1 and BL2 being further 
subtyping of the Basal-like subtype described in section 1.3.2.  
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1.3.3.2. Mesenchymal  
 
The gene expression profile of the M subtype shows enrichment for genes involved in 
cell motility, cell differentiation pathways, growth pathways and genes associated with 
ECM receptor interaction (Lehmann et al. 2011). The signalling pathway components 
present in the expression profile of the M subtype are also found in the profile of 
metaplastic breast cancer (Gibson et al. 2005). Metaplastic breast cancer is a rare form 
which occurs in between 0.02% to 5% of breast cancer patients (Hu et al. 2013). This 
form of cancer is characterised by mesenchymal and epithelial components and is 
known to be chemoresistant (Hu et al. 2013). The M subtype is described as having a 
low level of lymph node involvement as only 21% of cases had lymph node disease but 
displayed a significantly higher frequency of lung metastasis (46%) compared to all other 
subtypes (25%) (Lehmann et al. 2016). 
 
1.3.3.3. Luminal androgen receptor  
 
The gene expression profile of this subtype is the most varied among the TNBC subtypes. 
While the TNBC subtypes are ER negative, the luminal androgen receptor (LAR) subtype 
is heavily enriched for genes found in hormonally regulated pathways such as steroid 
synthesis, porphyrin metabolism and androgen/estrogen metabolism (Lehmann et al. 
2011). Interestingly, this LAR subtype displayed high expression of androgen receptor 
(AR) mRNA which is known to be highly expressed in ER-negative breast cancer subtypes 
(Hayes et al. 2008). The level observed was 9-fold greater than the other TNBC subtypes 
(Lehmann et al. 2011). Using IHC methods the level of AR protein was investigated across 
an array of TNBC tumours. The LAR subtype displayed a higher percentage of tumours 
with nuclear staining and higher intensity of staining compared to the other TNBC 
subtypes (Lehmann et al. 2011). Diagnosis of the LAR subtype occurred more often in 
older women, with these tumours being of the lowest grade, compared to all other 
subtypes (Lehmann et al. 2016). Cases of the LAR subtype presented with a significant 
level (nearly half (47%) of patients) of lymph node metastasis as well as a significantly 
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higher incidence of bone metastasis (46%) compared to all other subtypes (16%) 
(Lehmann et al. 2016). 
 
1.3.4. Other classifications 
 
Other publications divide TNBC into several other subtypes: 
• Claudin-low 
• Molecular Apocrine 
 
1.3.4.1. Claudin-low 
 
The claudin-low subtype recently identified has been characterised by loss of tight 
junction markers (notably claudins), high expression of EMT markers and enrichment of 
mammary stem cell markers. This is similar to the MSL subtype previously identified by 
the Lehmann study but which was recently shown to be due to tumour-associated 
mesenchymal cells (Jiao et al. 2014, Lehmann et al. 2016). Hierarchical clustering using 
the claudin-low predictor set identified a portion of the M and MSL subtypes with low 
claudin, cytokeratin and CD24 expression (Lehmann et al. 2011). The MSL subtype 
displayed low expression of claudins 3, 4 and 7 which indicates there may be a 
relationship between the MSL subtype and this Claudin-low subtype, the claudin-low 
subtype may also be due to tumour-associated mesenchymal cells as was the case with 
the MSL subtype.  
 
1.3.4.2. Molecular Apocrine 
 
In 2005 Farmer et al., subtyped breast cancer into three subtypes: luminal, basal and 
molecular apocrine (Farmer et al. 2005). This group performed a microarray study on 
large operable and locally advanced breast cancers. The molecular apocrine subtype 
observed had increased androgen signalling, a ‘molecular apocrine’ gene expression 
profile and possessed some apocrine morphological features. These gene expression 
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and morphological features were similar to the apocrine tissue of the breast, hence the 
name. Apocrine tissue in the breast is a benign fibrocystic change (Farmer et al. 2005). 
All of the tumours classified as molecular apocrine were ER negative and represented 8-
14% of the tumours tested (Farmer et al. 2005). Using the classifications of Lehmann et 
al., this molecular apocrine subtype is similar to the LAR subtype as both express the 
androgen receptor and are ER negative. In the study of the LAR subtype all 6 apocrine 
tumours strongly correlated with the LAR subtype and the Lehmann study concluded 
that the LAR subtype is composed of AR-driven tumours which include the molecular 
apocrine subtype (Lehmann et al. 2011). 
 
The topic of breast cancer subtypes and the subtypes within triple negative breast 
cancer can be ambiguous. Many papers describe different subtypes or describe similar 
subtypes divided in different ways. While the area can be indistinct the subtypes 
described above aim to give a clear insight into one way of subtyping TNBC identified by 
Lehmann et al., The four refined subtypes identified by this group have been discussed 
above as well as the crossover between papers, authors and other subtypes so as to give 
a clear and concise view. The four refined subtypes identified by Lehmann et al., were 
the accepted and used subtypes for the purpose of this study. 
 
1.4. Pancreatic cancer 
 
The pancreas is an organ that produces digestive enzymes and hormones. This organ 
has 3 sections: head, body and tail. There are two distinct pancreatic cell types. The 
endocrine component is composed of islet cells which are found in the body and the tail 
of the pancreas and produce hormones such as insulin that regulate carbohydrate 
metabolism (Omary et al. 2007). The exocrine component consists of clusters of acinar 
cells which are found throughout the organ and represent 95% of the cells in the 
pancreas. This cell type is responsible for secreting digestive enzymes into the 
duodenum (Omary et al. 2007).  
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Pancreatic cancer is one of the most lethal cancers worldwide. The 5-year survival rate 
is approximately 6%, due to late diagnosis by which time usually metastasis has occurred 
(Rucki and Zheng 2014). Over the last 40 years there has been very few advances in 
pancreatic cancer treatment and no change in the survival rate as shown by Figure 1-2. 
In Ireland 500 people are diagnosed each year (National Cancer Registry Ireland 2016), 
this number is expected to increase in coming years due to changes in lifestyle. In a 
report, The 2014 Euro Pancreatic Cancer Index, published by Swedish based research 
organisation Health Consumer Powerhouse, Ireland was ranked 4th out of 30 countries 
in a comparison of pancreatic cancer treatment (Yazbeck and Bjornberg 2014). This 
indicates Ireland has the 4th highest level of pancreatic cancer treatment out of the 30 
countries investigated. 
 
95% of pancreatic cancers are cancer of the exocrine cells. These cancers are classified 
as adenocarcinomas and usually originate in the head of the pancreas. The cancers of 
the endocrine pancreatic component, pancreatic endocrine tumours (PET), are quite 
different. These tumours are known as islet cell tumours or neuroendocrine tumours. 
They are slow growing with a different prognosis and treatment to the 
adenocarcinomas. Pancreatic adenocarcinomas are the focus of this project. Less than 
20% of pancreatic cancer adenocarcinoma patients are eligible for surgical resection at 
time of diagnosis due to the high level of metastasis (Rucki and Zheng 2014). Therefore, 
approximately 80% of patients present with locally advanced or distant disease at 
diagnosis. Even after surgery of the 20%, the 5-year survival of the patients eligible for 
resection is only 18-27% (Katz et al. 2009).  The 5-year survival rate differs based on the 
stage of the disease at diagnosis, with patients with localised disease having a 5-year 
survival rate of 25%, regional disease 10% and distant disease 2% with only 10% of 
pancreatic cancer patients presenting with localised stage I and II disease (Siegel, Miller 
and Jemal 2015). The lack of improvement in pancreatic cancer survival rates over the 
past 40 years is largely due to the advanced disease level present at diagnosis. Once a 
disease becomes systemic the possibility of complete recovery is infinitely smaller. 
Therefore, early detection is highly important in further advancing pancreatic cancer 
treatment. This has proven quite difficult so far, however a greater understanding of the 
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mechanisms of this early metastasis may play an important role in the development of 
early detection strategies, as well advanced treatment options.   
 
Figure 1-2. Trends in cancer survival by tumour site 1971-2011 (Pancreatic Cancer Action 
2017) 
 
Relative survival (1971-2011) across a range of cancer types based on tumour site. Very little change in 
the survival of pancreatic cancer is present across the 40-year period. 
 
1.4.1. Fibrosis 
 
A hallmark of pancreatic cancer is a high level of stroma in the tumours, as seen in Figure 
1-3, which is due to fibrosis also known as desmoplasia. Fibrosis is defined as an 
accumulation of extracellular matrix (ECM) proteins due to the loss of balance between 
the manufacture and degradation of ECM (Apte, Pirola and Wilson 2012), as seen in 
Figure 1-4. When an injury or insult causes damage to the pancreas, this tissue damage 
causes our body to induce inflammation as a part of our immune response to repair the 
tissue. This inflammation in turn activates pancreatic stromal cells, which once activated 
produce scores of ECM proteins. Over a period of time if repetitive cycles of damage and 
repair occur, this leads to a build up a fibrous tissue surrounding the pancreas. The 
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progressive replacement of pancreatic tissue with ECM-rich connective tissue leads to 
exocrine and endocrine insufficiency i.e. the levels of exocrine and endocrine tissue are 
reduced causing a reduction in pancreatic function (Jaster 2004). This fibrosis plays a 
major role in the development and progression of chronic pancreatitis and pancreatic 
cancer.  This dense stroma surrounding the pancreas is reported to give some protection 
to pancreatic tumours from anti-cancer drugs and furthermore stromal cells may induce 
progression of the cancer through promotion of migration and invasion in the pancreatic 
cancer cells (Hwang et al. 2008). 
 
Figure 1-3. Abundance of stroma in pancreatic cancer tumours 
 
Pancreatic tumour section with H and E stain showing tumour elements embedded in abundant stroma 
(Wilson, Pirola and Apte 2014). 
 
Pancreatic stellate cells (PSCs) along with pancreatic fibroblasts play a key role in ECM 
turnover in the healthy pancreas. As well as producing ECM the stromal cells are also a 
source of matrix degrading enzymes (MMPs) and their inhibitors tissue inhibitors of 
metalloproteinases (TIMPS) (Jaster 2004). Stromal cells are responsible for the 
maintenance of normal pancreatic architecture by maintaining a balance in production 
and degradation of ECM proteins as shown in Figure 1-4. They are also responsible for 
the fibrosis which plays a major role in the development and progression of chronic 
pancreatitis and pancreatic cancer.   
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Figure 1-4. The fine balance of production and degradation of ECM in the pancreatic 
microenvironment in both healthy and desmoplastic pancreas 
 
 
 
As seen in Figure 1-5, when an injury occurs in the pancreas the stromal cells become 
activated through inflammation. Once activated, stromal cells produce ECM proteins 
which provide a scaffold for epithelial cell regeneration. This regeneration resolves the 
injury. The stromal cells then secrete matrix metalloproteinases (MMPs) which function 
to degrade the excess ECM. Following this, the activated stromal cells then undergo 
apoptosis and normal pancreatic histology is resumed.  
 
 
 
 
Desmoplasia
Healthy 
pancreas
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Figure 1-5. The role of ECM in the recovery from injury in a healthy pancreas 
(information adapted from (Phillips 2012)) 
 
 
 
 
In the pancreatic tumour microenvironment the stromal cells become perpetually 
activated. As seen in Figure 1-6, when the pancreatic injury is resolved the activated 
stromal cells continue in the activated state. The stromal cells have the ability to secrete 
their own cytokines and growth factors maintaining this constant activation. MMPs are 
not secreted meaning the excess ECM proteins are not degraded and the activated 
stromal cells do not undergo apoptosis. The stromal cells continue to produce ECM 
proteins leading to fibrosis as seen in Figure 1-6. This fibrosis contributes to the 
progression of pancreatic cancer. This role of the tumour microenvironment in the 
progression of pancreatic cancer is becoming the focus of more and more pancreatic 
cancer research. This in part is due to the realisation that the stromal cells surrounding 
tumours play an important role in the progression and metastasis of this cancer.  
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Figure 1-6. Loss of balance in ECM production by stromal cells leads to fibrosis 
(information adapted from (Phillips 2012)) 
 
 
1.4.2. Pancreatic Microenvironment 
 
The pancreatic microenvironment consists of two components. The cellular component 
contains fibroblasts, stellate cells, immune cells, endothelial cells, nerve cells and 
epithelial cells. The acellular component is made up of enzymes, growth factors and the 
extracellular matrix (ECM). The ECM provides structural and biochemical support to the 
surrounding cells. This means the ECM acts as a physical structure for the acellular 
component to build around but also has a chemical influence on the cells behaviour by 
secreting enzymes and growth factors. Proteins such as collagen, fibrinogen, hyaluronan 
and fibrin make up the pancreatic ECM. In a healthy pancreas, the pancreatic 
microenvironment is responsible for the fine balance in production and degradation of 
ECM.  
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1.4.3. Pancreatic Stromal Cells 
 
As previously mentioned the cellular component of the pancreatic microenvironment 
contains a range of cell types. Two stromal cell types are the focus of this investigation, 
patient tumour derived fibroblasts and pancreatic stellate cells. Both cell types are 
responsible for the balance in production and degradation of ECM. When this balance is 
lost, ECM builds up and this is due to both pancreatic fibroblasts and stellate cells. This 
build up, known as fibrosis plays a role in the progression of pancreatic cancer. 
 
Fibroblasts have been called the cockroaches of the human body due to their extreme 
resilience (Kalluri 2016). They survive severe stress lethal to other cell types. They are 
the only normal cell type that can be live-cultured from post-mortem and decaying 
tissue, and they are undoubtedly the most versatile cell type owning to their ease of 
isolation and culture which has led to fibroblasts being the most extensively studied cell 
type in vitro (Bliss et al. 2012, Kalluri 2016). Fibroblasts are usually quiescent and 
become activated in a wound healing response. Fibroblasts associated with cancer have 
several terms including cancer-associated fibroblasts (CAFs), tumour-associated 
fibroblasts (TAFs), activated fibroblasts, activated myofibroblasts. In terms of this 
project, fibroblasts are referred to as patient tumour derived fibroblasts. The patient 
tumour derived fibroblasts were developed in house. Tumour samples, received from 
St. Vincent’s University Hospital, were enzymatically digested using hyaluronidase and 
collagenase. Following this digestion, the samples were then explanted into culture and 
outgrowth used to develop fibroblasts. 
 
Pancreatic stellate cells (PSCs) are a relatively new cell type isolated from human 
pancreas tissue. PSCs are myofibroblast-like cells and comprise approximately 4-7% of 
the total mass of pancreatic tissue (Apte, Pirola and Wilson 2012). The presence, role 
and functions of PSCs have come to light over the last 20 years but a large amount is still 
to be determined. This is principally due to the lack of an isolation method for PSCs 
which was not developed until 1998 (Bachem et al. 1998). Pancreatic stellate cells are a 
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part of the exocrine component of the pancreas. They can be found in the periacinar 
space, the perivascular and periductal regions of the pancreas and show a periacinar 
distribution i.e. the cells are found in the space surrounding the acinar cells and also 
surrounding blood vessels and ducts as can be seen in Figure 1-7 (Omary et al. 2007, 
Jaster 2004).  
 
Figure 1-7. Pancreatic stellate cells in the pancreatic tumour microenvironment 
 
This figure shows the exocrine component of the human pancreas. The quiescent PSCs are located in the 
periacinar space and encircle the base of the acinus (Omary et al. 2007). 
 
PSCs are so called due to their star like shape in situ (stella means star in Latin) and also 
after their liver counter-parts hepatic stellate cells (HSCs) (Apte, Pirola and Wilson 2012). 
Like HSCs, the major role of PSCs is in fibrosis. In a healthy pancreas, PSCs are in a non-
activated state known as quiescent state. Quiescent PSCs have a polygonal shape and 
contain large numbers of vitamin A droplets in their cytoplasm; the presence of these 
droplets is a key aspect to distinguish active and non-active PSCs (Apte, Pirola and 
Wilson 2012). The activated PSC state is recognisable by a change to a myofibroblast-
like phenotype, the loss of vitamin A droplets and by the expression of α smooth muscle 
actin (α-SMA) and ECM proteins such as fibronectin and collagen I and III (Omary et al. 
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2007). It is in this activated state that PSCs cause pancreatic fibrosis by producing ECM 
proteins and cytokines. The key step in development of pathogenesis of pancreatic 
cancer is the disruption of the balance between the quiescent and active PSCs along with 
the loss of elimination of activated PSCs (Jaster 2004).   
 
1.4.3.1. Fibroblasts vs Stellate cells 
 
Despite similarities at a cell biology level between fibroblasts and stellate cells, 
functional differences, if any, are yet to be clearly defined at a molecular level. There is 
a large crossover in terms of function, expression markers and morphology in both 
healthy and malignant pancreas. The shared expression markers are summarised in 
Table 1-1. One unshared characteristic, unique to quiescent PSCs is the presence of 
vitamin A droplets in their cytoplasm which determines there are differences between 
the two cell types but the extent and functional effects of these differences have yet to 
be determined. Due to this, this body of work investigated the interactions of pancreatic 
cancer cells with both tumour derived fibroblasts and PSCs to elucidate if any functional 
differences were present.  
 
Table 1-1. Expression markers of fibroblasts and stellate cells 
Marker Fibroblasts Stellate cells References 
αSMA   (Haag et al. 2010, Bachem et al. 1998) 
Desmin   
(Haag et al. 2010, Bachem et al. 1998, 
Lardon, Rooman and Bouwens 2002) 
FAP   (Haag et al. 2010) 
FSP-1   (Haag et al. 2010) 
GFAP   
(Bachem et al. 1998, Hainfellner et al. 
2001, Lardon, Rooman and Bouwens 
2002) 
Nestin   
(Bachem et al. 1998, Lardon, Rooman 
and Bouwens 2002, Janmaat et al. 
2015) 
Synemin   (Zhao and Burt 2007) 
Vimentin   
(Bachem et al. 1998, Lardon, Rooman 
and Bouwens 2002, Cheng et al. 2016a) 
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1.4.3.2. Activated vs Quiescent stromal cells 
 
The activation state of stromal cells is an area of research gathering a lot of attention. 
Whether the stromal cells in the pancreatic tumour microenvironment are activated or 
quiescent has a major impact on the influence the stromal cells have on the pancreatic 
cancer cells. There are a wide range of markers published to distinguish between 
activated and quiescent stromal cells, these include fibroblast-specific protein (FSP1), 
vimentin, αSMA, fibroblast activation protein (FAP), PDGF receptor-α, (PDGFRα), 
PDGFRβ, desmin and discoidin domain-containing receptor 2 (DDR2) (Sugimoto et al. 
2006, Haag et al. 2010). A small number of quiescent stromal cells are present in the 
stroma of healthy organs, embedded in the ECM. In tumour stroma, there is an 
increased number of activated stromal cells expressing activation markers such as αSMA 
or desmin. These stromal cells deposit increased levels of collagen fibrin and other ECM 
components compared to quiescent fibroblasts (Kalluri and Zeisberg 2006, Hanahan and 
Coussens 2012, Marsh, Pietras and McAllister 2013). Research focusing on the role of 
stromal cells is now including examinations of the activation state of the stromal cell 
populations. Several such studies have investigated new activation markers including 
palladin and podoplanin. A 90 kDa isoform of palladin has been shown to be 
overexpressed in CAFs of several different cancer types including pancreas (Goicoechea 
et al. 2010). One such study analysed palladin expression during the activation process 
of fibroblasts and found upregulated expression during activation and that palladin 
expression is required for αSMA upregulation in CAFs (Brentnall et al. 2012). A related 
study observed that palladin expression in CAFs enhanced the invasive capabilities of 
pancreatic cancer cells both in vitro and in vivo (Goicoechea et al. 2014). A similar study 
investigated podoplanin, a 17 kDa transmembrane glycoprotein, as an activation marker 
in CAFs. This study observed that CAFs positive for podoplanin expression enhanced the 
invasive capabilities of the pancreatic cancer cells compared to CAFs with no podoplanin 
expression (Shindo et al. 2013). More and more studies are emerging studying the 
activation status of stromal cells populations but as of yet no distinct marker or 
characteristic has been established which undoubtedly, uniquely distinguishes cultured 
activated stromal cells from quiescent stromal cells. 
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1.5. Metastasis 
 
Metastasis is a process which contributes to the high mortality rate in cancer (Jiang et 
al. 2015). In fact, without metastasis 90% of cancers would not be fatal (Hu et al. 2016). 
Metastasis is the ability of a cell to spread to another location in the body not only 
surviving in this foreign site, also surviving the journey and establishing further growth 
in this new location (Kozlowski, Kozlowska and Kocki 2015). Gaining a greater 
understanding of metastasis is required to further understand the progression of both 
triple negative breast cancer and pancreatic cancer. With this greater understanding 
comes a greater possibility of developing effective therapies. Metastasis occurs through 
a cascade of processes, signals and functions. This body of work aims to investigate 
metastasis through several metastatic characteristics, specifically anoikis, invasion, 
miRNA and the tumour microenvironment. These metastatic phenotypes are major 
factors in the success of metastasis. Each of these aspects of metastasis (which are 
explained in further detail below) are critical steps in the metastatic cascade.  
 
1.5.1. Anoikis 
 
Anoikis is a form of programmed cell death due to detachment of cells from the extra-
cellular matrix (ECM), first identified in by Frisch and Francis in 1994 (Frisch and Francis 
1994). Usually when a cell detaches from its natural location it dies, this death process 
is called anoikis, which is a Greek word meaning ‘homelessness’ (Chiarugi and Giannoni 
2008). Anoikis is induced by loss of cell adhesion or inappropriate cell adhesion (Chiarugi 
and Giannoni 2008). This process is important for the homeostasis of the living organism. 
Without anoikis, cells could freely travel around the body, attach and grow in foreign 
locations. Therefore, anoikis prevents detached epithelial cells from surviving and 
colonizing other locations or attaching to an incorrect ECM (Kim et al. 2012). Standard 
epithelial cells require adhesion to the ECM through cell surface receptors known as 
integrins (Kim et al. 2012). Cells may be anoikis resistant i.e. these cells do not require 
adhesion to the ECM to proliferate or survive (Chiarugi and Giannoni 2008). A small 
number of cell types have the ability to avoid anoikis, e.g. blood cells are naturally 
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anoikis resistant. However, in the cancer setting the ability of a cancer cell to resist 
anoikis is associated with a metastatic phenotype. Metastatic cancer cells lack sensitivity 
to anoikis unlike normal epithelial cells, meaning the cancer cells have developed the 
ability of anchorage independence. This ability is important in metastasis; it is a 
requirement for cancer cells to successfully spread.  
 
Anoikis, in the same way as apoptosis, is initiated by either of two pathways; one being 
the intrinsic pathway and the second being the extrinsic pathway. Both pathways 
progress differently but merge at the point of activation of caspases and lead to 
activation of endonucleases, DNA fragmentation and ultimately cell death (Chiarugi and 
Giannoni 2008). Both pathways rely on and require a family of proteins known as the 
Bcl-2 family. 
 
1.5.1.1. The Intrinsic Pathway 
 
The intrinsic pathway as seen in Figure 1-8 is triggered by cellular signals such as DNA 
damage, endoplasmic reticulum stress (Paoli, Giannoni and Chiarugi 2013). This pathway 
initiates anoikis through caspase activation which is induced due to perturbation of the 
mitochondria. This permeabilization of the mitochondria causes activation of caspases. 
The intrinsic pathway is initiated by BH3-only activator proteins Bid and Bim which 
become activated following detachment of cells from the ECM (Chiarugi and Giannoni 
2008). These activators promote the formation of oligomers of the pro-apoptotic 
proteins Bax and Bak within the OMM. Together these proteins translocate from the 
cytosol to the outer mitochondrial membrane where they form oligomers which create 
channels in the OMM (Kim et al. 2012). These channels or pores result in membrane 
permeability. This process is known as intrinsic pore forming activity. There is a 
suggestion that this pore forming activity may not be wholly due to Bax proteins but also 
due to the interaction of these proteins with mitochondrial channel proteins for 
example, VDACs (voltage-dependent anion channels) (Taddei et al. 2012). However, 
work carried out by Baines et al. appears to dispute this suggestion (Baines et al. 2007). 
The disruption of the OMM occurs along with release of cytochrome c leading to the 
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formation of the apoptosome (Wazir et al. 2015). Smac/DIABLO is also released; it acts 
to impede the function of inhibitor of apoptosis proteins, IAP and XIAP (Mawji et al. 
2007). The apoptosome is composed of caspase-9, the cofactor Apaf (apoptosis 
protease activating factor) and cytochrome c, this leads to activation of the effector 
capsase-3 and execution of apoptosis (Wazir et al. 2015). The BH3-only sensitizer 
proteins also play a role in the intrinsic pathway of anoikis. These proteins compete for 
the BH3-only binding site on Bcl-2 proteins which inhibits the anti-apoptotic actions of 
Bcl-2 (Paoli, Giannoni and Chiarugi 2013). This then allows the activator BH3-only 
proteins to induce Bax-Bak formation as Bim and Bid are no longer being sequestered 
by the Bcl-2 proteins. 
 
Figure 1-8. Schematic of the intrinsic and extrinsic pathways 
 
Schematic of the intrinsic and extrinsic pathways that lead to anoikis in a normal cell. Also shown is the 
process in which neither of these pathways occurs, leading to anoikis resistance in a cancer cell (Kim et al. 
2012). 
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1.5.1.2. The Extrinsic Pathway 
 
The extrinsic pathway triggers cell surface death receptors to activate anoikis. This 
pathway, shown in Figure 1-8, is initiated by the binding of members of the TNF receptor 
superfamily e.g. Fas Ligand and TNF-α; to their transmembrane death receptors e.g. Fas 
and TNF-α receptor (TNFR) (Taddei et al. 2012). This results in the assembly of the Death-
Inducing Signalling Complex (DISC). The role of DISC is to recruit adaptor proteins e.g. 
Fas-associated death domain (FADD); which engages and aggregates molecules of 
caspase-8 (FLICE), promoting its activation and autoprocessing (Chiarugi and Giannoni 
2008). Active caspase-8 is released into the cytoplasm where it proteolytically processes 
and cleaves caspase-3 and caspase-7 causing their activation (Taddei et al. 2012). This 
causes more caspase activation and results in substrate proteolysis and cell death. FLIP 
(FLICE-inhibitory protein) is an inhibitor of caspase-8, many malignant cells overexpress 
FLIP to avoid anoikis (Kim et al. 2012). Upregulation of FLIP plays a role in developing 
anoikis resistance, as shown in Figure 1-8.There are two classes of cells that respond to 
extracellular death cells: 
 
• Type I: activation of caspase-8 is sufficient to cleave effector caspases leading to 
cell death 
• Type II: caspase-8 cannot initiate apoptosis itself. The extrinsic death signals 
crosstalk with intrinsic pathway.  
 
Both pathways converge on the activation of the effector caspase-3. This initiates a 
downstream proteolytic cascade which is a central event in programmed cell death. The 
cleavage of signalling molecules such as focal adhesion-kinase, Cas and paxillin are 
particularly important for the progression of this cascade (Chiarugi and Giannoni 2008). 
FAK is one of the key players in integrin-mediated signal transduction leading to anoikis, 
along with integrin-linked kinase (ILK), Src tyrosine kinase, PI3K, ERK and the adaptor 
protein Shc. Over expression of FAK or ILK blocks anoikis despite loss of cell anchorage, 
showing the role of these kinases in anoikis regulation. 
 
27 
 
1.5.1.3. Bcl-2 Family of Proteins 
 
This family of proteins consists of 3 groups: Anti-apoptotic proteins, Multidomain Pro-
apoptotic proteins, and Pro-apoptotic BH3-only proteins. 
 
1.5.1.3.1. Anti-apoptotic proteins 
 
The proteins in this group, which include Bcl-2, Bcl-XL and Mcl-1 (Myeloid Leukaemia 
Cell Differentiation Protein 1), prevent and inhibit apoptosis. These proteins prevent 
apoptosis by avoiding outer mitochondrial membrane disruption, pore formation and 
maintaining membrane integrity (Chiarugi and Giannoni 2008). Anti-apoptotic proteins 
are structurally related to pro-apoptotic proteins Bax and the BH3-only family (Chiarugi 
and Giannoni 2008). Inhibition of apoptosis can also be carried out due to sequestering 
of BH3-only proteins, mainly Bid and Bim therefore preventing formation of an oligomer 
of Bax and Bak which is essential for anoikis (Chiarugi and Giannoni 2008).  
 
1.5.1.3.2. Multidomain Pro-apoptotic proteins 
 
The role of these proteins is to encourage apoptosis by regulating the intrinsic pathway 
of anoikis activation. The major members are Bax, Bak and Bok (Tan et al. 2013). Bax and 
Bak form oligomers resulting in pore channels in the outer mitochondrial membrane 
(OMM) (Chiarugi and Giannoni 2008). These pores cause permeability of the membrane, 
which therefore leads to cell death (Taddei et al. 2012). The role Bax and Bak play in 
anoikis is key. For the successful formation of OMM pores multidomain pro-apoptotic 
proteins require assistance from the BH3-only proteins (Danial 2007). 
 
1.5.1.3.3. Pro-apoptotic BH3-only proteins 
 
BH3-only proteins initiate the intrinsic pathway to cause cell death. This is the largest 
group in the family with members including Bid, Bad, Bim, Bik, Bmf, Noxa, Puma and Hrk 
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(Taddei et al. 2012). These proteins are further subdivided into activators and 
sensitizers. Bid and Bim are known as activators. Following detachment of the cell from 
the ECM, Bid and Bim are activated and then cause formation of Bax-Bak oligomers in 
the OMM (Taddei et al. 2012). This is a key step in the anoikis process. Investigations 
have shown that siRNA knockdown of Bid inhibits anoikis in several cell types (Gilmore 
2005). Bad, Bik, Bmf, Noxa, Puma and Hrk are the sensitizers in the group. These proteins 
compete for the BH3-only binding site on Bcl-2 proteins thus inactivating Bcl-2’s anti-
apoptotic actions (Chiarugi and Giannoni 2008). This then allows the activator BH3-only 
proteins to induce Bax-Bak formation. Sensitizer proteins are unique in that they do not 
directly regulate anoikis; they sensitize cells to the effects of apoptosis (Paoli, Giannoni 
and Chiarugi 2013). There is some evidence that in certain cell lines overexpression of 
Bad does not induce apoptosis but only sensitizes cells to the effects of anoikis (Idogawa 
et al. 2003). 
• Noxa and Puma are transcriptionally regulated by p53 and are shown to be 
involved in fibroblast anoikis 
• Bim and Bad can be controlled by PI3K and ERK pathways. Bid may also be 
cleaved in the extrinsic pathway. Bim is contained in the dynein complex until it 
is released due to loss of integrin attachment; Bim then relocates to the 
mitochondria. Here it interacts with Bcl-XL neutralizing the Bcl-XL pro-survival 
function (Paoli, Giannoni and Chiarugi 2013). 
• Loss of ECM contact leads to an accumulation of Bim as usually integrin 
engagement means ERK and PI3K phosphorylate Bim and cause proteasome-
dependent degradation of Bim. The loss of ECM contact means no integrin 
engagement and therefore the above degradation does not occur (Paoli, 
Giannoni and Chiarugi 2013). 
• Bmf (Bcl-2 Modifying Factor) plays a role in anoikis due to its interaction with the 
myosin V motor complex. Bmf is usually sequestered in these complexes but 
upon detachment from the ECM Bmf is released. Similar to Bim, Bmf counteracts 
the activity of the anti-apoptotic Bcl-2 protein when cell adhesion is disrupted. 
Suppression of Bim and Bmf may confer anoikis resistance (Kim et al. 2012). 
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Expression of these proteins can be decreased with hypoxia which blocks anoikis 
in mammary epithelial cells (Kim et al. 2012).  
 
1.5.2. Anoikis resistance 
 
Anoikis resistance, a hallmark of cancer progression, is a critical step in tumour 
metastasis (Kim et al. 2012, Attwell, Roskelley and Dedhar 2000). Cells which have 
become anoikis resistant can detach from their appropriate ECM, survive and travel 
through the vascular system to a secondary site where they can reattach and begin to 
grow a new colony. There are many strategies involved in malignant cells developing 
anoikis resistance. One such strategy is a change in the pattern of integrin expression. 
As previously stated integrins play an important role in determining if a cell is going to 
survive (Kim et al. 2012). Cancer cells have the ability to change the integrin expression 
on their surface to signal cascades that can enhance cell survival. (Taddei et al. 2012). 
There is large amount of evidence to support this finding; many different cancer cell 
types have been shown to have altered integrin expression, with this new expression 
improving survival while detached (Huang et al. 2016b, Puchsaka, Chaotham and 
Chanvorachote 2016, Mizejewski 1999). Another process in development of anoikis 
resistance is inducing cell survival pathways to become constitutively activated e.g. 
prosurvival pathways induced by PI3K, MEK/ERK and NF-κB (Chiarugi and Giannoni 
2008). Hypoxia has been shown to induce anoikis resistance by decreasing expression of 
pro-apoptotic BH3-only proteins Bim and BMF (Kim et al. 2012). Epithelial-mesenchymal 
transition (EMT) also plays a role in gaining anoikis resistance (Tiwari et al. 2012). EMT 
is a fast, reversible change of cell phenotype (Savagner 2010). Through EMT epithelial 
cells loosen cell-cell adhesion structures, become isolated, motile and anoikis resistant. 
Cells also acquire several mesenchymal characteristics, hence the name; the process is 
a transition from epithelial cell type towards mesenchymal (Chunhacha, Sriuranpong 
and Chanvorachote 2013). Cells undergoing EMT dissolve their adherent and tight 
junctions resulting in a loss of cell-cell junctions (Tiwari et al. 2012). Cells undergoing 
EMT lose several proteins involved in adhesion such as E-cadherin, β-catenin, and γ-
catenin (Kim et al. 2012). This loss of junctions and proteins involved in adhesion are 
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important steps in cells detaching from their primary site and becoming anoikis 
resistant.  
 
Many processes contribute to the development of anoikis resistance but how the 
extrinsic pathway of anoikis is actually blocked is shown in Figure 1-8.  FLIP, a caspase-8 
inhibitor, is overexpressed in anoikis resistant cancer cells. FLIP inhibits the extrinsic 
pathway of anoikis by blocking activation of caspase-8. Anisomycin, an antibiotic, has 
been shown to sensitize cells to anoikis by decreasing FLIP levels and also inhibited distal 
tumour formation in a mouse model of prostate cancer (Kim et al. 2012). Figure 1-8 also 
shows the role of hypoxia by downregulating Bim and Bmf resulting in inhibition of the 
mitochondrial pathway (Kim et al. 2012). While a large amount is known about the 
pathways inducing anoikis resistance, the way the pathways especially the intrinsic 
pathways are actually blocked still needs to be explained. This body of work investigated 
anoikis resistance in TNBC through microarray analysis, in pancreatic cancer the effects 
of indirect co-culture and altered miRNA expression on anoikis were examined. 
 
1.5.3. Invasion 
 
A hallmark of both triple negative breast cancer and pancreatic cancer is the level of 
metastasis present at diagnosis. Both have the ability to metastasise early on soon after 
the development of the cancer. This metastasis usually occurs before symptoms are 
present. Less than 20% of pancreatic cancer patients are eligible for surgical resection 
at time of diagnosis due to the high level of metastasis (Rucki and Zheng 2014). Invasion 
is a key process in metastasis i.e. the development of cancer at a secondary location. 
Invasion is the process which transforms a locally growing tumour into a metastatic 
systemic disease. Invading tumour cells engage the blood and lymph vessels; penetrate 
through the basement membrane and endothelial walls to then disseminate through 
the vessel lumen allowing colonisation of distant sites to occur (Friedl and Alexander 
2011). Tumours can use different cellular and molecular modes of invasion depending 
on specific cell-type, autonomous mechanisms and also the surrounding 
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microenvironment which can induce changes in invasion level or mechanism (Friedl et 
al. 2012). The process of invasion can occur in several different ways. These include 
single-cell invasion, multi-cellular streaming and collective invasion, a schematic 
diagram of these different forms can be seen in Figure 1-9 below.  
 
Figure 1-9. Schematic of different forms of invasion 
 
A schematic diagram showing different forms of invasion including amoeboid and mesenchymal single 
cell invasion, multicellular streaming and collective invasion (Friedl et al. 2012). 
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1.5.3.1. Single-cell invasion 
 
Individual cells invade singly – shown in Figure 1-10 A. Single cell invasion occurs through 
a five-step process which changes the cell shape, position & structure (Friedl and 
Alexander 2011).  
o Step 1: Actin polymerisation causes the cytoskeleton to polarise causing 
a leading protrusion to form. 
o Step 2: The leading protrusion engages with the extracellular matrix 
causing recruitment and adhesion of cell surface receptors. This 
extracellular adhesion causes intracellular signalling leading to the 
generation of traction force. 
o Step 3: Several micrometres back from the tip of the leading protrusion 
proteases engage with extracellular scaffold proteins causing proteolysis 
(Friedl and Alexander 2011). This causes the surrounding tissue 
properties to change allowing space for the advancing cell body. 
o Step 4: Tension is created inside the cell through contraction mediated 
by actomyosin (Friedl and Alexander 2011). 
o Step 5: The adhesion bonds at the trailing edge of the invading cell are 
gradually turned over causing the trailing edge to slide forward as the 
leading edge protrudes further 
 
This five-step process can vary depending on which form of single cell invasion is 
occurring. There are two forms, mesenchymal like and amoeboid invasion. 
Mesenchymal like invasion is a slow, mesenchymal like process in which cells are spindle 
shaped, elongated and require high levels of cell-matrix adhesion and proteolysis (Wolf 
et al. 2007). This form of invasion is dependent on proteases, integrins and stress-fibers 
(Valastyan and Weinberg 2011). 3D models have shown this invasion to have quite slow 
velocities of 0.1-2µm/min (Friedl and Wolf 2003). Amoeboid invasion is the faster form 
that resembles an amoeboid action in which the cells are rounded. The velocities of this 
action have been shown to be 10-30 times faster than mesenchymal invasion (Friedl and 
Wolf 2003). Amoeboid invasion requires no proteolytic ECM remodelling with little cell-
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matrix adhesion but relies on cortical actomyosin contractility (Geiger and Peeper 2009) 
(Friedl et al. 2012). This form is independent of proteases, integrins and stress-fibers 
(Valastyan and Weinberg 2011). 
 
Figure 1-10. Representative images of two different forms of invasion 
  
Representative images of two different forms of invasion – (A) Individual invasion and (B) Collective 
invasion. 
 
 
1.5.3.2. Multi-cellular streaming 
 
This form of invasion involves cells moving individually but as one, in multi-cellular 
strands or in small strands of cells (Friedl et al. 2012). The cells move individually as the 
cytoskeleton of each cell acts independently to generate traction on the ECM while the 
cells form only weak cell-cell adhesions (Friedl et al. 2012). These strands of cells are 
directed in their movement through the guidance of external sources such as a 
chemokine gradient or extracellular tissue structures (Friedl et al. 2012). Due to the 
transient cell-cell adhesions and the ability of each individual cell to generate traction 
force which is a key feature of this invasion process, this multi-cellular streaming permits 
rapid migration (1 µm min-1, or faster) (Friedl et al. 2012).  
 
 
A B 
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1.5.3.3. Collective invasion 
 
Collective invasion – shown in Figure 1-10 B, is the form of invasion seen most often in 
carcinomas. Cells invade as a cohesive, multicellular group maintaining cell-cell 
adhesions and multi-cellular coordination is also required (Friedl and Alexander 2011). 
Collective invasion can possess several different morphologies which depend on the cell 
type, number of cells and the tissue structure being invaded (Friedl and Alexander 2011). 
These morphologies are: 
o Small clusters 
o Solid strands 
o Cells files 
o Presence of a lumen, which can be formed if polarity is retained (Friedl 
and Gilmour 2009) 
 
The morphology of the collective invasion structure is determined by the specific 
combinations of cell-cell adhesions, cell-matrix adhesions and proteolysis involved 
(Friedl et al. 2012). Usually in collective invasion the tip of the strand is formed by several 
leading cells known as the leading edge. These leader cells generate traction and 
proteolysis of the surrounding tissue (Khalil and Friedl 2010). This traction force is 
generated by actomyosin-mediated protrusion and contractility; often cells at the lateral 
regions join in as a part of this action (Friedl et al. 2012). The energy for this traction is 
provided by substrate binding integrins. The leading cells express several different 
integrins to connect to ECM components such as fibronectin, collagen and fibrin-rich 
surfaces (Alizadeh, Shiri and Farsinejad 2014). The structure of the leading edge can 
vary, it is determined by several factors including level of proteolysis, protrusion, 
expansion and the type of tissue encountered (Friedl et al. 2012). Cancer cell models 
have shown the leading cells in collective cancer invasion to have mesenchymal 
characteristics as well as actin-rich protrusions (Friedl and Alexander 2011). These 
protrusions generate adhesive traction for forward movement and matrix proteolysis. 
This results in a zone of re-aligned, partially proteolysed ECM which guides the group 
(Wolf et al. 2007). The remainder of the collection reinforce this alignment and increase 
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the diameter of the invading strand (Friedl et al. 2012). It has been shown in collective 
cancer invasion that cancer-associated fibroblasts perform a similar function to this 
(Gaggioli et al. 2007). In collective invasion, the cells inside the group have no direct 
access to the ECM unlike the cells at the border of the group. These interior cells only 
have contact with neighbouring cells and intercellular matrix that may be present along 
cell-cell junctions (Friedl et al. 2012).  
 
1.5.4. Indirect Co-culture 
 
As the significance of the tumour microenvironment has been realised in recent years 
the role of stromal cells in the progression of pancreatic cancer has become the centre 
of a great deal of pancreatic cancer research.  It has become clear that the interaction 
between pancreatic tumour cells with the surrounding stromal cells is critical to the 
progression of pancreatic cancer. Due to the heterogeneity of the stroma an exact 
understanding of these interactions and how they contribute to the progression of 
pancreatic cancer is still to be determined. A small number of publications to date have 
investigated the interaction between the stroma and pancreatic tumour cells, each 
focusing on different hallmarks of cancer progression. In this current project these 
interactions were investigated using an indirect co-culture system. The type of 
interaction studied in this work was based on the hypothesis that soluble factors 
produced by stromal cells & secreted into the media of the pancreatic cancer cells may 
stimulate signalling pathways related to metastatic phenotypes. This type of interaction 
represents the indirect contact between stromal cells & pancreatic cancer cells i.e. 
soluble factors are investigated without physical contact between the two cell types. Co-
culture which investigates the physical contact of different cell populations is known as 
direct co-culture. The indirect co-culture system used in this work uses co-culture inserts 
similar to invasion inserts but with a smaller pore. The insert contains a polyester 
membrane with a pore size of 3.0µm, too small to allow cells to pass through. This 
membrane allows secretions to pass from the stromal cells into the pancreatic cancer 
cells without the cells ever being in direct contact (Fujita et al. 2009). As seen in Figure 
1-11, the pancreatic cancer cells are seeded in a 6 well plate with a co-culture insert 
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placed above which contains the stromal cell population. The effects of this co-culture 
on anoikis, proliferation, colony formation and invasion were examined across a panel 
of pancreatic cancer cell lines. 
 
Figure 1-11. A schematic of the indirect co-culture model used to investigate the 
pancreatic tumour microenvironment 
Schematic of the indirect co-culture model set up. Pancreatic cancer cells are seeded in a 6 well plate with 
the stromal cell population above in a co-culture insert. The insert contains a polyester membrane with a 
3.0µm pores which allow secretions to pass between the two cell types (Crosson 2014). 
 
1.5.5. miRNA 
 
MicroRNA (miRNA) are short, naturally occurring non-coding RNA molecules, typically 
19-24 nucleotides in length. They play a major role in regulating gene expression at a 
post-transcriptional level. These small RNA molecules are vital to the appropriate 
function of the organism and due to this they are highly conserved across a wide range 
of species. miRNA target messenger RNA (mRNA) of protein-coding genes. it is predicted 
30% of protein-coding genes in mammals are regulated by miRNA (Rachagani et al. 
2015). miRNA act to downregulate gene expression of target mRNA through one of two 
actions which both induce gene silencing. The first being degradation of the target 
mRNA, the second is inhibition of translation of the target mRNA resulting in effective 
expression inhibition. This repression is a result of the miRNA binding through direct 
base-pairing interactions to the 3’-untranslated region (3’-UTR) leading to degradation 
or translational arrest of the target mRNA (Tay et al. 2015). Target degradation occurs 
when perfect complementarity exists between the miRNA and the mRNA target.  This 
type of repression is very rare in mammals; it occurs most often in plants (Pasquinelli 
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2012). Usually in mammals incomplete complementarity exists between the miRNA and 
the mRNA target which leads to inhibition of translation. This incomplete 
complementarity is due to mismatches present in the miRNA sequence which cause 
bulges to form when the miRNA and mRNA interact (Hibio et al. 2012). The specificity of 
a miRNA is determined by nucleotides 2-8 at the 5’ end, this is known as the seed region 
(Bartel 2009). This short sequence is common in the 3’UTR of many mRNA transcripts, it 
is this which allows miRNA to target multiple mRNAs, in fact each miRNA has the 
potential to regulate thousands of genes (Lewis, Burge and Bartel 2005). In line with this, 
the expression of each protein-coding gene may be controlled by multiple miRNA. 
Through this gene silencing miRNA play a role in virtually all biological functions such as 
development, growth, differentiation and apoptosis.  
 
1.5.5.1. Biogenesis 
 
The biogenesis of miRNA, explained visually in Figure 1-9, is tightly controlled, both 
temporally and spatially (Ha and Kim 2014). miRNA begin in the nucleus where it is 
transcribed by RNA polymerase II, resulting in a long hairpin loop structure known as a 
primary miRNA (pri-miRNA) (Romero-Cordoba et al. 2014). These pri-miRNA structures 
have a 5’-cap and a 3’-poly A tail (Hawa et al. 2016). A microprocessor consisting of 
Drosha and DGCR8 cleave this pri-miRNA into a shorter, ~60-100 nucleotide hairpin 
structure called a precursor-miRNA (pre-miRNA) (Hawa et al. 2016). Following these 
steps of processing the pre-miRNA is transported from the nucleus into the cytoplasm 
for further processing. This transportation occurs through an interaction of the pre-
miRNA with the nuclear transport receptor Exportin-5 and the nuclear protein Ran-GTP 
(Chitkara, Mittal and Mahato 2015). The next step in the process is performed by an 
RNase III endonuclease protein, Dicer, together with TAR-binding protein (TRBP) which 
acts as a catalytic partner (Baumann and Winkler 2014). This duo removes the hairpin 
loop from the transcript, cleaving the pre-miRNA into a short double stranded RNA 
molecule (Pai et al. 2013). This duplex is then loaded into the RNA-induced silencing 
complex (RISC). The RISC complex consists of TRBP, Dicer and Argonaute-2 (Ago-2) 
(Hawa et al. 2016). One of the loaded strands known as the guide strand is destined to 
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be the mature miRNA, while the other, the passenger strand will be degraded. The 
passenger strand is cleaved by Ago-2 of the RISC complex leaving the guide strand to 
function as a mature miRNA i.e. binding an mRNA target to either degrade the transcript 
or inhibit translation (Romero-Cordoba et al. 2014).  
 
39 
 
Figure 1-12. miRNA biogenesis and processing 
 
miRNA are transcribed in the nucleus by either RNA Pol II or III producing a pri-miRNA. Drosha and DGCR8 
cleave this pri-miRNA into a shorter, ~60-100 nucleotide hairpin structure, a pre-miRNA. The pre-miRNA 
is transported through Exportin-5 with Ran-GTP. Dicer, together with TAR-binding protein (TRBP) removes 
the hairpin loop, producing a short double stranded RNA molecule. This duplex is then loaded into the 
RNA-induced silencing complex (RISC). The RISC complex consists of TRBP, Dicer and Argonaute-2 (Ago-
2).  The passenger strand is cleaved by Ago-2 of the RISC complex leaving the guide strand to function as 
a mature miRNA (Winter et al. 2009). 
 
1.5.5.2. Nomenclature  
 
There are several different forms of miRNA names, some of which can be seen in Table 
1-2. During the biogenesis of miRNA which has been discussed previously, the immature 
miRNA is double stranded. The mature miRNA can result from either of these strands. 
The two strands of miRNA are termed 5p, produced from the 5’ strand and 3p, produced 
from the 3’ strand (Ha and Kim 2014). This form of naming is used when it is not possible 
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to determine which sequence is the predominant one. In some instances, one of the 
strands is prevalently expressed over the other. In this instance the mature miRNA 
produced from the less commonly expressed strand is assigned the term * after the 
miRNA number e.g. miR-21* (Ha and Kim 2014). Another adjustment in naming miRNA 
include the addition of a letter after the number, e.g. miR-200a, miR-220b. These letters 
are used to distinguish two miRNA which are almost identical but differ by just one or 
two nucleotides (Ambros et al. 2003). miRNA names can also include a number preceded 
by a dash after the miRNA number, e.g. miR-121-1 and miR-121-2, these mature miRNA 
are identical but originate from different locations in the genome (Lagos-Quintana et al. 
2001).  
 
 
 
Table 1-2. miRNA nomenclature, different forms of miRNA titles 
Nomenclature Meaning 
hsa/mmu/rno – miR-XX 
Mature sequence designated miR-XX (hsa – homo 
sapiens; mmu – mouse; rno – rat) 
miR-XX Refers to miR XX gene 
miR-XX-1; miR-XX-2 
Refers to mature identical sequences that come from 
different genes (i.e. distinct hairpin pre-miRNA loci) 
miR-XXa/b 
Closely related mature sequences (differ at only one or 
two positions) 
miR-XX-5p; miR-XX-3p 
From 5′- and 3′-arms (i.e. two different mature miRNA 
sequences are excised from opposite arms of the same 
precursor). N.B. This will become the new uniform 
nomenclature for the next version of miRBase instead of 
miR*. 
miR-XX* 
“Passenger” strand of the mature miRNA. Usually 
thought to be degraded but in some instances also 
shown to be functional. 
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1.5.5.3. miRNA in cancer 
 
Due to the range of biological functions regulated by miRNA, miRNA have been shown 
to be important in regulating many disease states. As such important regulators of gene 
expression, the involvement of miRNA in cancer has been a topic of a large amount of 
research over the past decade and it has become apparent that miRNA are key in the 
development and progression of cancer. miRNA influence many cancers related 
processes, such as proliferation, cell cycle control, apoptosis, migration and metabolism. 
In fact, miRNA have been shown to affect all six hallmarks of cancer. The six hallmarks 
of cancer being: 
1. Sustaining proliferative signalling 
2. Evading growth suppressors 
3. Tissue invasion and metastasis 
4. Limitless replicative potential 
5. Inducing angiogenesis 
6. Evading apoptosis 
As a single miRNA can target hundreds of mRNAs, altered expression of a miRNA can 
have a vast affect. This may cause a range of genes to be silenced therefore allowing 
miRNA to majorly influence a condition such as cancer. This has been established by the 
observation of wide dysregulation of miRNA across various cancers. Further evidence of 
the importance of miRNA in cancer is found in that approximately 50% of the annotated 
miRNA are found to be in fragile chromosomal sites (sites that are deleted, amplified, 
translocated) or cancer-associated loci in the genome (Calin et al. 2004).  
 
miRNA in cancer can be considered oncogenic or tumour suppressive in cancer 
(Baumann and Winkler 2014). Oncogenic miRNA are upregulated and therefore silence, 
tumour suppressor genes allowing further progress of the cancer. miRNA with 
upregulated expression in cancer i.e. oncogenes, include miR-21 and miR-155 (Farazi et 
al. 2011). miRNA targeting oncogenic genes are considered tumour suppressive as they 
inhibit the translation of an oncogenic target. Tumour suppressor miRNA i.e. miRNA with 
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downregulated expression in cancer include miR-10b, miR-125b and miR-145 (Farazi et 
al. 2011). Interestingly however, in the majority of cases miRNA expression is supressed 
in cancer cells and tissues in comparison to normal cells and tissue, meaning that in the 
presence of cancer, tumour suppressive miRNA are usually downregulated allowing the 
oncogene to be translated and expressed (Volinia et al. 2006, Lu et al. 2005). This is 
unsurprising due to the important roles miRNA play in maintaining homeostasis of the 
organism. This global downregulation may indicate the miRNA bioprocessing machinery 
to be inhibited in malignancy formation. Convincing evidence of this has been shown, 
genetic deletion of the miRNA processing machinery e.g. DICER, resulted in cell 
transformation and tumourigenesis in vivo (Lambertz et al. 2010, Kumar et al. 2009). 
Downregulated expression of the machinery members Dicer and Drosha has been 
observed in a wide range of cancer types (Allegra et al. 2014, Guo et al. 2012, Dedes et 
al. 2011, Torres et al. 2011). This lowered expression has also been associated with 
advanced stage and poor clinical outcome. Downregulation of miRNA can occur due to 
several mechanisms such as deletion of the genomic region which encodes the miRNA, 
genetic mutation, epigenetic silencing or alterations to the miRNA processing 
machinery. The downregulation of miRNA can be a causative step in the development 
of cancer, these tumour suppressor miRNA once inhibited allow oncogenes to be 
expressed and aberrant control of cellular processes to occur.  
 
However, it is important not to classify any specific miRNA as either oncogenic or tumour 
suppressive as the miRNA may behave differently in different cancer types. The genetic 
diversity of tumours and cancer cell lines means an upregulated and therefore 
considered an oncogenic miRNA in one cancer may be downregulated and considered 
tumour suppressive in another. For example, miR-26a is downregulated in 
hepatocellular carcinoma and its reintroduction induces apoptosis, in this instance miR-
26a plays a tumour suppressive role (Kota et al. 2009). However, miR-26a is 
overexpressed in gliomas and non-small cell lung cancer, in NSCLC overexpression of 
miR-26a promotes a metastatic phenotype (Liu et al. 2012, Huse et al. 2009).  
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As well as investigations into the miRNA bioprocessing machinery in malignant 
situations, the role of specific miRNA in a range of cancer types has received a large 
amount of interest and research over the past 15 years since their regulatory function 
was discovered. Among the first miRNA identified to have a functional role in cancer, 
were miR-15 and miR-16. Studies have shown the loci for miR-15 and miR-16 are absent 
in the majority of samples from B cell chronic lymphocytic leukaemia (B-CLL) patients. 
There is a homozygous loss of the 13q14 region which is associated with the deletion of 
miR-15 and miR-16, reported in 68% of B-CLL cases (Calin et al. 2002). The target of these 
miRNA is an anti-apoptotic gene, BCL2. These miRNA act as tumour suppressors to 
negatively regulate the BCL2 gene therefore their deletion leads to overexpression of 
this target which results in uninhibited proliferation of the cancer cells (Lin et al. 2014b). 
Due the large amount of data available regarding the role of miRNA in cancer, Table 1-3 
and Table 1-4 below give an insight into the different roles and targets of specific miRNA 
in different cancers. These tables show the function of miRNA as tumour suppressors 
and oncogenes. 
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Table 1-3. List of tumour suppressor miRNAs, their targets and functions in different 
cancer types (Di Leva, Garofalo and Croce 2014) 
miRNA Tumour/Cell line Target Notes 
miR-
15/16 
Chronic 
lymphocytic 
leukaemia 
BCL2 
miR-15 and miR-16 target BCL2, 
inducing apoptosis in a leukemic 
cell line model 
Colon cancer COX-2 
miR-16 targets COX-2; elevated 
levels of HuR antagonize miR-16 
function 
Fibroblast 
CEBPβ, CDC-25a, 
CCNE1 
Upon cell-cycle re-entry, rapid 
decay of miR-16 alleviates 
repression of target genes, 
allowing proper resumption of 
the cell cycle 
Fibroblast 
VEGF, VEGFR2, 
FGFR1 
miR-16 plays important roles in 
regulating cell-intrinsic 
angiogenic activity of endothelial 
cells 
CAFs FGF2, FGFR1 
Downregulation of miR-15 and 
miR-16 in cancer-associated 
fibroblasts promotes tumour 
growth and progression 
Multiple 
Myeloma 
FGFR1, PI3KCA, 
MDM4, VEGFα 
Deletion of miR-15/16 is 
observed in early stages of 
multiple myeloma 
Breast Cancer WIP1 
miR-16 regulates WIP1 
phosphatase in the DNA-damage 
response and mammary 
tumorigenesis 
Ovarian Cancer BMI-1 
miR-15a and miR-16 target BMI-
1, leading to low proliferation 
and clonal growth 
Lung Cancer 
CCND1, CCND2, 
CCNE1 
Overexpression of miR-15/16 
induces arrest in G1-G0 
Colon Cancer SIRT1 
miR-34 targets SIRT1, leading to 
apoptosis only in the context of 
wild-type p53 
Gastric cancer 
BCL2, NOTCH, 
HMGA2 
miR-34 targets BCL2, NOTCH, 
and HMGA2 
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miR-34 
Fibroblast MYC 
During senescence, miR-34a 
targets MYC and controls a set of 
cell-cycle regulators 
Lung Cancer AXL 
miR-34a and miR-199a/b target 
the AXL receptor; both miRNAs 
are silenced by promoter 
methylation 
Ovarian Cancer MET miR-34 targets MET 
Colon cancer SNAIL1 
A new link was found between 
p53, miR-34, and SNAIL1 in the 
regulation of cancer cell 
epithelial-to-mesenchymal 
transition programs 
Lung Cancer KRAS 
The let-7 family negatively 
regulates let-60/KRAS in 
Caenorhabditis elegans and lung 
tumours 
Burkitt lymphoma MYC 
Dysregulation of let-7 
participates in genesis and 
maintenance of Burkitt 
lymphoma and other MYC-
dysregulated cancers 
Fibroblast CDC-34 
let-7 represses CDC-34, 
stabilizesWEE1 kinase, and 
increases the fraction of cells in 
G2-M in primary fibroblasts 
let-7 
family 
Breast Cancer IL-6 
Inflammation activates a positive 
feedback loop that maintains the 
epigenetic transformed state 
Prostate cancer E2F2, CCND2 
let-7a targets E2F2 and CCND2, 
acting as a tumour suppressor in 
prostate cancer 
Liver cancer BCL-XL 
let-7 targets BCL-XL and 
potentiates sorafenib-induced 
apoptosis 
Breast Cancer ZEB1, ZEB2 
Downregulation of the miR-200 
family may be an important step 
in tumour progression 
Bladder cancer ERRFI-1 
miR-200 restores EGFR 
dependency 
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Nasopharyngeal 
carcinoma 
ZEB1, CTNNB1 
miR-200a inhibits cell growth, 
migration, and invasion 
Pancreatic cancer BMI-1 
ZEB1 links epithelial-to-
mesenchymal transition and 
stemness maintenance by 
suppressing the miR-200 family 
and thereby promotes migration 
Breast Cancer PLCγ1 
miR-200 negatively regulates 
EGF-driven invasion, viability, 
and cell-cycle progression 
Breast Cancer SUZ12 
miR-200b–Suz12–cadherin 
pathway sustains cancer stem 
cell growth and invasiveness 
miR-200 
family 
Lung Cancer FLT1, VEGFR1 
miR-200 suppresses metastasis 
by targeting FLT1 
Breast and 
endometrial 
cancer 
FN1, LEPR, 
NTRK2, 
ARHGAP19 
miR-200c inhibits cell motility 
and anoikis resistance 
Ovarian Cancer p38α 
miR200a-dependent stress 
signature correlates with 
improved survival and response 
to treatment 
 
 
Table 1-4. List of oncogenic miRNAs, their targets and functions in different cancer types 
(Di Leva, Garofalo and Croce 2014) 
miRNA Tumour/Cell line Target Notes 
miR-
17/92 
Colon TSP-1, CTGF 
Upregulated in colonocytes that 
co-express KRAS, c-Myc, and a 
non-functional p53 
Prostate cancer, 
Burkitt 
lymphoma, testis 
carcinoma 
E2F2, E2F3 
Auto-regulatory feedback loop 
exists between E2F factors and 
miR-17/92 
Myc-induced 
lymphoma 
BIM, PTEN 
Transgenic mice have higher 
expression of miR-17/92 in 
lymphocytes 
Lung cancer HIF1α 
Intricate and finely tuned circuit 
involving c-Myc, miR-17/92, and 
HIF1α 
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Cervix tumour 
cell line 
PTPRO 
E2F1 and miR-17/92 control 
PTPRO 
Myeloid cell p63 
miR-92 increases cell proliferation 
by repressing p63 
T cell acute 
lymphoblastic 
leukaemia 
BIM, PTEN, 
PRKAA1, 
PPP2R5e 
Functional genomics reveals a 
repression of regulators of PI3K 
survival signals by miR-19 
Endothelial cell JAK1 
miR-17/92 family provides a 
therapeutic perspective to 
enhance therapeutic angiogenesis 
Breast cancer HBP1 
miR-17/92 family inhibits HBP1 
and regulates invasion by 
activating Wnt/β-catenin 
Ras-induced 
senescent 
fibroblast 
p21WAF1 
miR-17/92 family disrupts 
senescence 
Glioblastoma TGF-ΒII 
miR-17/92 family suppresses TGF-
β, stimulating angiogenesis and 
tumour cell growth 
Prostate cancer 
MnSOD, GPX2, 
TRXR2 
miR-17/92 family suppresses 
tumourigenicity by inhibiting 
mitochondrial antioxidant 
enzymes 
miR-
222/221 
Glioblastoma, 
prostate and 
thyroid 
carcinoma 
p27Kip1 
High miR-222/221 maintains low 
p27Kip1 and stimulates 
proliferation 
Normal fibroblast p57Kip2 
Upregulation initiates S phase 
with growth factor signalling 
pathways that stimulate cell 
proliferation 
Non-small cell 
lung cancer and 
hepatocellular 
carcinoma 
PTEN, TIMP3 
Target PTEN and TIMP3, induce 
TRAIL resistance, and enhance 
cellular migration; MET oncogene 
activates miR-222/221 through 
the c-Jun transcription factor 
Breast cancer FOXO3A 
Target FOXO3A to suppress 
p27Kip1 at a transcriptional level 
Endothelial cell KIT 
miR-222 targets c-Kit, controlling 
the ability of endothelial cells to 
form new capillaries 
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Breast cancer ESR1 
Modulation of ERαis associated 
with anti-estrogen therapy 
Glioblastoma PUMA 
Directly regulate apoptosis by 
targeting PUMA 
Breast cancer TRSP1 
Promote epithelial-to-
mesenchymal transition, 
contributing to the more 
aggressive clinical behaviour of 
basal-like breast cancers 
Glioblastoma PTPµ 
Target PTPμ and regulate 
glioblastoma tumorigenesis 
Breast cancer DICER 
Repress DICER in ERα-negative 
breast cancers 
Non-small cell 
lung cancer 
APAF1 
Activated by EGFR and MET; by 
targeting APAF1, responsible for 
gefitinib resistance 
miR-21 
Cholangiocarcinoma PTEN 
Modulates gemcitabine-induced 
apoptosis by PTEN-dependent 
activation of PI3K 
Breast cancer 
TPM1 
Suppression inhibits tumour 
growth 
PDCD4 
Suppresses PDCD4 to control 
apoptosis 
Glioblastoma 
RECK, TIMP3 
Inhibition provides a novel 
therapeutic approach for 
physiological modulation of 
multiple proteins whose 
expression is deregulated in 
cancer 
p63, JMY, 
TOPORS, 
TP53BP2, DAXX, 
HNRPK, TGF-
βRII 
Targets multiple important 
components of p53, TGF-β, and 
mitochondrial apoptosis tumour-
suppressive pathways 
Prostate cancer MARKS 
Promotes apoptosis resistance, 
motility, and invasion 
Breast cancer SOCS1 
May serve as a bridge between 
inflammation and cancer 
miR-155 
Acute Myeloid 
Leukaemia 
CEBPB, PU.1, 
CUTL1, PICALM 
Contributes to physiological 
granulocyte/macrophage 
49 
 
expansion during inflammation 
and to certain pathological 
features associated with acute 
myeloid leukaemia 
Lymphocyte C-MAF 
BIC/miR-155 plays a key role in the 
homeostasis and function of the 
immune system 
Diffuse large B 
cell lymphoma 
HGAL 
Cell dissemination and 
aggressiveness are a phenotype of 
diffuse large B cell lymphoma, 
typically with high levels of miR-
155 expression and no HGAL 
expression 
Nasopharyngeal 
carcinoma 
JMJD1A 
LMP1 and LMP2A activate miR-
155 to repress JMJD1A 
Breast cancer WEE1 
Targets WEE1 and enhances 
mutation rates by decreasing the 
efficiency of DNA safeguard 
mechanisms 
Pancreatic cancer TP53INP1 - 
Breast cancer FOXO3A 
Molecular links between miR-155 
and FOXO3A affect cell survival 
and response to chemotherapy 
Colon cancer 
hMSH2, 
hMSH6, hMLH1 
Inactivates mismatch repair 
 
 
1.5.5.4. miRNA in Pancreatic Cancer 
 
Despite an influx of research in pancreatic cancer in recent years very little progress has 
been made and the development of new, more effective therapies is needed. One such 
area which shows promise for these new developments is the area of miRNA in 
pancreatic cancer. Investigations of miRNA in pancreatic cancer have covered several 
topics from large studies aiming to profile pancreatic cancer through both cell lines and 
tumour samples, to studies of miRNA as biomarkers and the therapeutic potential of 
miRNA. 
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Many studies have investigated the impact miRNA have on pancreatic cancer, with some 
miRNA being involved in progression of the disease, some inhibiting its development or 
treatment, among many other cellular functions. Below in Table 1-5 and Table 1-6 is a 
summary of a range of findings about the role of miRNA in pancreatic cancer. These 
tables give a glimpse into what is already known about miRNA in pancreatic cancer. The 
therapeutic potential of miRNA in pancreatic cancer is vast. Considering the fact that 
each miRNA can target hundreds of mRNA transcripts, targeting a single miRNA using 
RNAi can yield dramatic results.  
 
 
Table 1-5. List of oncogenic i.e. upregulated miRNA in pancreatic cancer 
miRNA Impact Target Reference 
miR-10a 
↑ invasive/metastatic 
behaviour 
HOXA1, HOXB1, 
HOXB3 
(Weiss et al. 2009) 
miR-21 
↑ proliferation 
↑ drug resistance 
PTEN 
(Song et al. 2013, Wei 
et al. 2016) 
miR-155 ↓ apoptosis TP53INP1 (Seux et al. 2011) 
miR-192 ↑ cell cycle progression 
SIP1 and cell 
cycle regulatory 
genes 
(Zhao et al. 2013) 
miR-208 ↑ EMT E-cadherin (Liu et al. 2014) 
miR-221 ↑ EMT TRPS1 
(Sarkar et al. 2013, Su 
et al. 2013) 
miR-424-5p ↑ proliferation and invasion SOCS6 (Wu et al. 2013) 
List of oncogenic i.e. upregulated (red indicates upregulation) miRNA in pancreatic cancer, the impact this 
expression has on cellular processes and the targets affected. 
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Table 1-6. List of tumour suppressor i.e. downregulated miRNA in pancreatic cancer 
miRNA Impact Target Reference 
miR-34a 
↑ cell cycle progression and 
angiogenesis 
↓ apoptosis and DNA repair 
P53 
(Chang et al. 
2007) 
miR-124 
↑ proliferation, invasion and 
metastasis 
RAC1 (Wang et al. 2014) 
miR-126, 
let-7d 
↑ proliferation KRAS (Jiao et al. 2012) 
miR-143 
↑ growth, invasive and 
migration 
GEF1, GEF2, 
KRAS 
(Hu et al. 2012) 
miR-146a ↑ invasive EGFR (Ali et al. 2014) 
miR-200 
family 
↑ EMT ZEB1 
(Lu et al. 2014, 
Burk et al. 2008) 
miR-203 
↑ EMT, cell cycle progression 
↓ apoptosis 
BIRC5 (Survivin), 
CAV1 
(Xu et al. 2013, 
Miao et al. 2014) 
List of tumour suppressor i.e. downregulated (green indicates downregulation) miRNA in pancreatic 
cancer, the impact this expression has on cellular processes and the targets affected. 
 
1.5.5.5. RNAi 
 
There are several methods to alter miRNA expression in cell culture. These methods can 
be used to induce over expression of the target miRNA or reduce expression of the 
target miRNA. The change in expression can be transient, meaning a short-term change 
or stable, meaning a permanent, long lasting effect. A schematic of the four methods 
used in this project and summarised below is shown in Figure 1-13. 
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Figure 1-13. Schematic of RNAi methods used to alter miRNA levels 
 
Schematic of RNAi methods used to alter miRNA levels. A) Pre-miR technology induces transient 
overexpression of the target miRNA and inhibits translation of the target mRNA. B) Anti-miR technology 
binds the target miRNA, transiently inhibiting its function and allowing translation of the target mRNA. C) 
miRNA overexpression vectors induce stable overexpression of the target miRNA and translation 
inhibition of the target mRNA. D) miRNA sponges bind the target miRNA at multiple sites, stably inhibiting 
its function and allowing translation of the target mRNA (Ruberti, Barbato and Cogoni 2012). 
 
Transient transfections of cells are with either Pre-miRs or Anti-miRs for a target miRNA. 
These tools are synthetic oligonucleotides, used to alter the level of expression of the 
chosen miRNA to then allow for assessment of phenotypic changes. These tools do not 
alter the miRNA expression or stability, rather they intervene by increasing (Pre-miR) or 
preventing (Anti-miR) the translational repression of the target mRNA by the specific 
miRNA. Pre-miR or mimic miRNA are used to restore miRNA levels to induce a loss of 
function (Bader et al. 2011). Pre-miR technology is used to increase the level of the 
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target miRNA in the cell, i.e. they act in the same way as endogenous miRNA resulting 
in the translation of the target mRNA being repressed therefore reducing expression, 
shown in Figure 1-13. However, they are structurally different in that they are double 
stranded 22 nucleotide duplexes, double stranded duplexes were shown to be 100-1000 
fold more effective than single stranded (Martinez et al. 2002). They are structured and 
act in a similar fashion to siRNA in that the guide stand is loaded into the RISC complex 
to inhibit translation. Pre-miR molecules have, at the 5’ end, a partial complementary 
motif to the 3’UTR of the target mRNA (Robertson, Amand and Vermeulen). As 
previously stated mRNA transcripts share common sequences in their 3’UTRs which 
allows them to be regulated by the same miRNA. Due to this Pre-miRs are designed to 
be partially complementary to a unique motif in the 3’UTR of the target mRNA this 
should ensure a gene-specific action (Zhang et al. 2013). Pre-miRs have potential as 
therapeutic tools in cancer, as previously stated miRNA expression is overall 
downregulated in cancer (Lu et al. 2005). miRNA downregulated in cancer are 
considered tumour suppressor miRNA and target oncogenes. The overexpression of 
oncogenes induced by decreased expression of tumour suppressor miRNA contributes 
to the development and progression of the cancer. Pre-miRs can be used to restore 
expression of the tumour suppressor miRNA therefore inhibit the expression of these 
oncogenes and possibly reduce the cancer progression. A Pre-miR known as MRX34 
entered clinical testing in 2013. miR-34a, a tumour suppressor, has little to no expression 
across a variety of cancers including lung, breast, liver and colon. This miRNA is involved 
in the p53 and Wnt/β-catenin pathways and restoration of its expression through Pre-
miR transient transfection has been shown to inhibit tumour growth and progression 
(Liu et al. 2011). Unfortunately, as of September 2016, this clinical trial was halted due 
to immune related adverse effects. Pre-miR technology shows huge promise especially 
as an insight into the role of specific miRNA in cancer but to translate this technology to 
the clinic has yet to be achieved. 
 
An anti-miR is an antagonistic oligonucleotide which acts to inhibit the action of 
endogenous miRNA by intercepting, binding and degrading the target miRNA therefore 
allowing expression of the target mRNA, allowing for a gain of function (Baumann and 
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Winkler 2014). These are single stranded antisense-like molecules which bind efficiently 
to the target miRNA inhibiting their ability to function as translation inhibitors, displayed 
in Figure 1-13. Anti-miRs are fully complementary to the target miRNA and function by 
either possessing a higher binding affinity to the target miRNA then the complementary 
mRNA sequence or are present in greater abundance than the mRNA target (Kasinski 
and Slack 2012). Anti-miRs are considered a more favourable tool to use than Pre-miRs 
for several reasons. One being that it is not necessary to find a gene-specific sequence 
in the 3’UTR as there is when using Pre-miRs as the Anti-miR is designed to be specific 
to the miRNA of choice (Krützfeldt et al. 2005). Another advantage Anti-miRs have over 
Pre-miRs is their pharmacokinetic properties. These properties consist of chemical 
modifications which grant a greater stability to Anti-miRs against degradation and rapid 
elimination (Pai et al. 2013). Studies have shown that using anti-miR technology it is 
possible to reduce miRNA level to virtually zero. Since the invention of the technology 
in 2004, ~90% of publications investigating the effects of miRNA loss of functions studies 
have used this technology in some form. A disadvantage of Anti-miRs is that while they 
are miRNA specific they are not gene specific meaning that when the miRNA is inhibited 
and gene expression increases, the expression of multiple genes may increase. This is 
due to the fact that one miRNA can target multiple mRNA transcripts so if a phenotype 
is observed it may be due to the increased expression of multiple protein-coding genes. 
It is also important to be aware that while Anti-miRs are designed to be specific there 
may be cross-reactivity amongst families of miRNA, meaning miRNA that have similar 
sequences.  With families of closely sequenced related miRNA non-specific effects may 
be present. The use of anti-miRs in vivo has been attempted such as miR-122 in mouse 
liver. In this case a relatively high dose (80mg/kg) was required to illicit downregulated 
expression, this led to it being unsuitable for therapeutic applications (Thakral and 
Ghoshal 2015).  
 
Another potential therapeutic agent for cancer is a plasmid miRNA vector, which aims 
to achieve efficient and long-term gene silencing. These vectors overcome some of the 
disadvantages of transient transfections specifically the short half-life. Plasmid vectors 
once introduced induce a virtually permanent change in expression as the plasmid stably 
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integrates into the host genome. This technology has long been used to alter gene 
expression but in more recent times has been utilised to alter miRNA expression. Once 
inserted these vectors act to produce the mature target miRNA therefore increasing the 
levels of endogenous miRNA and inhibiting translation of the target mRNA, seen in 
Figure 1-13. Post transfection the cells undergo a selection process; this involves 
exposing the cells to an antibiotic. The resistance gene for the selection marker is 
included into the plasmid vector therefore successfully transfected cells can survive the 
antibiotic treatment. This aims to remove untransfected cells from the cell population, 
thus allowing for a greater examination of functional changes due to the miRNA 
expression alteration. A reporter gene, such as Green Fluorescent Protein (GFP), can be 
included in the vector to allow for identification of cells containing the plasmid. The 
vectors used in this project consist of short hairpin RNA (shRNA) sequences using an RNA 
Pol II promoter to reduce expression of the target mRNA (Rossi 2008). shRNA, which 
consists of short inverted repeats linked by small loop sequences are processed into 19-
22nt sequences and act in a similar fashion to siRNA to suppress target mRNA expression 
(Xu et al. 2009). However, using plasmid vectors for miRNA overexpression can lead to 
the processing machinery, for example, exportin 5 and RISC becoming saturated, then 
affecting the processing of endogenous miRNA in the cell i.e. potential side effects of 
inhibiting unrelated endogenous miRNA functions (Yi et al. 2005, Zeng, Wagner and 
Cullen 2002). The vectors in this project are inducible vectors, meaning that the action 
of the vector can be controlled to a certain extent. The transcription of the vector is 
controlled through treatment with an inducement agent. Whether a sponge or 
overexpression vector, the alteration of the miRNA expression level does not occur until 
the inducer is added. Doxycycline Hyclate is the inducer for the vectors used. This is an 
antibiotic which activates transcription of the sponge/overexpression miRNA.  
 
miRNA sponges or decoys are plasmid constructs used to inhibit miRNA function by 
preventing binding of the miRNA to their mRNA targets. These plasmids are longer DNA 
structures which contain multiple miRNA binding sites for a specific miRNA (Ebert and 
Sharp 2010). This miRNA will then be sequestered by the sponge inhibiting it from 
functioning to silence gene expression, shown in Figure 1-13. This technology was 
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developed by Sharp’s laboratory and published in 2007 in “MicroRNA sponges: 
competitive inhibitors of small RNAs in mammalian cells” by Ebert et al., A typical sponge 
construct consists of an RNA Pol II promoter (Pol III is sometimes used) containing a 
reporter gene and multiple tandem miRNA binding sites in the 3’UTR (Ebert, Neilson and 
Sharp 2007). The miRNA multiple binding sites, typically four to ten sites, are present in 
the 3’UTR of the reporter gene. When the mRNA for this reporter gene is transcribed so 
is the miRNA sponge (Jung et al. 2015). Sponge vectors, in the same way as 
overexpression vectors, require a selection process to remove untransfected cells from 
the population. miRNA sponges are not fully complementary for the target miRNA. They 
contain a mismatch in the seed region, specifically at positions 9-12 which creates a 
bulge when the sponge is bound to its target. This bulge functions to inhibit cleavage 
and degradation of the sponge by Argonaute 2 through endonucleolytic cleavage (Ebert, 
Neilson and Sharp 2007).  This cleavage is inhibited as the bulge is positioned at the site 
normally cleaved by Argonaute 2 (Ebert, Neilson and Sharp 2007). Inhibition of this 
cleavage impedes quick turnover of the sponge allowing a longer time of inhibition of 
the target miRNA through sequestering. Sponges are similar to anti-miRs in that they 
are antisense, base-pair to their target miRNA and that the transcripts are present in a 
higher abundance than the target mRNA allowing them to bind the majority of the 
endogenous miRNA. This results in more of the target mRNA being translated into 
functional protein. miRNA sponges differ from anti-miRs in that they are not fully 
complementary to the target miRNA. Unlike anti-miRs, miRNA sponges do not cause the 
target miRNA to be degraded they only sequester the miRNA and inhibit it from binding 
its target mRNA.   
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1.6. Aims 
 
The aim of this thesis was to investigate the mechanisms of metastasis in breast cancer 
and pancreatic cancer utilising a variety of techniques listed below. 
 
1. Investigate the role of anoikis resistance in the metastatic phenotype of TNBC 
using microarray analysis  
a) Gene expression profiling of two anoikis resistant TNBC cell lines (MDA-
MB-231 and MDA-MB-468) and two anoikis sensitive TNBC cell lines 
(HCC1954 and HS578T).  
b) Identify targets contributing to anoikis resistance 
c) Induce downregulated expression of selected targets 
d) Assess functional changes of this downregulation on metastatic 
phenotypes 
 
2. Investigate the role of the tumour microenvironment in the metastatic 
phenotype of pancreatic cancer 
a) Develop a co-culture model to mimic the tumour microenvironment in 
vitro.  
b) Optimise this model to assess a range of metastatic phenotypes including 
anoikis, invasion, proliferation and colony formation 
c) Assess phenotypic changes in metastatic cellular functions due to co-
culture of PDAC cells with human pancreatic stromal cells 
 
3. Investigate the role of altered miRNA expression in the metastatic phenotype of 
pancreatic cancer 
a) Alter the expression of selected miRNA targets, both transiently and 
stably. 
b) Compare transient and stable alteration of selected miRNA target 
c) Validate if sponge knockdown technology can successful induce 
phenotypic changes in pancreatic cancer 
d) Assess the effect of altered miRNA expression on the metastatic 
phenotypes of pancreatic cancer
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2. Materials and Methods
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2.1. Cell culture 
 
All cell culture work was carried out in a class II laminar air-flow cabinet (Nuaire). The 
laminar was turned on and the air flow was allowed to acclimatize for 15 min before 
use. Both before and after use the laminar air-flow cabinet was cleaned with 70% 
industrial methylated spirits (IMS). Any items brought into the laminar were also 
swabbed down with IMS and regular cleaning of gloved hands with IMS was carried out 
to insure the prevention of contamination. At any time, only one cell line was used in 
the laminar air-flow cabinet and upon completion of work with any given cell line, the 
laminar airflow cabinet was allowed to clear for at least 15 minutes before further use. 
This was to eliminate any possibilities of cross-contamination between the various cell 
lines. The cabinet was cleaned weekly with Virkon (Antech International, P0550) 
followed by water and IMS. Each laminar air-flow cabinet was validated by annual 
inspection by a certified contractor. Details pertaining to the cell lines used in this body 
of work are provided in Table 2-1. All cells were incubated at 37°C and where required, 
in an atmosphere of 5% CO2. Cells were fed with fresh media or sub-cultured (see section 
2.1.3) every 2-3 days or as required in order to maintain active cell growth. Cell lines 
were used within a range of 10 passages from thaw at which point fresh stocks were 
revived, see section 2.1.6. All the cell lines listed in Table 2-1 are anchorage-dependent 
cell line
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2.1.1. Cell Lines 
 
Table 2-1. Cell lines with culture media details as well as histology information 
Cell Line Culture media Histology Source 
MDA-
MB-231 
Leibovitz L-15 media 
supplemented with 10% FBS 
Non-CO2 conditions 
(Gibco 11415064) 
Derived from a pleural effusion of a 
breast adenocarcinoma 
NICB 
MDA-
MB-468 
Leibovitz L-15 media 
supplemented with 10% FBS 
Non-CO2 conditions 
Derived from a pleural effusion of a 
breast adenocarcinoma 
NICB 
HS578T 
DMEM media supplemented 
with 10% FBS and 2mM L-
glutamine (Sigma D5671) 
Derived from a carcinoma of the 
breast. 
NICB 
HCC1954 
RPMI media supplemented 
with 10% FBS (Sigma R8758) 
Derived from a primary stage IIA, 
grade 3 invasive ductal carcinoma with 
no lymph node metastases 
NICB 
DLKP-M 
DMEM:F12 media 
supplemented with 5% FBS 
(D8437) 
Mesenchymal-like subpopulation of 
DLKP, a non-small cell lung cancer 
NICB 
AsPc-1 
RPMI media supplemented 
with 10% FBS 
Derived from nude mouse xenografts 
initiated with cells from an ascites site 
in a patient. Produce abundant mucin. 
NICB 
BxPc-3 
RPMI media supplemented 
with 10% FBS 
Obtained from a patient with cancer 
of the body of the pancreas. No 
metastasis had occurred 
NICB 
Mia 
PaCa-2 
DMEM media supplemented 
with 10% FBS and 2mM L-
glutamine 
Developed from a tumour involving 
the body and tail of the pancreas and 
had infiltrated the periaortic area 
NICB 
Panc-1 
DMEM media supplemented 
with 10% FBS and 2mM L-
glutamine 
Originated from a tumour in the head 
of the pancreas which invaded the 
duodenal wall 
NICB 
Pt-102 
RPMI media supplemented 
with 10% FBS 
Fibroblasts derived from a poorly 
differentiated cholangiocarcinoma 
diagnosed in a 61-year-old Irish male. 
NICB 
Developed 
in-house 
Pt-127 
RPMI media supplemented 
with 10% FBS 
Fibroblasts derived from an invasive, 
moderately differentiated 
adenocarcinoma diagnosed in a 72-
year-old Irish male. 
NICB 
Developed 
in-house 
hPSC24 
RPMI media supplemented 
with 10% FBS 
Pancreatic stellate cells were a kind 
gift from Dr. Atsushi Masamune in 
Tohoku University, Japan and were 
isolated as previously described 
(Bachem et al. 2005) 
Tohoku 
University, 
Japan 
61 
 
The patient tumour derived fibroblasts were developed in house by Dr. Sinéad Aherne. 
Tumour samples, received from St. Vincent’s University Hospital, were enzymatically 
digested using hyaluronidase and collagenase. Following this digestion, the samples 
were then explanted into culture and outgrowth used to develop fibroblasts. As these 
fibroblast cell lines were primary cultures, a high level of confluency in culture was 
always maintained as low cell densities led to a halt in growth. The cells were also used 
within a range of 10 passages from thaw at which point fresh stocks were revived, see 
section 2.1.6, to ensure the cells did not become senescent. While both fibroblast 
primary cell lines were developed in the same way, they have differences. Pt-102 
fibroblasts were derived from a Whipple surgery performed on an Irish male diagnosed 
at 61 years of age. This tumour measured 23mm at the time of surgery and was later 
characterised as a poorly differentiated cholangiocarcinoma.  A cholangiocarcinoma is a 
cancer of the bile duct, patient 102 was diagnosed with a tumour of the distal common 
bile duct. This tumour was staged as T3 N1, meaning the cancer had grown into nearby 
structures such as the gallbladder, duodenum and pancreas, the cancer had also spread 
to the nearby lymph nodes (N1). There is a strong link between cholangiocarcinoma and 
pancreatic cancer as both are cancers of the ducts but also several other links. One being 
that the common bile duct passes through part of the pancreas before joining with the 
pancreatic duct which empties into the duodenum. Also, both conditions have the 
peribiliary glands in common, cholangiocarcinoma of the common bile duct arises in 
these glands and these glands have been shown to be interspersed with pancreatic acini 
(Terada, Nakanuma and Kakita 1990, Cardinale et al. 2012). Table 2-2 summaries the 
similarities between cholangiocarcinoma and pancreatic cancer (Schmuck et al. 2016). 
While pathology analysis of the Pt-102 tumour unexpectantly showed it to be a 
cholangiocarcinoma, these fibroblasts may still have relevance in the pancreatic cancer 
microenvironment shown by the strong relationship between pancreatic cancer and 
cholangiocarcinoma. Pt-127 fibroblasts were derived from a Whipple surgery performed 
on an Irish male diagnosed at 72 years of age. This tumour measured 48mm at time of 
surgery and was later characterised as an invasive, moderately differentiated 
adenocarcinoma. The tumour derived fibroblasts (Pt-102) underwent STR profiling to be 
used as a reference for future STR profiling to determine if any genetic drift is occurring. 
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This STR profile is displayed in . The pancreatic cancer cell lines also underwent STR 
profiling shown in Table 2-4.  
 
Table 2-2. Similarities and differences between cholangiocarcinoma of common bile 
duct and pancreatic cancer (Schmuck et al. 2016) 
 
 
 
 
 
 
 
 
 
 
 Cholangiocarcinoma Pancreatic cancer 
Development 
origin 
Ventral part of forgut forms 
main extrahepatic bile ducts 
Ventral part of forgut forms 
main pancreatic duct 
Tumourigenesis 
Ductal system or periductal 
glands 
Ductal system or periductal 
glands 
Premalignant 
lesion 
Biliary intraepithelial neoplasia 
(BilIN) 
Pancreatic intraepithelial 
neoplasia (PanIN) 
Precursor lesions 
with malignant 
potential 
Intraductal papillary mucinous 
neoplasms (IPMN) 
Intraductal papillary neoplasm 
of the biliary tract (IPNB) 
Molecular 
pattern 
KRAS+, p53+ KRAS+, p53+ 
Phenotype CK20+, MUC1+, S100P+ CK20+, MUC1+, S100P+ 
Surgery 
PPPD/Kausch-Whipple, 
extended hemihepatectomy for 
Klatskin tumours 
PPPD/Kausch-Whipple 
Response to 
Chemotherapy 
5-FU + Gemcitabine + CapOx + 
Gemcitabine + cisplatin + nab-
Paclitaxel 
- Gemcitabine + CapOx + 
Gemcitabine + cisplatin - nab-
Paclitaxel 
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Table 2-3. STR profiling of Pt-102 tumour derived fibroblasts 
  
 
Marker Allele 1 Allele 2 
AMEL X Y 
CSF1PO 12 12 
D13S317 10 12 
D16S539 11 11 
D18S51 10 12 
D21S11 29 29 
D3S1358 15 16 
D5S818 11 11 
D7S820 9 10 
D8S1179 10 14 
FGA 22 24 
Penta D 9 10 
Penta E 7 12 
TH01 6 7 
TPOX 8 11 
vWA 14 18 
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Table 2-4. STR profiling of the pancreatic cancer cell lines 
 
The STR profiling or DNA fingerprinting of the pancreatic cancer cell lines and the Pt-102 tumour derived fibroblasts was carried out by Source 
BioScience UK Limited. The method used looked at STR profiling of 16 polymorphic regions. These markers include those as used by the ATCC 
such as Amelogenin, CSF1PO, D135317 and TH01. Using gene amplification technologies, the genomic DNA was mapped and analysed resulting 
in the genomic fingerprint of each cell line which was then compared to that provided by the ATCC. All cell lines matched perfectly to the ATCC 
profile with the exception of the AsPc-1 cell line which had one deviation in the TH01 marker. ATCC states that the AsPc-1 cell line should have 
one allele of 7 and a second of 9.3 for the TH01 marker but the AsPc-1 cell line used in this body of worked had two alleles of 9.3. As there was 
only one alteration out of 9 markers and it was not extremely different from the ATCC profile this cell line was deemed suitable to use in the 
current research project.
 Amelogenin CSF1PO D13S317 D16S539 D5S818 D7S820 TH01 TPOX vWA 
AsPc-1          
BxPc-3          
Mia PaCa-2          
Panc-1          
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2.1.2. Monitoring of sterility of cell culture solutions  
 
Sterility testing was performed on all cell culture media and related culturing solutions. 
Samples of complete basal media were added to Tryptone Soya Broth and Thioglycollate 
broth and incubated at 37°C for a period of seven days. This ensured that no bacterial 
or fungal contamination was present in the media. 
 
2.1.3. Sub-culturing of adherent cell lines 
 
Spent cell culture medium was removed from the tissue culture flask and discarded into 
a sterile bottle. The flask was then rinsed out with autoclaved/sterile PBS solution in 
order to remove any residual media. Depending on the size of the flask, 2-5mL of trypsin 
solution (0.25% (v/v) of trypsin (Gibco, 043-05090) and 0.01% (v/v) of EDTA (Sigma, 
E9884) solution in PBS) was then added. The flask was incubated at 37°C for the required 
period of time until all cells were detached from the surface of the culture flask. The 
trypsin was deactivated with an equal volume of complete media. The cell suspension 
was removed from the flask and placed into a 30mL sterile universal container and 
centrifuged at 1000 rpm (Thermo Electron Jouan C3i Multifunction centrifuge) for 5 
minutes. The supernatant was discarded from the universal and the pellet was re-
suspended in fresh complete media. A cell count was performed using a 
haemocytometer and an aliquot of cells was then used to re-seed a flask at the required 
cell density with fresh media. All cell waste or media exposed to cells was autoclaved 
before disposal. 
 
2.1.4. Assessment of cell number and viability 
 
Prior to cell counts, cells were prepared by sub-culturing as detailed in section 2.1.3 An 
aliquot of the cell suspension was then added to trypan blue (Gibco, 525) at a ratio of 
1:1 (v/v). The mixture was incubated for 2-3 minutes at room temperature. An aliquot 
(20µL) was then applied to the chamber of a glass coverslip-enclosed haemocytometer. 
Viable cells exclude the Trypan Blue dye as their membranes remain intact and therefore 
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remain unstained while non-viable cells stain blue. For each of the four corner grids of 
the haemocytometer (see Figure 2-1), cells in the 16 squares were counted using an 
inverted light microscope. The average of the four grids was multiplied by a factor of 104 
(Volume of the grid) and the relevant dilution factor to determine the average cell 
number per mL of the cell suspension. Using the data for viable and non-viable cells, 
percentage viability was calculated. 
 
Figure 2-1. Haemocytometer grid layout 
 
 
 
 
2.1.5. Cryopreservation of cells 
 
Cells for cryopreservation were harvested in the mid-log phase of growth and counted 
as described in section 2.1.4. Cells were frozen down at a cell density of 1.5-3.0 x106 
cells/mL depending on the cell size (smaller size, higher cell number). Cell pellets were 
re-suspended in a suitable volume of warm fetal calf serum (FCS) and aliquoted in 500µL 
volumes into cryovials (Greiner, 122278). A solution of fetal calf serum containing 10% 
(v/v) DMSO (Sigma D5879) was prepared, filter sterilised and cooled to 4°C. 500µL of 
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this solution was added in a dropwise fashion to each cell suspension. Cryovials were 
immediately placed in a -20°C freezer overnight and then transferred to a -80°C freezer 
for long term storage. 
 
2.1.6. Thawing of cryopreserved cells 
 
A volume of 5mL of fresh warmed growth media was added to a sterile universal. The 
cryopreserved cells were removed from the -80°C freezer and slightly thawed, rapidly at 
37°C. The cells were removed from the vials and transferred to the aliquoted media 
using a Pasteur pipette. The resulting cell suspension was centrifuged at 1000 rpm for 5 
minutes to remove the toxic DMSO. The supernatant was removed and the pellet re-
suspended in fresh culture medium. Certain cell lines, e.g. BxPc-3, did not respond well 
to centrifugation post thaw, for these cell lines this step was skipped. Thawed cells were 
then added to an appropriately sized tissue culture flask with a suitable volume of 
growth medium and allowed to attach overnight. The following day, flasks were fed with 
fresh media to remove any non-viable cells. 
 
2.1.7. Mycoplasma analysis of cell lines 
 
Mycoplasma testing was carried out quarterly for all cell lines for possible Mycoplasma 
contamination in house by a technician at the NICB, according to the SOP 007-01 using 
the in-direct test. All cell lines are found to be Mycoplasma free. 
 
2.2. Anoikis Assay Optimisation 
 
The anoikis assay previously used and the method which most often published involves 
coating tissue culture plates with polyhema (Frisch and Francis 1994). Polyhema (Sigma 
P3932) is a polymer that forms a hydrogel which inhibits cell attachment, therefore 
coating plates with polyhema causes the cells to be in suspension. A concentration of 
20mg/mL was used and dissolved in 95% ethanol overnight at 50°C (Yu et al. 2013). A 
volume of 200µL was used to coat a well in a 24 well plate and allowed to dry at room 
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temperature overnight (Chunhacha, Sriuranpong and Chanvorachote 2013). Once dried 
a second coating of 200µL was added and allowed to dry. The control used was non-
coated wells on a tissue culture plate i.e. the cells attach and grow as a monolayer. When 
all coatings had dried 1x105 cells were seeded and incubated for 24hr. The metabolic 
activity was then assessed using a dye, Alamar blue, which measures metabolic activity. 
The levels of activity between the control (attached) and coated (suspension) wells were 
then compared allowing the level of anoikis in the suspension wells to be calculated.  
 
Unfortunately, a successful smooth coating was rarely achieved using this method. The 
coatings appeared cloudy instead of clear and cells were able to attach to them in some 
instances. Sigma Aldrich, the company which produce the polyhema were first 
contacted to report the problems incurred. Sigma provided a new protocol which the 
company uses for quality control (QC) of the polyhema product. This method dissolved 
the polyhema (120mg/mL) in 95% isopropanol as opposed to the ethanol used in other 
methods. The QC protocol also dissolved the polyhema at a lower temperature, 37°C 
overnight, instead of the 50°C previously used. Both of these new conditions were used 
in the further steps to optimise the assay. Many different conditions were then 
investigated in an attempt to achieve a clear coating. These conditions included: 
• A range of polyhema concentrations (10, 12.5, 20, 120mg/mL) 
• A range of drying conditions (in the incubator, laminar, air tight container) 
• Varied number/volume of polyhema coatings (1-2 coats, volumes of 200/400uL) 
Taking all these conditions into account the most consistent coatings within a 
reasonable drying time was two coatings of 200µL of polyhema dried in its original 
packet in the press. 20mg/mL was chosen as the optimal concentration as it achieved a 
clear coating and the cost and usage of polyhema was taken into account. The plates 
required 48hr to dry with the second coat being added on the second day. Using these 
new optimum conditions, smooth coatings were achieved and the anoikis assay was 
successfully carried through until completion, although a small number of cells (≤5%) 
still attached to the coating, a problem observed from all coating methods investigated. 
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Following determination of the optimum coating conditions the reproducibility of the 
assay was investigated. To determine this, the cell line DLKP-M which was anoikis 
sensitive was used. This cell line was chosen as it displays a moderate level of anoikis of 
50% (Keenan et al. 2012). The next step was to optimise the assay using the two TNBC 
cell lines, MDA-MB-231 and MDA-MB-468. Minor optimisation had to be completed on 
the cell number used to ensure that optimal cell confluency at the end of the assay was 
achieved. Following this optimisation in cell number, replicate anoikis assays were 
performed and it was determined the assay was not reproducible as there was a large 
amount of variability present between biological replicates. This optimised assay could 
not be used due to large variability, therefore a new technique to assess anoikis was 
required. This led to the purchase of Corning® Costar® Ultra-Low attachment multiwall 
plates. These plates offered much less variability due to the consistency of the coatings 
and the results from each cell line showed consistent levels of anoikis. Therefore, going 
forward these plates were used as opposed to using Polyhema coated plates to induce 
anoikis.  
 
2.3. Anoikis Assay 
 
For this assay two types of 24 well plates were required. One a regular tissue culture 
plate which acted as the control as the cells attached and the other a Corning® Costar® 
Ultra-Low attachment plate (Sigma CLS3473) which induced suspension conditions. The 
cells were trypsinised and counted according to sections 2.1.3 and 2.1.4. A 1mL volume 
of cell suspension at a concentration of 1x105 cells/mL was added to each plate 
(attachment & suspension). The plates were then incubated for 24 hours at the 
appropriate culture conditions for each cell line.  Four hours prior to the end of the 
assay, 100µL (1/10th volume of media in the well) Alamar Blue (LifeTech DAL1100), an 
indicator dye was added.  Cells in suspension were mixed at this point to break up 
clumps. At the 24hr time point, the colour development was measured on a Bio-Tec 
plate reader at 570nm with reference wavelength of 600nm.  Before reading the wells 
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were mixed thoroughly to ensure break up of clumps as these clumps cause variation 
between wells.  
 
Alamar blue is a cellular health indicator that uses the natural reducing power of living 
cells to convert resazurin to the fluorescent resorufin (O'Brien et al. 2000). It 
incorporates a fluorometric/colorimetric growth indicator based on detection of 
metabolic activity. Alamar blue specifically incorporates a REDOX indictor that both 
fluoresces and changes colour in response to chemical reduction of the growth medium 
resulting from cell growth (Lancaster and Fields 1996). The innate metabolic activity of 
viable, growing cells induces a chemical reduction of the Alamar blue, while a lack of 
growth i.e. a lack of metabolism, maintains the oxidised environment. The oxidised form 
of the REDOX indicator is a non-fluorescent, blue, the metabolic change of the Alamar 
blue induces a reduced, fluorescent, red form (Lancaster and Fields 1996). Using a 
microtiter plate reader, these absorbance (570 and 600nm) or fluorescent (excitation 
530-560nm, emission 590nm) readings are quantitative of the cellular activity of the 
cells (Rampersad 2012). The amount of fluorescence or absorbance is proportional to 
the number of living cells and corresponds to the cells metabolic activity (Al-Nasiry et al. 
2007).  In relation to the above anoikis assay, Alamar blue was used as an indicator of 
cellular health through metabolic rate. Cells undergoing anoikis displayed a reduced 
metabolic rate and therefore induced less reduction of the Alamar blue resulting in little 
to no colour change. This lack of colour change was detected by the microtiter plate 
reader and expressed as a percentage survival. This survival was calculated using the 
control sample in attached conditions as a comparison, meaning the control in attached 
conditions was expressed as 100% survival with everything else relative to this. 
Therefore, samples which reduced the Alamar blue to a greater or lesser extent than the 
control were displayed as having a greater or lesser percentage survival. 
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2.4. Microarray Profiling 
 
All microarray profiling was performed in-house by Dr. Sinéad Aherne. 
 
2.4.1. Microarray GeneChip® Human Gene 1.0 ST Array processing and hybridization 
 
This microarray featured 28,869 well-annotated genes with 764,885 distinct probes. 
Preparation of cRNA, hybridization, and scanning of microarrays was performed 
according to the manufacturer’s protocol (Affymetrix). In brief, 300ng of total RNA was 
converted into double-stranded cDNA by reverse transcription. Biotin-labelled cRNA 
was generated by converting the cDNA sample using the Genechip WT plus reagent kit 
(Affymetrix). Labelled cRNA was hybridized to the Affymetrix GeneChip® Human Gene 
1.0 ST Array while rotating at 60 rpm for 16 hours at 45°C. After hybridization, the 
microarray was washed using the Affymetrix Fluidics Station according to the 
manufacturer’s protocol. The chips were scanned in an Affymetrix 3000 7G scanner. 
 
2.4.2. Microarray miRNA 3.0 processing and hybridization 
 
The GeneChip® miRNA 3.0 Array was a single array comprised of 179,217 probes that 
represent 19,913 mature microRNA. The Flash Tag Biotin HSR kit (Affymetrix) was used 
according to manufacturer’s protocol to label the miRNA. In brief, the process started 
with total RNA containing low molecular weight RNA and the procedure began with a 
brief tailing reaction followed by ligation of the biotinylated signal molecule to the target 
RNA sample. The labelled sample was then hybridized to the Affymetrix miRNA 
GeneChip while rotating at 60 rpm for 16 hours at 48°C. After hybridization, the 
microarray was washed using the Affymetrix Fluidics Station according to the 
manufacturer’s protocol. The chips were scanned in an Affymetrix 3000 7G scanner. 
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2.5. Western Blotting 
 
2.5.1. Whole cell extract preparation 
 
Cells were grown to 80-90% confluency, spent cell culture medium was removed from 
the tissue culture plate/flask and cells were washed twice with PBS in order to remove 
any residual media. All procedures from this point forward were performed on ice. Cells 
were lysed in 100-200µL of NP-40 lysis buffer and incubated on ice for 30 minutes with 
regular agitation, to ensure complete cell lysis of the cell culture monolayer by the lysis 
buffer. Table 2-5 below provides the details of the NP-40 lysis buffer.  
 
Table 2-5. NP-40 Lysis Buffer Recipe  
Component Volume (µL) 
DTT 100mM 10 
PMSF 100mM 10 
Protease Inhibitors 25x 40 
NP-40 Lysis Buffer 940 
Total 1000 
 
After incubation on ice, lysates were transferred to a microcentrifuge tube and 
centrifuged on a bench centrifuge at 14000 rpm for 15 minutes at 4°C. Supernatant 
containing extracted protein was transferred to a fresh chilled microcentrifuge tube. 
Protein concentration was quantified using the Biorad assay as detailed in section 2.5.2. 
Samples were then stored in aliquots at -80°C. 
 
2.5.2. Protein Quantification 
 
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500-0006) 
as follows. A 2mg/mL bovine serum albumin (BSA) solution (Sigma, A9543) was prepared 
fresh in lysis buffer. A protein standard curve (0, 0.2, 0.4, 0.6, 0.8 and 1.0 mg/mL) was 
prepared from the BSA stock with dilutions made in lysis buffer. The Bio-Rad reagent 
was diluted 1:5 in UHP water. A 20µL volume of protein standard dilution or sample 
73 
 
(diluted 1:10) was added to 980µL of diluted dye reagent and the mixture vortexed. 
After 5 minutes’ incubation, absorbance was assessed at 570nm on the BioTek plate 
reader. The concentration of the protein samples was determined from the plot of the 
absorbance at 570nm versus concentration of the protein standard. 
 
2.5.3. Immunoblotting 
 
Protein (30μg) was electrophoretically resolved on 4-12% Bolt™ Bis-Tris Plus (Invitrogen 
NW04120BOX) denaturing polyacrylamine gels. The resolved proteins were then 
transferred to nitrocellulose membranes (Invitrogen, IB3010-01) using the iBlot® 2 
transfer system (Invitrogen, IB21001). Protein transfer was visually confirmed using 
Ponceau S staining (Sigma, P7170). Membranes were blocked with 2.5% skimmed milk 
powder in PBS and incubated overnight at 4°C with primary antibodies, listed in Table 
2-6. Membranes were washed with 0.1% PBS-tween 3 times for 10 minutes each, both 
prior to and following incubation with secondary antibodies, listed in Table 2-6. 
Following the final washing, the membranes were exposed to ECL Prime reagent (GE 
Healthcare, RPN 2232) in the dark room and the membrane was exposed to 
autoradiographic film (Kodak,) for various times (from 10 seconds to 30 minutes 
depending on the signal). The exposed autoradiographic film was developed for 3 
minutes in developer (Kodak, LX-24). They were then washed in water and transferred 
to fixative (Kodak FX-40) for 5 minutes. The film was then washed with water and 
allowed to dry at room temperature. 
 
Table 2-6. Details of Primary and Secondary antibodies. 
Antibody Dilution Cat. No. 
Purified Mouse Anti-BiP/GRP78 1:1000 BD Biosciences (610978) 
Rabbit Anti-Podoplanin/GP36 1:1000 Abcam (ab128994) 
Goat Anti-Mouse HRP 1:3000 Bio-Rad (170-6516) 
Goat Anti-Rabbit HRP 1:3000 Bio-Rad (170-6516) 
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2.6. Transfection 
 
2.6.1. siRNA Transfection Optimisation 
 
Before beginning alteration of expression of target genes it was necessary to determine 
the optimum transfection conditions for both triple negative breast cancer cell lines. 
GAPDH was chosen as a positive control and as the gene to use for the optimisation 
process as it is expressed at a relatively constant level in both the TNBC cell lines.  
The efficiency of each transfection was determined using q-RT-PCR to assess the 
expression of GAPDH post transfection using B2M as an endogenous control. The 
transfection parameters optimised included: 
• Transfection direction i.e. forward or reverse transfection 
• Cell number 
• Transfection reagent 
• Concentration of transfection reagent 
• siRNA concentration 
The optimisation of transfecting MDA-MB-231 and MDA-MB-468 has shown the optimal 
conditions to result in sufficient gene knockdown while maintaining cell viability to be 
the following:  
• Reverse transfection 
• Cell number of 1 x 105/mL 
• Lipofectamine® 2000 as the transfection reagent 
• Lipofectamine® 2000 at a concentration of 1ul per well in a 24 well plate 
• siRNA at a concentration of 3nM per well in a 24 well plate 
 
2.6.2. siRNA Transfection Protocol - 24 well plate format 
 
Lipofectamine® 2000 (Invitrogen 11668027) and Opti-MEM® (Gibco 31985062) were 
brought to room temperature before use. Lipofectmine® 2000 was diluted to the 
optimum concentration (1µL/well) using Opti-MEM® with a total volume of 50µL per 
75 
 
well in a 24 well plate. This was incubated for 5min at room temperature. siRNA 
(Ambion) were diluted to the optimum concentration previously determined, using 
Opti-MEM® with a total volume of 50µL per well. siRNA used are detailed in Table 2-7. 
This was incubated for 5min at room temperature. Next 50µL of the Lipofectamine® 
2000 dilution was mixed with the 50µL of siRNA dilution and incubated for 20min at 
room temperature. In each transfection, an untransfected control and negative control 
were included. As an untransfected control 100µL of Opti-MEM® was added to a well in 
place of siRNA/Lipofectamine® solution. A negative control was also included. This 
negative control was Silencer® Select Negative Control No. 2 (Ambion 4390846) and is 
an siRNA sequence which does not target any known gene. According to the 
manufacturer, these negative control siRNA are carefully designed and extensively 
tested to have no significant sequence similarity to mouse, rat or human. Testing has 
also shown that these negative controls have minimal effect on global gene expression 
and no significant effect on cell proliferation, viability or morphology. This negative 
control was transfected at the same concentration as the target being transfected in 
order to represent a true negative control. After 20min incubation at room temperature, 
100µL of each siRNA/Lipofectamine® solution was added to a well in a 24 well plate. A 
cell concentration of 1x105/mL was used with 500µL of this cell suspension added on 
top of the 100µL siRNA/Lipofectamine® 2000 solution or Opti-MEM® control. The cells 
were then incubated for 48hr. 
 
Table 2-7. Details of Ambion® Silencer® Select siRNA used through transfection 
siRNA Ambion® Cat. No. 
Silencer® Select GAPDH Positive Control 4390849 
Silencer® Select Negative Control No. 2 4390846 
Silencer® Select GRP78 siRNA 4392420 – s6979 
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2.6.3. Pre/Anti-miR Transfection Protocol 
 
Lipofectamine® 2000 and Opti-MEM® were brought to room temperature before use. 
Lipofectmine® 2000 was diluted to the optimum concentration (3µL/well) using Opti-
MEM® with a total volume of 150µL per well in a 6 well plate. This was incubated for 
5min at room temperature. Pre/Anti-miR was diluted to the 25nM per well using Opti-
MEM® with a total volume of 150µL per well. This was incubated for 5min at room 
temperature. Pre-miRs and Anti-miRs used are detailed in Table 2-8. Next the 150µL of 
Lipofectamine® 2000 dilution was mixed with the 150µL of Pre/Anti-miR dilution and 
incubated for 20min at room temperature. In each transfection, an untransfected 
control and negative control were included. As an untransfected control 300µL of Opti-
MEM® was added to a well in place of Pre/Anti-miR /Lipofectamine® solution. The 
negative controls were Anti-miR miRNA Inhibitor Negative Control #1 (AM17010) and 
Pre-miR miRNA Precursor Negative Control #1 (AM17110). According to the 
manufacturer, the Anti-miR negative control is a random sequence, designed in the 
same way as Anti-miRs which specifically bind to and inhibit endogenous miRNA, except 
the negative control has been extensively validated to have no effects on known miRNA 
function.  Similarly, the manufacture states that the Pre-miR negative control is a 
random sequence, designed in the same way as Pre-miRs which mimic endogenous, 
mature miRNA, except the negative control has been extensively validated to have no 
effects on known miRNA function.  After 20min incubation at room temperature, 300µL 
of each Pre/Anti-miR /Lipofectamine® solution was added to a well in a 6 well plate. A 
cell concentration of 2x105/mL was used with 1.5mL of this cell suspension added on 
top of the 300µL Pre/Anti-miR/Lipofectamine solution or Opti-MEM® control. The cells 
were then incubated for 48hr. 
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Table 2-8. Details of Pre-miR and Anti-miRs used through transfection 
miRNA Ambion® Cat. No. 
Pre-miR Negative Control #1 Ambion® (AM17110) 
Anti-miR Negative Control #1 Ambion® (AM17010) 
Pre-miR-204 Shanghai Gene Pharma (B02003) 
Pre-miR-224 Ambion® (PM12571) 
Anti-miR-224 Ambion® (AM12571) 
Pre-miR-320a Shanghai Gene Pharma (B02003) 
Anti-miR-320a Shanghai Gene Pharma (B03001) 
Anti-miR-378 Shanghai Gene Pharma (B03001) 
 
 
2.6.4. Plasmid Transfection Protocol 
 
The Mirus TransIT-X2 (Mirus MIR 6000) transfection reagent was used to transfect 
plasmid DNA. 24hr prior to transfection cells were seeded at a density of 3x105 in 2mL 
in a 6 well plate. The following day the TranIT-X2 reagent was brought to room 
temperature. 250µL of Opti-MEM® was mixed with 5µg of plasmid DNA and 7.5µL of 
TransIT-X2, these conditions were optimised, see section 7.2.3. The solution was mixed 
gently and incubated at room temperature for 30min. The solution was then added in a 
dropwise fashion to the cells seeded the previous day. The cells were incubated for 48hr. 
 
2.6.5. Selection of stably transfected cells 
 
48hr post transfection with plasmid DNA the cells were fed with complete media 
containing the selection agent, Hygromycin B (Roche 10843555001) at a concentration 
of 400µg/mL. This concentration was optimised, see section 7.2.3.1. Cells were under 
selection until their growth profile matched that of the parental cell line, at this point 
they were determined to be resistant and selected. 
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2.7. RNA Extraction 
 
Total RNA was extracted from cells in the mid-log phase of growth using TRIzol® Reagent 
(Ambion 15596026) and according to the manufacturer’s isolation protocol. Spent cell 
culture medium was removed from the tissue culture plate/flask and cells were washed 
twice with PBS in order to remove any residual media. Depending on the culture vessel, 
1-3mL of TRIzol® Reagent was added. TRIzol® is a mixture of guanidine thiocyanate and 
phenol in a monophase solution. It effectively dissolves DNA, RNA and protein on lysis 
of cell culture samples. The flask was incubated at room temperature for 5min to allow 
full lysis of the cells. Samples were then mixed well by pipetting and transferred to a 
microcentrifuge tube. Samples were allowed to stand for 5 min at room temperature to 
allow complete dissociation of nucleoprotein complexes. Phase separation was 
achieved with the addition of 200µL of Chloroform (Sigma C2432) to the cell lysate per 
1mL of TRIzol® used. Samples were shaken by hand for 15sec and incubated for 2-3 min 
at room temperature. Samples were centrifuged at 12,000 x g for 15min at 4°C which 
resulted in phase separation. The three distinct phases were 1) red organic phase 
containing protein, 2) intermediate phase containing DNA and 3) an upper aqueous 
colourless phase containing RNA. The aqueous phase (upper-clear layer) was transferred 
to a fresh microcentrifuge tube and 500µL of isopropanol (Sigma I9516) was added per 
1mL of TRIzol® used.  This sample was then mixed vigorously by vortexing at high speed 
for 15 seconds and allowed to stand at room temperature for 10 min. Following this the 
sample was centrifuged at 12,000 x g for 10 min at 4°C. The supernatant was removed 
and the pellet (RNA precipitant) washed with 1mL of 75% ethanol per 1mL of TRIzol® 
used. The samples were vortexed briefly and centrifuged at 7,500 x g for 5min at 4°C. 
Following this, as much ethanol as possible was removed without disturbing the RNA 
pellet which was then air dried. The pellet was then suspended in 20µL of nuclease-free 
water which had been heated to 60°C, this helps to re-suspend the RNA pellet. The 
extracted RNA was stored at -80°C until required for PCR analysis. 
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2.8. RNA quantification using the Nanodrop spectrophotometer 
 
RNA samples were quantified using the Nanodrop® ND-1000 spectrophotometer 
(NanoDrop Technologies). Before applying the RNA sample, the pedestal was wiped 
down using a lint-free tissue. A volume of 1µL of nuclease-free water was then loaded 
onto the lower measurement pedestal to initialise the instrument. 1µL of nuclease-free 
water was used to blank the instrument. RNA was quantified spectrophotometrically at 
260nm and 280nm with the ratios of A260/A280 was used to indicate the purity of the 
RNA A A260/A280 ratio ~2 and an A260/A230 of ~1.8-2.2 is indicative of a pure RNA/DNA 
sample with an absorbance considerably above or below these values indicating the 
presence of contaminants such as protein or phenol. The concentration of RNA was 
calculated by software using the following formula:  
OD260nm x Dilution factor x 40 = ng/µL RNA 
An optical density of 1 at 260nm is equivalent to 40mg/mL RNA. The range of accurate 
quantification of RNA is 10ng/µL minimum to 3000ng/µL maximum. 
 
2.9. Reverse Transcription PCR 
 
2.9.1. cDNA synthesis 
 
The High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 4368814) was 
used to synthesise cDNA from total RNA according to the manufacturers protocol. The 
RT and No RT master mixes were prepared as described in Table 2-9, No RT samples 
lacked the Reverse Transcriptase enzyme to act as a control. 
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Table 2-9. RT and No RT master mixes made using the High Capacity cDNA RT Kit 
 
The maximum RNA allowed in each sample for PCR was 2µg diluted to 10µL in nuclease-
free water in a 0.5mL PCR tube. To this 10µL of the appropriate master mix was added. 
The PCR was performed using the G-Storm thermocycler (Model GS1, Somerton 
Biotechnology Centre, Somerset, UK) and the conditions listed Table 2-10. Synthesised 
cDNA was stored at -20°C. 
 
Table 2-10. Conditions used to perform PCR using the G-Storm thermocycler 
Parameter Step 1 Step 2 Step 3 Step 4 
Temp (°C) 25 37 85 4 
Time 10min 120min 5min ∞ 
 
 
2.9.2. miRNA Reverse Transcription 
 
The Taqman® miRNA Reverse Transcription Kit (Applied Biosystems 4366597) was used 
to synthesise miRNA from total RNA according to the manufacturer’s protocol. The 
master mix was prepared as stated Table 2-11. 
 
 
 
Master Mix component x1 (µL) No RT x1 (µL) 
   
RT Buffer 2 2 
dNTP Mix 0.8 0.8 
Random Primers 2 2 
Reverse Transcriptase 1 - 
RNase Inhibitor 1 1 
H2O 3.2 4.2 
   
Total per Reaction 10 10 
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Table 2-11. Master mix used to synthesise miRNA using the Taqman® miRNA RT Kit 
 
10ng of RNA was used in each sample diluted to 5µL with nuclease-free water in a 0.5mL 
PCR tube. Each reaction has a total volume of 15µL, 10µL of master mix with 5µL of the 
RNA sample added. The PCR was performed using the G-Storm thermocycler (Model 
GS1, Somerton Biotechnology Centre, Somerset, UK) and the conditions listed below. 
Synthesised miRNA was stored at -20°C. 
 
Table 2-12. Conditions used to perform PCR using the G-Storm thermocycler 
Parameter Step 1 Step 2 Step 3 Step 4 
Temp. (°C) 16 42 85 4 
Time 30min 30min 5min ∞ 
 
 
2.10. Quantitative Reverse Transcription PCR 
 
2.10.1. Gene expression Assays 
 
Taqman® qPCR was used to assess gene expression. Taqman® qPCR involved using 
individual Taqman® gene expression assays (Applied Biosystems 4453320) for each 
gene, these assays contain the individual primers and probe for each gene and are listed 
in Table 2-13. These assays were used with Taqman® Fast Advanced Master Mix (Applied 
Biosystems 4444556) and MicroAmp® Fast Optical 96 well reaction plates (Applied 
Master Mix component x1 (µL) 
  
100mM dNTPs 0.15 
MultiScribe™ RT 1 
RT Buffer 1.5 
RT Primer 3 
RNase Inhibitor 0.19 
H2O 4.16 
  
Total per Reaction 10 
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Biosystems 4346907). cDNA sample was diluted between 1pg to 100ng per reaction. The 
cDNA was diluted using nuclease-free water and 1µL was loaded per well with 1µL of 
Taqman® assay and 10µL of Taqman® Master Mix. The plate was then sealed using 
MicroAmp® Optical Adhesive Film (Applied Biosystems 4311971) and the cycles listed in 
Table 2-14 were performed in Applied Biosystems 7900 Real-Time PCR System. 
 
Table 2-13. Details of Taqman Gene Expression assays used 
Assay Name Assay ID 
B2M Hs00984230_m1 
GAPDH Hs03929097_g1 
HSPA5 (GRP78) Hs00607129_gH 
 
 
Table 2-14. Conditions used to perform qPCR using the Applied Biosystems 7900 Real-
Time PCR System  
Parameter Hold Hold 40 cycles 
Temp. (°C) 50 95 95 60 
Time 2min 20sec 1sec 20sec 
 
 
2.10.2. miRNA expression Assays 
 
Taqman® qPCR was used to assess miRNA expression. Taqman® qPCR involved using 
individual Taqman® miRNA expression assays (Applied Biosystems 4427975) for each 
miRNA, these assays contain the individual primers and probe for each miRNA and are 
listed in Table 2-15. These assays were used with Taqman® Fast Advanced Master Mix 
and MicroAmp® Fast Optical 96 well reaction plates. 1.33µL of each miRNA cDNA sample 
loaded per well with 1µL of Taqman® assay, 10µL of Taqman® Master Mix and 7.67µL of 
nuclease-free water. The plate was then sealed using MicroAmp® Optical Adhesive Film 
and the cycles listed in Table 2-16 were performed in Applied Biosystems 7900 Real-
Time PCR System. 
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Table 2-15. Details of Taqman miRNA Expression assays used 
miRNA Assay 
Applied Biosystems Cat. 
No. 4427975 
miR-7a 000386 
miR-10a 000387 
miR-23b 000400 
miR-34a 000426 
miR-144 002676 
miR-204 000508 
miR-206 000510 
miR-338 002252 
miR-378 002243 
miR-409 002331 
miR-451 001105 
miR-455 001280 
miR-497 001043 
miR-505 002089 
 
Table 2-16. Conditions used to perform qPCR using the Applied Biosystems 7900 Real-
Time PCR System 
 
 
 
2.11. Proliferation Assay 
 
Proliferation was measured using an acid phosphatase assay (Martin Clynes 1991). This 
colorimetric assay uses p-nitrophenyl phosphate to determine the percentage of live 
cells. 5x104 cells were seeded in a 6 well plate in 2mL of complete medium. Following 
the incubation period of 7 days, media was removed from the plates. Each well on the 
plate was washed twice with 1mL PBS. This was then removed and 2mL of freshly 
prepared phosphatase substrate (10mM p-nitrophenyl phosphate (Sigma 1048) in 0.1M 
sodium acetate (Sigma, S8625) with 0.1% Triton X (BDH, 30632) at pH 5.5) was added to 
each well. The plates were then incubated in the dark at 37°C for 2 hours. Colour 
development was monitored during this time. The enzymatic reaction was stopped by 
Parameter Hold Hold 40 cycles 
Temp. (°C) 50 95 95 60 
Time 2min 20sec 1sec 20sec 
84 
 
the addition of 1mL of 1M NaOH. The plate was read in a dual beam plate reader at 
405nm with a reference wavelength of 620nm using the Synergy HT plate reader 
(BioTek, Winooski, Vermont, USA). Proliferation was calculated relative to the control 
samples, i.e. control samples were calculated as 100% with test samples made relative 
to this. 
 
2.12. Invasion assay 
 
Invasion assays were carried out in Boyden chambers with a pore size of 8µm (Sigma 
CLS3463) using the method of Albini (Albini 1998). Matrigel® (Sigma E-1270)) which is a 
basement membrane matrix diluted to 1 mg/mL in serum-free DMEM medium was 
defrosted overnight at 4°C. Matrigel® was kept cold at all times. Each transwell insert 
was coated in 100μL of Matrigel® and incubated over-night at 4 °C. The inserts and the 
plate were incubated at 37°C for 1 hour prior to use to allow the gel to polymerise. Cells 
were harvested and re-suspended in complete culture media at a concentration of 1x106 
cells/mL. Before use excess un-polymerised Matrigel® was removed and 100µL of 
complete medium added to each insert. Cell suspensions were prepared in complete 
basal media. A volume of 100μL of the cell suspension was added into the insert. 500µL 
of complete media was added to the lower chamber of the insert in the 24-well plate. 
The invasion assays were incubated for 24-48 hours depending on the cell line, at 37 °C 
and 5% CO2. After incubation, the media from inside the insert was removed and the 
non-invading cells were removed by wiping the apical side of the insert with a PBS 
soaked cotton swab. The insert was dipped in PBS to remove any media from the 
basolateral side of the insert. The insert was then submerged in 0.25% (w/v) crystal 
violet dye for 5-10min to stain the invaded cells. Three washes with sterile water were 
used to remove excess stain. The inserts were allowed to dry. The inserts were viewed 
and counted under a microscope with a graticule at 40X magnification. The number of 
cells per field in 14 fields were counted and used to calculate the average number of 
invading cells per field of view. 
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2.13. 2D Colony Formation 
 
Cells were seeded at 250-2000 cells/well in 2mL in a 6 well plate. Cells were incubated 
and allowed to form colonies for ~14 days. Colony formation was visually assessed 
regularly under the microscope to ensure colonies had not joined together, at this point 
the assay must be stopped to allow for analysis of individual colonies. At the assay end 
point, the cells were washed gently with PBS and fixed in cold Methacare (75% v/v 
methanol, 25% v/v acetic acid) for 15 minutes. Methacare fixative was removed and 
fixed colonies were washed twice with PBS. The colonies were then stained using 1% 
Crystal Violet for 30 minutes then washed three times with UHP and allowed to dry. The 
plates were then scanned and MetaMorph software was used to analyse colony 
formation. 
 
2.14. 3D Colony formation – Soft Agar Assay 
 
This assay involved a high concentration of agar, dissolved in cell culture media which 
formed a solid layer. This solid layer was used as a base for a semi-solid, lower 
concentration layer of agar dissolved in media which contained the cell population. The 
cells were seeded at a low cell density in the semi-solid layer and could not attach 
therefore they formed colonies. The agar stock was set up with 1.5g of powder agar 
added to 50mL of water which was autoclaved to ensure sterility. Agar was heated in a 
water bath to 55°C along with a small volume of media. The media was heated so as to 
avoid clumping when the agar is added to the media. If the media was much cooler than 
the agar a homogenous mixture could not be formed. A 24 well plate format was used. 
The solid bottom layer of agar was 20% agar- media solution. A total bottom layer 
volume of 500µL was used; therefore, 100µL of solution agar was added to 400µL of pre-
heated media for each well. This 500µL solution was added to a well in a 24 well plate 
and allowed to solidify. The semi-solid top layer was a 15% agar- media solution. A total 
top layer volume of 500µL was used. Therefore, 75µL of solution agar was added to 
425µL of pre-heated media for each well. This solution was returned to the water bath 
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to inhibit the agar solution from solidifying. The cells were trypsinised and counted 
according to sections 2.1.3 and 2.1.4. A cell concentration of 5x103 cells/well was used.  
The cells were centrifuged at 1000 rpm for 5min, during this 5min the agar solution was 
removed from the water bath and allowed to cool slightly. If the solution was at 55°C it 
would kill the cells but the agar would solidify ~35°C, therefore it was important to 
manage the temperature and the solidifying of the agar. The cell pellet was then re-
suspended in 500µL of the agar-media solution and added on top of the solid bottom 
layer of agar. The assay was then incubated for 14 days with 200µL of fresh media added 
every 3-4 days to inhibit the agar layer from dehydrating. The colonies were then 
counted by eye under an inverted light microscope. 
 
2.15. Indirect Co-culture 
 
The indirect co-culture system used in this work uses Corning® Transwell cell culture 
inserts (Sigma 3452). The insert contains a polyester membrane with a pore size of 
3.0µm. As seen in Figure 2-2, the pancreatic cancer cells were seeded in a 6 well plate 
with a co-culture insert placed above which contains the stromal cell population.  
 
Figure 2-2. A schematic of the indirect co-culture model used to investigate the 
pancreatic tumour microenvironment 
 
Schematic of the indirect co-culture model set up. Pancreatic cancer cells are seeded in a 6 well plate with 
the stromal cell population above in a co-culture insert above. The insert contains a polyester membrane 
with 3.0µm pores which allow secretions to pass between the two cell types (Crosson 2014). 
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The cells were trypsinised and counted according to sections 2.1.3 and 2.1.4. The 
pancreatic cancer cells were seeded at a density of 2.5x105 in 2mL in a 6 well plate. The 
stromal cells were seeded at a density of 1x105 in 2mL in a co-culture inserts. Both cell 
populations were allowed to attach for 4 hours before the co-culture began. After 4hr 
the insert was added into the well containing the pancreatic cancer cells. The co-culture 
was incubated for 48 hours. 
 
2.16. Statistical Analysis 
 
Statistical analysis performed on all experimental data used a two-tailed Student’s t-
test. A variation of t-tests containing equal and unequal variation were used, which to 
use was determined by carrying out an F-test on the data. With an F statistic of lower 
value than the critical F value indicating equal variance and conversely an F statistic of 
greater value than the critical F value indicating unequal variance. Data with a p-value 
of ≤ 0.05 was considered significant and the level of significance is shown in the Table 
2-17 below. 
 
Table 2-17. Significance and p-value representation 
p-value ≤ Indicator Significance 
0.05 * Lowly significant 
0.01 ** Significant 
0.001 *** Highly significant 
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3. Results – Microarray Analysis of 
Anoikis Resistance in Triple Negative 
Breast Cancer  
89 
 
3.1. Aim 
 
Identify targets using microarray profiling, which contribute to anoikis resistance in 
triple negative breast cancer. Anoikis, a form of cell death was investigated due to the 
role anoikis plays in metastasis. Metastasis is the ability of a cell to spread to another 
location in the body, colonising this secondary site with tumour growth. TNBC has a 
higher rate of early metastasis than the other intrinsic breast cancer subtypes which 
contributes to the poor prognosis of TNBC. Anoikis is an important step in the metastatic 
cascade as the metastatic cells must be anoikis resistant to survive in suspension while 
travelling in the blood stream from the primary tumour to the secondary site. It is these 
three factors; metastasis, TNBC and anoikis which led to the experimental design. 
Microarray profiling of both anoikis resistant and anoikis sensitive cell lines in 
suspension and attached conditions, was used with the aim to identify targets which 
showed differential expression in the anoikis resistant cell lines while in suspension. The 
hypothesis was that targets upregulated in anoikis resistant cells in suspension may be 
genes which allow the cells to survive while detached. These targets were then 
investigated using siRNA knockdown for a change in anoikis resistance. Ultimately, the 
aim was to identify targets which contribute to anoikis resistance in TNBC. 
 
3.2. Anoikis in metastasis 
 
Anoikis is a form of programmed cell death due to detachment of cells from the extra-
cellular matrix (ECM) (Frisch and Francis 1994). Usually when a cell detaches from its 
natural location it dies, this death process is known as anoikis, (Chiarugi and Giannoni 
2008). Anoikis is induced by loss of cell adhesion or inappropriate cell adhesion (Chiarugi 
and Giannoni 2008). Anoikis prevents detached epithelial cells from surviving and 
colonizing other locations or attaching to an incorrect ECM (Kim et al. 2012). Cells may 
be anoikis resistant i.e. these cells do not require adhesion to the ECM to proliferate or 
survive (Chiarugi and Giannoni 2008). A small number of cell types have the ability to 
avoid anoikis, e.g. blood cells, metastatic cancer cells. These cells have developed 
anchorage independence. Metastatic cancer cells lack sensitivity to anoikis unlike 
healthy epithelial cells, meaning the cancer cells have developed the ability of anchorage 
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independence. This ability is important in metastasis; it is a requirement for cancer cells 
to successfully metastasise.  
 
3.3. Microarray Analysis 
 
The aim of this study was to investigate anoikis resistance in triple negative breast 
cancer (TNBC). Microarray analysis was used to evaluate differential expression in both 
anoikis sensitive and anoikis resistant triple negative breast cancer cells. Gene and 
miRNA expression profiling was performed on two anoikis resistant TNBC cell lines 
(MDA-MB-231 and MDA-MB-468) and two anoikis sensitive TNBC cell lines (HCC1954 
and HS578T). The anoikis status of each cell line is shown in Figure 3-1. The TNBC 
subtypes of these cell lines using the classifications described in section 1.3.3 are as 
follows, HCC1954 is classified as basal which may be non-triple negative while the other 
three cell lines are identified as the mesenchymal subtype (Lehmann and Pietenpol 
2014). This microarray profiling was performed in-house by a microarray technician, 
prior to the beginning of this Ph.D. project. The profiling was performed on the four cell 
lines in two different conditions: 
• Cells in normal monolayer cell culture conditions i.e. attached 
• Cells exposed to anoikis conditions i.e. in suspension 
Anoikis was induced by exposing the cells to polyhema which induces suspension, for 
4hr prior to microarray analysis. This time point for analysis was chosen as viability of 
the cells reduces over time while in anoikis conditions. However, this time point was not 
ideal for assessing expression changes due to attachment, as complete attachment can 
take longer than 4hr; also, significant changes in mRNA expression can be difficult to 
detect after 4hr. The experiment involved microarray profiling of all four TNBC cell lines 
(MDA-MB-231, MDA-MB-468, HS578T and HCC1954) in two conditions, anoikis 
conditions i.e. suspension and attached culture conditions. 
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Figure 3-1. Percentage anoikis across the range of TNBC cell lines 
 
Characterisation of the anoikis status of a panel of TNBC cell lines at a 24hr timepoint, HCC1954, MDA-
MB-468, HS578T and MDA-MB-231. Anoikis was assessed using an older Polyhema coating method 
(Keenan et al. 2012) (this graph is a personal communication from Dr. Joanne Keenan, NICB). 
 
3.4. Interrogation of microarray data 
 
The analysis compared each of the four cell lines, both anoikis resistant and anoikis 
sensitive, in both attached conditions and suspension conditions. Analysis of the 
microarray data was carried out by an in-house Bioinformatician, Dr. Stephen Madden. 
The gene and miRNA expression profiles were used as the basis for further experimental 
analysis. This analysis identified genes and miRNA which showed differential expression 
in both the anoikis resistant cells lines in suspension compared to attached and showed 
no differential expression in the anoikis sensitive cell lines in suspension compared to 
attached. In simplistic terms the anoikis sensitive cell lines were used as a minus. In more 
detail the gene and miRNA expression profiles of the MDA-MB-231 cell line were 
analysed in the following way; the genes and miRNA expressed by the MDA-MB-231 cell 
line grown attached were compared to the genes and miRNA expressed when the MDA-
MB-231 cell line was exposed to suspension conditions. The same analysis was 
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performed on the MDA-MB-468, HS578T and HCC1954 cell lines. This analysis focused 
on the genes and miRNA that were differentially expressed in both anoikis resistant cell 
lines in the same direction (upregulated/downregulated) when in suspension compared 
to attached and did not show differential expression in either anoikis sensitive cell line 
in suspension compared to attached. The aim was to identify a gene/miRNA which 
contributed to the ability of the anoikis resistant cells to survive in suspension. This 
profiling identified 26 significantly differentially expressed genes in the anoikis resistant 
cell lines when in suspension compared to attached and not differentially expressed in 
the anoikis sensitive cell lines, with significance being considered as an adjusted p value 
<0.05. These 26 genes and their fold changes can be seen in Table 3-1. No miRNA were 
identified as significantly differentially expressed. 
 
Table 3-1. Differential expression of anoikis resistant cell lines 
Gene 
Log2 FC 
MDA-MB-231 
Log2 FC 
MDA-MB-468 
Gene 
Log2 FC 
MDA-MB-231 
Log2 FC 
MDA-MB-468 
AHDC1 0.523 0.891 MAK 0.743 0.532 
ALDH1A3 0.784 0.686 MEF2A 1.158 0.471 
CRISPLD2 1.167 1.321 NPAS2 0.483 1.263 
DNAH5 0.681 1.085 PXK 0.933 1.639 
DUSP1 -1.489 -1.448 RAPH1 -0.598 -0.814 
EDC3 0.565 0.791 RTP4 0.671 0.988 
FOS -1.673 -1.816 SECTM1 0.825 0.680 
FZD7 0.700 0.852 SEMA3C -0.598 -0.581 
GADD45B -0.673 -0.668 SGMS2 0.760 1.002 
GNAO1 0.765 0.640 SLC25A45 0.555 0.785 
GPR39 -0.782 -0.668 SLC7A5 1.155 0.783 
HERPUD1 1.218 0.637 TNFRSF11A 1.023 0.776 
HSPA5 
(GRP78) 
0.430 0.775 ZMIZ1 0.850 0.590 
The log2 fold changes of the 26 significantly differentially expressed genes in the anoikis resistant cell 
lines, red indicates increased expression in suspension compared to attached while green indicates 
decreased expression in suspension compared to attached. 
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3.4.1. Literature Mining 
 
The microarray profiling analysis identified 6 genes to be downregulated while the other 
20 genes were upregulated in both anoikis resistant cell lines in suspension compared 
to attached conditions, with these targets showing no differential expression in the 
anoikis sensitive cells in suspension compared to attached conditions. Literature mining, 
utilising PubMed and Pathway Studios analysis software was performed on this list of 
26 significantly differentially expressed genes. Pathway studios uses published scientific 
data to analyse a vast range of cellular characteristics including pathways, disease, 
functions etc., that are shared among the list of targets. A focus was placed on the 
targets that were found to be upregulated, as functional validation utilising siRNA 
knockdown was of interest. Figure 3-2 displays the diseases common among the list of 
targets from the profiling data, meaning the diseases that more than one target has 
been published as playing a role in. This figure also displays the effect the specific target 
has in that disease, either positive or negative, indicated by green or red respectively. 
For example, FZD7, a receptor, is displayed as having a positive effect (green) on 
metastasis. This data also indicates the protein classification of each target, for example 
SEMA3C is a ligand and is represented by a diamond shape.  displays the cellular 
processes common among the list of targets from the profiling data, meaning the 
cellular processes that more than one target has been published as playing a role in. This 
figure also indicates the effect each target has on the specific cellular process, either 
positive or negative as described previously. For example, DUSP1, a protein 
phosphatase, is displayed as having a negative effect on cell migration meaning 
expression of DUSP1 inhibits cell migration. Using these tools and figures along with the 
p values and log2 fold change values from the microarray data analysis, a target gene 
was chosen. 
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Figure 3-2. Pathway Studios analysis of common priority diseases by effect 
 
 
Analysis of all 26 targets identified by the microarray profiling using Pathway Studios. This analysis displays the diseases in common, meaning 
the disease that multiple targets from the profiling data have been published to play a role in. It also shows the effect each target has in that 
specific disease, red indicates the target negatively effects the disease while green indicates a positive effect by the target. 
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Figure 3-3. Pathway Studios analysis of common cellular processes 
Analysis of all 26 targets identified by the microarray profiling using Pathway Studios. This analysis displays the cellular processes in common, 
meaning the cellular processes that multiple targets from the profiling data have been published to play a role in. It also shows the effect each 
target has on that specific process, red indicates the target negatively effects the process while green indicates a positive effect by the target. 
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3.4.2. Target gene – GRP78 
 
Using the tools and data discussed previously, GRP78 (shown as HSPA5 in the microarray 
and Pathway Studios data) was chosen as a target to investigate further. GRP78 (also 
known as Bip and HSPA5) is a glucose regulated protein involved in the endoplasmic 
reticulum (ER) stress response (Lee 2007). From the literature mining using PubMed, 
many of the differentially expressed genes from the microarray profiling showed a role 
in the ER stress response which may indicate that stress response was highly important 
in the development of anoikis resistance. GRP78 is a member of the heat shock protein 
family, specifically the HSP70 protein family which is ubiquitously expressed in 
mammalian cells (Zhang and Zhang 2010). GRP78 is so highly conserved that its presence 
or the presence of a homologue are found in almost every organism from bacteria to 
man (Quinones, Ridder and Pizzo 2008). GRP78 plays an important part in cellular 
survival through several different functions including as a chaperone for folding, 
maturation and transport of proteins in the ER (Raiter, Yerushalmi and Hardy 2014). A 
major function is as part of the unfolded protein response (UPR) which is a response to 
stress conditions to protect the cell from apoptosis. When the protein level in the cell 
exceeds the folding capacity of the ER, the UPR is initiated in response to this stress (Lee 
2007). This response activates several signalling pathways which result in attenuation of 
translation, upregulation of chaperones and folding enzymes as well enhanced 
degradation of misfolded proteins (Lee 2007). The other functions of GRP78 include 
inhibiting aggregation of protein intermediates, targeting misfolded proteins for 
degradation and Ca2+ binding to act as an ER stress signal regulator (Lee 2007).  
 
Using the Pathway Studios data, GRP78 appeared to play a role in breast cancer, 
specifically triple negative breast cancer. This data also indicated a function of GRP78 in 
cell survival, cell migration, colony formation and anoikis. However, the literature mining 
did not show any evidence GRP78 played a part in anoikis in TNBC which vastly 
contributed to the decision to further investigate the part GRP78 had in anoikis 
resistance in TNBC. Additional Pathway Studios analysis was performed focusing on 
GRP78. Figure 3-4 shows the diseases GRP78 had been shown to play a role in and the 
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effect GRP78 played indicated by green or red as previously described. This data 
indicated a function of GRP78 in triple negative breast cancer, metastasis, invasion and 
carcinogenesis, as well as others, with GRP78 playing a positive part in the majority of 
these conditions. Figure 3-5 displays the cellular processes that GRP78 was known to 
play a part in and whether this part was positive or negative. GRP78 was shown to play 
a positive role in cell migration, invasion, survival and colony formation. Interestingly, 
GRP78 was shown to have both a positive and negative effect on survival. The effect 
GRP78 had in anoikis was unknown, indicated by the grey arrow and literature mining 
using PubMed showed no publications directly linking GRP78 with anoikis, this 
contributed to the interest in investigating the role GRP78 has in anoikis resistance.  
 
While determining the potential of GRP78 as a functional target in TNBC, survival 
analysis was also performed. This analysis utilised software and data available through 
kmplot.com which yielded a Kaplan-Meier (KM) survival plot, shown in Figure 3-6. This 
database uses publicly available datasets integrated with clinical data of relapse free 
survival (RFS) and overall survival (OS) to analyse the prognostic value of a particular 
gene. The patient samples are split into two groups, according to various quantile 
expressions of the target. These cohorts are then compared by Kaplan-Meier survival 
analysis yielding a plot, hazard ratio and logrank P value. The KM plot of GRP78 
expression was for the basal subtype of breast cancer as no triple negative subtype 
option was available in the analysis software. This plot displays GRP78 mRNA expression 
in terms of RFS of 618 patients over a period of 200 months (Szász et al. 2016). The KM 
survival analysis indicated that high expression of GRP78 was significantly (p value = 
0.0308) associated with poorer RFS in basal breast cancer patients. The low expression 
cohort of patients possessed a median survival time of 24.05 months while the high 
expression cohort displayed a median survival time of 17.45 months. This high 
expression-poorer survival was in agreement with the original hypothesis in this body of 
work that high GRP78 expression may be significant in anoikis resistance. In the data 
from the microarray profiling, GRP78 showed a p value of 0.001 and a log2 fold change 
(FC) value of 0.43 in the MDA-MB-231 cell line and a p value of 0.000004 and a log2 FC 
value of 0.775 in the MDA-MB-468 cell line. These values along with the knowledge 
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gained from the Pathway Studios and Kaplan-Meier survival analysis led to GRP78 being 
chosen as a target to investigate in the development of anoikis resistance. 
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Figure 3-4. Pathway Studios analysis of HSPA5 effect in diseases 
 
Analysis of HSPA5 using Pathway Studios. This analysis displays the diseases HSPA5 has been published to play a role in. It also shows the effect each target 
has in that specific disease, red indicates the target negatively effects the disease while green indicates a positive effect by the target. 
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Figure 3-5. Pathway Studios analysis of the role of HSPA5 in cellular processes 
 
Analysis of HSPA5 using Pathway Studios. This analysis displays the cellular processes HSPA5 has been published to play a role in. It also shows the effect 
each target has in that specific disease, red indicates the target negatively effects the disease while green indicates a positive effect by the target. 
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Figure 3-6. Kaplan Meier plot showing the relationship of GRP78 expression with survival  
 
Kaplan Meier plot of GRP78 expression relative to survival in basal breast cancer patients. Analysis of 
GRP78 mRNA expression in terms of relapse-free survival (RFS) of patients over a period of 20 months. 
The basal intrinsic subtype as no triple negative subtype was available. Auto select best cut off was used 
(n=618, p value = 0.0308) (Szász et al. 2016).
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3.4.3. Validation of target gene GRP78, expression profile 
 
The microarray data indicated that GRP78 was expressed at a higher level in both the 
anoikis resistant cell lines (MDA-MB-231 and MDA-MB-468) in comparison to both the 
anoikis sensitive cell lines (HCC1954 and HS578T). To confirm this trend was present in 
the TNBC panel, Western blot analysis was performed, described in section 2.5. As seen 
in Figure 3-7 and Figure 3-8, the protein abundance of GRP78 was higher in both the 
MDA-MB-231 and MDA-MB-468 cell lines compared to both the HCC1954 and HS578T 
cell lines. This appears to validate the microarray data and confirms that GRP78 shows 
higher expression in the anoikis resistant cell lines compared to the anoikis sensitive cell 
lines. Following on from this, the expression of GRP78 was reduced using transient siRNA 
transfections and functional effects were assessed. This was used to investigate if GRP78 
played a role in anoikis resistance as well as other metastatic phenotypes such as 
proliferation, invasion and colony formation.  
 
Figure 3-7. Level of GRP78 and β-actin protein across a panel of TNBC cell lines 
 
 
A) Trend of GRP78 protein, 78 kDa, in both anoikis resistant cell lines (MDA-MB-231 and MDA-MB-468) 
and both anoikis sensitive cell lines (HS578T and HCC1954) validating the microarray expression profile. 
B) Level of β-actin protein, 42 kDa, (loading control) in both anoikis resistant cell lines (MDA-MB-231 and 
MDA-MB-468) and both anoikis sensitive cell lines (HS578T and HCC1954). 
Anoikis resistant  Anoikis sensitive 
A) MDA-MB-231    MDA-MB-468      HS578T      HCC1954 
Anoikis resistant  Anoikis sensitive 
    B) MDA-MB-231   MDA-MB-468   HS578T  HCC1954 
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Figure 3-8. Densitometry analysis of GRP78 protein across a panel of TNBC cell lines 
 
Densitometry analysis of the trend of GRP78 protein in both anoikis resistant cell lines (MDA-MB-231 and 
MDA-MB-468) and both anoikis sensitive cell lines (HS578T and HCC1954) using TotalLab Quant software 
relative to β-actin, used as the loading control (n=1). 
 
3.5. GRP78 Knockdown Optimisation 
 
Both breast cell lines (MDA-MB-231 and MDA-MB-468) were transfected with siRNA 
targeting GRP78, as described in section 2.6.2. A negative control was also included. This 
negative control is Silencer® Select Negative Control No. 2, this negative control is an 
siRNA sequence which does not target any known gene, as described in section 2.6.2. 
Originally two concentrations (3nM and 5nM) of GRP78 siRNA were assessed to examine 
which concentration resulted in the most efficient knockdown. GRP78 knockdown was 
assessed through qPCR, described in section 2.10.1. A higher level of knockdown of 
GRP78 was achieved in the MDA-MB-468 cells (3-fold) than in the MDA-MB-231 cells (2-
fold) compared to the negative control. Following this, two higher concentrations of 
GRP78 siRNA (8nM and 10nM) were assessed with the aim to achieve a higher GRP78 
knockdown, especially in the MDA-MB-231 cells. From these results 10nM was observed 
to be optimum as it achieved a 4-fold knockdown in MDA-MB-468. No greater level of 
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knockdown was achieved in the MDA-MB-231 cell line but a 2-fold reduction in GRP78 
expression was deemed sufficient to observe functional effects. The results from both 
transfections can be seen in Figure 3-9. 
 
Figure 3-9. GRP78 knockdown through optimisation of siRNA concentration 
 
Reduction in GRP78 expression induced using varying concentrations of GRP78 siRNA (3, 5, 8, 10nM) in 
MDA-MB-231 and MDA-MB-468 cell lines displayed as fold change, assessed through qPCR 48hr post 
transfection, with a negative control (Neg) included and B2M used as an endogenous control. Error bars 
represent +/- standard deviation between technical replicates, (n=1). 
 
3.6. Functional effects of GRP78 knockdown 
 
Following knockdown of GRP78 expression using optimised siRNA conditions, functional 
effects of this alteration were investigated using proliferation, anoikis, invasion and 
colony formation assays. The percentage knockdown of GRP78 observed in each cell line 
as well the negative and positive control knockdown are displayed in Figure 3-10. The 
results from the functional assays post GRP78 knockdown can be seen in Figure 3-13 – 
effect on proliferation at 24hr, Figure 3-14 and Figure 3-15 – effect on anoikis, Figure 
3-16 – effect on invasion, Figure 3-18 – effect on proliferation at 7days, Figure 3-19 – 
effect on 2D colony formation and Figure 3-21 – effect on 3D colony formation. These 
functions were assessed as each function plays an important role in metastasis. 
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Figure 3-10. Validation of transfection 
 
Fold change of negative control (Neg), GAPDH and GRP78 following a 48hr transfection using siRNA at a 
10nM concentration in MDA-MB-231 and MDA-MB-468 cell lines. GAPDH acting as a positive control for 
knockdown and using B2M as an endogenous control for assessment of knockdown through qPCR. Error 
bars represent +/- standard deviation between technical replicates, (n=1). 
 
Figure 3-11. GRP78 protein knockdown post transfection 
 
 
A. Western blot showing knockdown of GRP78 protein, 78 kDa, in both anoikis resistant cell lines (MDA-
MB-231 and MDA-MB-468) post transfection, samples included untransfected (Un), negative control 
(Neg) and GRP78 KD (GRP78). B. α- Tubulin levels across all six samples was included as a loading control. 
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Figure 3-12. Densitometry analysis of GRP78 knockdown 
 
Densitometry analysis of GRP78 knockdown following a 48hr transfection using siRNA at a 10nM 
concentration in both anoikis resistant cell lines (MDA-MB-231 and MDA-MB-468) using TotalLab Quant 
software. Untransfected (Un) and negative (Neg) controls were included, relative to α-Tubulin used as the 
loading control (n=1). 
 
Figure 3-10., analysis of qPCR data displays the fold change reduction of GRP78 achieved 
through transient transfection using siRNA of GRP78 in both the MDA-MB-231 and 
MDA-MB-468 cells lines as well the levels of knockdown in the negative control. A 
transient knockdown of GAPDH was included as a positive control. A 2-fold reduction of 
GAPDH was achieved in the MDA-MB-231 cell line with a 19-fold reduction present in 
the MDA-MB-468 cell line. The reduction in GAPDH mRNA validates that the transfection 
was successful. Figure 3-10 also shows that the expression of GRP78 was successfully 
reduced in both the anoikis resistant TNBC cell lines. MDA-MB-231 cells displayed a 2-
fold decrease while the MDA-MB-468 cell lines possessed an 8-fold reduction in GRP78 
expression. Figure 3-11 shows Western blot analysis of GRP78 protein knockdown post 
transfection. Further analysis of this protein knockdown using densitometry is displayed 
in Figure 3-12. Both figures are in agreement and show GRP78 protein knockdown was 
achieved in both the MDA-MB-231 and MDA-MB-468 cell lines. This result is in 
agreement with the mRNA reduction as a much greater decrease in GRP78 mRNA was 
induced in the MDA-MB-468 cell line compared to the MDA-MB-231 cell line. This 
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confirmation of successful reduction in GRP78 mRNA expression and GRP78 protein 
knockdown led to assessment of functional effects resulting from GRP78 knockdown. 
 
Figure 3-13. Percentage proliferation at 24hr in both anoikis resistant cell lines post 
GRP78 knockdown 
 
Percentage proliferation at a 24hr time-point following GRP78 knockdown post 48hr transfection in MDA-
MB-231 and MDA-MB-468 cell lines relative to the negative control (Neg) with the untransfected (Un) 
control included. Error bars represent +/- standard deviation between biological replicates, (n=3). 
 
Figure 3-13 displays the level of proliferation observed in both anoikis resistant TNBC 
cell lines after 24hr of incubation and post GRP78 knockdown. This time point was 
utilised to accommodate the anoikis and invasion analysis detailed below. Both 
functions were assessed at a 24hr timepoint therefore to ensure any changes observed 
in either anoikis or invasion were not due to proliferation changes, proliferation was 
assessed at a 24hr timepoint as well after a 7-day period. The levels of proliferation are 
relative to the negative control with the untransfected control included to show the 
effects the transfection process had on proliferation. The reduction of GRP78 expression 
induced no change in proliferation of either TNBC cell line after 24hr of culture.
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Figure 3-14. Percentage survival of the MDA-MB-231 cell line post GRP78 knockdown 
 
Percentage survival in both attached and anoikis i.e. suspension, conditions following GRP78 knockdown 
post 48hr transfection in the MDA-MB-231 cell line relative to the negative control (Neg) in attached 
conditions with the untransfected (Un) control included. Error bars represent +/- standard deviation 
between biological replicates, (n=3).  
 
Figure 3-15. Percentage survival of the MDA-MB-468 cell line post GRP78 knockdown 
 
Percentage survival in both attached and anoikis i.e. suspension, conditions following GRP78 knockdown 
post 48hr transfection in the MDA-MB-468 cell line relative to the negative control (Neg) in attached 
conditions with the untransfected (Un) control included. Error bars represent +/- standard deviation 
between biological replicates, (n=3).  
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Figure 3-14 and  show the observed effects of GRP78 knockdown on anoikis i.e. survival 
in suspension, of both TNBC cell lines after a 48hr transfection and a further 24 hours 
exposed to anoikis conditions. For the evaluation of anoikis, two conditions were 
utilised, attached and suspension. Cells in suspension were in anoikis conditions i.e. 
unattached, meaning cells underwent anoikis cell death, if they were anoikis sensitive. 
To assess anoikis, Alamar blue was used as an indicator of cellular health through 
metabolic rate. Cells undergoing anoikis displayed a reduced metabolic rate and 
therefore induced less reduction of the Alamar blue resulting in little to no colour 
change. This lack of colour change was detected by the microtiter plate reader and 
expressed as a percentage survival i.e. the percentage of cells that are surviving while in 
attached and suspension conditions post GRP78 knockdown. This survival was 
calculated using the control sample in attached conditions as a comparison, meaning 
the control in attached conditions was expressed as 100% survival with other 
experimental conditions relative to this. Therefore, samples which reduced the Alamar 
blue through metabolism, to a greater or lesser extent than the control were displayed 
as having a greater or lesser percentage survival. Using this method of analysis, the 
effect of GRP78 knockdown on anoikis was determined and expressed as percentage 
survival for both TNBC cell lines with the negative control in attached conditions 
expressed as 100% survival. It was determined there was no change in the level of 
survival observed in either anoikis resistant cell line post GRP78 knockdown in both 
attached and suspension conditions relative to the negatively transfected control. 
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Figure 3-16. Percentage invasion post GRP78 knockdown in both anoikis resistant TNBC 
cell lines 
 
Percentage invasion of both TNBC cell lines, MDA-MB-231 (24hr) and MDA-MB-468 (48hr) following 
GRP78 knockdown post 48hr transfection, with percentage invasion relative to the negative control (Neg) 
and the untransfected (Un) control included. Error bars represent +/- standard deviation between 
biological replicates, (n=3).  
 
Figure 3-17. Representative images of invasion levels of both MDA-MB-231 and MDA-
MB-468 cells post GRP78 knockdown 
 Untransfected Neg GRP78 
MDA-MB-
231 
   
MDA-MB-
468 
   
 
Representative images of invasion following GRP78 knockdown in both MDA-MB-231 (24hr) and MDA-
MB-468 (48hr) cell lines with the untransfected (Un) and negative control (Neg) included. 
0
50
100
150
200
250
300
MDA-MB-231 MDA-MB-468
%
 In
va
si
o
n
Un Neg GRP78
111 
 
Assessment of changes in invasion levels induced by GRP78 knockdown showed no 
significant effect in either TNBC cell line, as seen in . Representative images of the 
invasion levels in both cell lines in each transfection condition are displayed in Figure 
3-17. An increase in invasion was present in the MDA-MB-231 cell line while a decrease 
was observed in the MDA-MB-468 cell line. Neither result showed any statistical 
significance due to variation between biological replicates. 
 
Figure 3-18. Percentage proliferation over 7 days in both anoikis resistant cell lines post 
GRP78 knockdown 
 
Percentage proliferation after 7 days’ incubation following GRP78 knockdown post 48hr transfection in 
MDA-MB-231 and MDA-MB-468 cell lines relative to the negative control (Neg) with the untransfected 
(Un) control included. Error bars represent +/- standard deviation between biological replicates, (n=3, *** 
= p value ≤ 0.001). 
 
As seen in Figure 3-13 no effect on proliferation was observed due to GRP78 knockdown 
at a 24hr time-point. This time point was utilised to accommodate the anoikis and 
invasion analysis detailed previously. To fully assess if GRP78 knockdown had any effect 
on proliferation acid phosphatase assays were performed after 7 days of culture. Figure 
3-18 displays there was no change in proliferation in the MDA-MB-231 cell line post 
GRP78 knockdown. A significant 20% reduction in proliferation (p value = 0.00013) was 
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induced in the MDA-MB-468 cell line due to decreased GRP78, this is compared to the 
negative control. 
 
Figure 3-19. Percentage 2D colony formation of the MDA-MB-231 cell line post GRP78 
knockdown 
 
Percentage colony area and staining intensity of colonies formed over 14 days in 2D relative to the 
negative control (Neg) following a 48hr transfection to induce GRP78 knockdown in the MDA-MB-231 cell 
line. Colonies were analysed using ImageJ software. Error bars represent +/- standard deviation between 
biological replicates, (n=3). 
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Figure 3-20. Representative image of 2D colony formation of the MDA-MB-231 cell line 
post GRP78 knockdown 
 
 
Representative image of 2D colony formation of the MDA-MB-231 cell line at 14 days following GRP78 
knockdown post 48hr transfection with the untransfected (Un) and negative control (Neg) included. 
 
 
Figure 3-21. Percentage 3D colony formation of both anoikis resistant TNBC cell lines 
post GRP78 knockdown 
 
Percentage colonies formed over 14 days relative to the negative control (Neg) following GRP78 
knockdown post 48hr transfection in MDA-MB-231 and MDA-MB-468 cell lines. Error bars represent +/- 
standard deviation between biological replicates, (n=3). 
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The functional effect of reduced GRP78 on the ability of the TNBC cell lines to form 
colonies was assessed using two different methods. The first being in 2D, with the 
method described in section 2.13. It was determined however that the MDA-MB-468 
cells do not form colonies in 2D, meaning the effect on 2D colonies was investigated in 
only the MDA-MB-231 cell line. Displayed in Figure 3-19 is the percentage area and 
percentage intensity with area equating to colony number and intensity equating to 
colony size. The 2D colonies of MDA-MB-231 cells could not be analysed using the 
method used to analyse colonies from other cell lines i.e. Metamorph image analysis. 
This was due to the lack of staining of the colonies, the cells did not take up a large 
amount of the crystal violet stain therefore the software could not distinguish colonies 
from the background. Due to this a different software method was used, ImageJ. This 
software was similar to Metamorph but allows less control of the analysis, it was this 
aspect of ImageJ which led to Metamorph being the favoured software for colony 
formation analysis. Using ImageJ software, the percentage colony formation of MDA-
MB-231 cells post GRP78 knockdown is shown in Figure 3-19 with a representative 
image displayed in Figure 3-20. A 40% reduction in both colony area and intensity was 
induced due to reduced GRP78, while no statistical significance was present, this may 
be due to the analysis software, a trend of reduced colony forming ability post GRP78 
knockdown was present and is shown in Figure 3-20. The largest functional effect 
observed post GRP78 knockdown was a reduction in the TNBC cells ability to form 
colonies in 3D, as shown in Figure 3-21. The method used to investigate colony 
formation in 3D, the soft agar assay is described in section 2.14. The MDA-MB-231 cell 
line displayed a 15% reduction in colonies formed while a 40% reduction in colonies 
formed was observed in the MDA-MB-468 cell line. While no statistical significance was 
observed a very strong trend of reduced colony forming ability was present, with MDA-
MB-468 cell line displaying a p value of 0.06.  
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4. Discussion – Microarray Analysis of 
Anoikis Resistance in Triple Negative 
Breast Cancer
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4.1. Microarray Analysis 
 
Microarray analysis of a panel of TNBC cell lines was performed in order to develop 
knowledge in the area of anoikis resistance. The ability of cancer cells to resist cell death 
post detachment from the ECM is an important hallmark of cancer progression. Anoikis 
was induced by exposing cells to suspension conditions for 4hr prior to profiling. This 
time point was chosen to ensure optimal cell viability. The longer the cells are detached 
the more viability was reduced; this was especially true for the anoikis sensitive cell lines. 
Gene expression profiling with microarrays was performed on the two anoikis resistant 
TNBC cell lines (MDA-MB-231 and MDA-MB-468) and two anoikis sensitive TNBC cell 
lines (HCC1954 and HS578T). The anoikis status of the four cell lines was confirmed in 
Figure 3-1. The anoikis sensitive cell lines (HCC1954 and HS578T) display anoikis levels 
of 90% and 58% respectively. The anoikis resistant cell lines (MDA-MB-231 and MDA-
MB-468) display levels of only 10% and 20% anoikis respectively. There are very few 
publications to investigate if these anoikis levels are observed in other studies. However, 
one such study does exist, the MDA-MB-231 cell line is described as anoikis resistant in 
comparison to MCF-7 cells due to a 1.7-fold higher survival in anoikis conditions in a 
study of the protein profiles of anoikis resistant cell lines (Akekawatchai et al. 2016). The 
profiling was performed on the four cell lines in two different conditions at 4hr: 
• Cells in normal monolayer cell culture conditions i.e. attached 
• Cells exposed to anoikis conditions i.e. in suspension 
 
4.2. Investigation of microarray data 
 
The analysis compared each of the four cell lines, both anoikis resistant and anoikis 
sensitive, in both attached conditions and suspension conditions i.e. the genes being 
expressed in the MDA-MB-231 cell line in suspension were compared to the genes being 
expressed in the MDA-MB-231 cell line in attached conditions. This analysis focused on 
the genes and miRNA that were differentially expressed in both anoikis resistant cell 
lines in the same direction (upregulated/downregulated) when in suspension compared 
to attached and did not show differential expression in either anoikis sensitive cell line 
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in suspension compared to attached. This was with the aim of identifying a gene or 
miRNA which contributed to the ability of the anoikis resistant cells to survive in 
suspension. This profiling identified 26 significantly differentially expressed genes in the 
anoikis resistant cell lines when in suspension compared to attached, and not 
differentially expressed in the anoikis sensitive cell lines, with significance being 
considered as an adjusted p value <0.05. Literature mining was performed to reduce this 
list and using a range of literature mining tools including PubMed, Pathway Studios and 
Kaplan-Meier survival analysis, the target GRP78 was chosen to further investigate. 
GRP78 is an ER stress response protein as were several of the differentially expressed 
genes from the microarray analysis. 
 
GRP78 (also known as Bip and HSPA5) is a glucose regulated protein involved in the 
endoplasmic reticulum (ER) stress response (Lee 2007). It is a member of the heat shock 
protein family, specifically the HSP70 protein family which is ubiquitously expressed in 
mammalian cells (Zhang and Zhang 2010). GRP78 plays an important role in cellular 
survival through several different functions including as a chaperone for folding, 
maturation and transport of proteins in the ER (Raiter, Yerushalmi and Hardy 2014). A 
major function of GRP78 is as part of the unfolded protein response (UPR) which is a 
response to stress conditions to protect the cell from apoptosis. When the protein level 
in the cell exceeds the folding capacity of the ER, the UPR is initiated in response to this 
stress (Lee 2007). This response activates several signalling pathways which result in 
attenuation of translation, upregulation of chaperones and folding enzymes, as well 
enhanced degradation of misfolded proteins (Lee 2007). The other roles of GRP78 
include inhibiting aggregation of protein intermediates and Ca2+ binding to act as an ER 
stress signal regulator (Lee 2007). 
 
Using literature mining tools, PubMed, Pathway Studios and Kaplan-Meier survival 
analysis, GRP78 was chosen as a target to investigate further for a functional effect on 
metastatic phenotypes in TNBC. The Pathway Studios analysis, shown in Figure 3-2 and 
Figure 3-3, indicated a function of GRP78 in TNBC as well a role in the functions of cell 
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survival, colony formation and anoikis. However, the literature mining did not show any 
evidence GRP78 played a part in anoikis in TNBC which vastly contributed to the decision 
to further investigate the part GRP78 played in anoikis resistance in TNBC. Additional 
Pathway Studios analysis was performed focusing on GRP78. This data, shown in Figure 
3-4 and Figure 3-5, indicated a role of GRP78 in triple negative breast cancer, metastasis, 
invasion and carcinogenesis, with GRP78 playing a positive role in the majority of these 
conditions. Analysis of cellular processes indicated GRP78 had an effect on cell 
migration, invasion, survival and colony formation. The effect GRP78 had in anoikis was 
unknown, indicated by the grey arrow and literature mining using PubMed showed no 
publications directly linking GRP78 with anoikis, this contributed to the interest in 
investigating the part GRP78 had in anoikis resistance. The survival analysis of GRP78 
utilised software and data available through kmplot.com which yielded a Kaplan-Meier 
(KM) survival plot, shown in Figure 3-6. The KM plot of GRP78 expression was for the 
basal subtype of breast cancer as no triple negative subtype option was available in the 
analysis software. This plot displays GRP78 mRNA expression in terms of relapse-free 
survival (RFS) of 618 patients over a period of 200 months (Szász et al. 2016). The KM 
survival analysis indicated that high expression of GRP78 was significantly (p value = 
0.0308) associated with poorer RFS in basal breast cancer patients. This high expression-
poorer survival relationship was in agreement with the original hypothesis that high 
GRP78 expression may be significant in anoikis resistance. In the data from the 
microarray gene expression profiling, GRP78 showed a p value of 0.001 and a log2 fold 
change (FC) value of 0.43 in the MDA-MB-231 cell line and a p value of 0.000004 and a 
log2 FC value of 0.775 in the MDA-MB-468 cell line. These values along with the 
knowledge gained from the Pathway Studios and Kaplan-Meier survival analysis led to 
GRP78 being chosen as a target to investigate in the development of anoikis resistance. 
 
The first step in investigating the role of GRP78 in anoikis resistance was to confirm the 
expression levels of GRP78 across the TNBC panel. The microarray data indicated that 
GRP78 was expressed at a higher level in both the anoikis resistant cell lines (MDA-MB-
231 and MDA-MB-468) in comparison to both the anoikis sensitive cell lines (HCC1954 
and HS578T). To confirm this trend was present in the TNBC panel, Western blot analysis 
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was performed. As seen in Figure 3-7 the protein abundance of GRP78 was higher in 
both the MDA-MB-231 and MDA-MB-468 cell lines compared to both the HCC1954 and 
HS578T cell line. This appears to validate the microarray data and confirms that GRP78 
shows higher expression in anoikis resistant cell lines compared to anoikis sensitive cell 
lines. With this higher expression being confirmed the next step was to determine if 
reduction of GRP78 mRNA could be successfully achieved using transient siRNA 
transfections. As seen in Figure 3-10, a 2-fold change decrease in GRP78 mRNA was 
induced in the MDA-MB-231 cell line and an 8-fold decrease was achieved in the MDA-
MB-468 cell line. Preliminary analysis of GRP78 protein levels, shown in Figure 3-11, 
displays GRP78 protein knockdown in the MDA-MB-468 cell line. Figure 3-11 shows 
Western blot analysis of GRP78 protein knockdown post transfection with densitometry 
analysis of these protein levels is displayed in Figure 3-12. Both figures indicate GRP78 
protein knockdown was achieved in both the MDA-MB-231 and MDA-MB-468 cell lines 
with a greater protein reduction displayed in the MDA-MB-468 cell line. This result is in 
agreement with the mRNA reduction as a much greater decrease in GRP78 mRNA was 
induced in the MDA-MB-468 cell line compared to the MDA-MB-231 cell line. This 
confirmation of successful reduction in GRP78 mRNA expression and GRP78 protein 
knockdown led to assessment of functional effects resulting from GRP78 knockdown. 
 
Post knockdown, the functional effects of reduced GRP78 expression were assessed. The 
changes in proliferation, anoikis, invasion and colony forming ability were investigated. 
The microarray data showed GRP78 as upregulated in both anoikis resistant cell lines in 
suspension compared to attached culture, therefore, it was proposed that a reduction 
in GRP78 may result in the anoikis resistant cell lines having a reduced ability to survive 
under anoikis conditions i.e. in suspension, unattached. As seen in Figure 3-14 and Figure 
3-15, this result was not observed. It appears that lowering GRP78 expression had no 
effect on either anoikis resistant cell lines ability to survive in suspension. As there are 
no publications discussing GRP78 and its direct role in anoikis, it was difficult to conclude 
if this data is representative of the role of GRP78 in anoikis. Basing conclusions on this 
data it appeared GRP78 had no influence on anoikis resistance in either the MDA-MB-
231 or the MDA-MB-468 cell line. One conclusion which can be drawn from Figure 3-14 
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and Figure 3-15 was that the cells displayed an 80-90% survival in suspension, this re-
affirms their status as anoikis resistant cell lines and reiterates the data seen in Figure 
3-1.   
 
Assessment of changes in invasion levels induced by GRP78 knockdown showed no 
significant effect in either TNBC cell line, as seen in  and Figure 3-17. An increase in 
invasion was present in the MDA-MB-231 cell line while a decrease was observed in the 
MDA-MB-468 cell line. Neither result showed any statistical significance due to variation 
between biological replicates. From these results, it was difficult to determine the role 
GRP78 played in invasion in TNBC. A positive effect on cell invasion by GRP78 was 
indicated by the Pathway Studios analysis, seen in Figure 3-5. It has also been shown 
that overexpression of GRP78 promotes invasion levels in both triple negative breast 
cancer and hepatocellular carcinoma (Lee et al. 2011, Su et al. 2010). This published 
study of breast cancer involved the MDA-MB-231 cell line, as did this current 
investigation of anoikis resistance. In the published study overexpression of GRP78 was 
induced through silencing of MMP-26 and this led to a significant 50% increase in 
invasion. This result contrasted with the increase in invasion observed in the MDA-MB-
231 cell line post GRP78 knockdown in this project. It was difficult to determine if this 
result due to GRP78 knockdown was accurate due to the lack of statistical significance 
however in the study of inhibition of MMP-26 several other targets as well as GRP78 
were overexpressed so the increase in invasion observed may have been due to other 
targets or a combinational effect. 
 
Proliferation was assessed post transfection through an acid phosphatase method as 
described in section 2.11. Analysis showed no significant effect on proliferation due to 
altered expression of GRP78 in either TNBC cell lines at a 24hr timepoint. This time point 
was utilised to accommodate the anoikis and invasion analysis. Both functions were 
assessed at a 24hr timepoint therefore to ensure any changes observed in anoikis or 
invasion were not due to proliferation changes, proliferation was assessed at a 24hr 
timepoint. It has been shown that overexpression of surface GRP78 increases 
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proliferation in breast cancer cells in vitro and that when the receptor for this surface 
GRP78 is blocked the level of cellular proliferation was reduced (Yao et al. 2015). This 
assessment of proliferation was over a 24hr period so this indicates it was possible to 
detect a change in proliferation due to altered GRP78 over a short time frame. As the 
doubling time of the TNBC cell lines is greater than 24hr (Limame et al. 2012), 
proliferation post GRP78 knockdown was also assessed after a 7-day period. This 
showed a highly significant 20% decrease in proliferation of the MDA-MB-468 cell line. 
The role of GRP78 in proliferation of cancer has been published, the previously 
mentioned paper using a 24hr assay showed overexpression of GRP78 increased the 
proliferation of breast cancer cells (Yao et al. 2015). Similar results have been observed 
in other cancer types such as gastric and colon cancer, with overexpression causing an 
increase in proliferation and reduced expression inducing a decrease in proliferation 
(Zhang et al. 2015, Fu et al. 2014, Yeung et al. 2008).  
 
The most noteworthy functional effect due to GRP78 knockdown was a large reduction 
in the number of colonies formed in both cell lines. A reduction in colony formation was 
observed in both 2D and 3D in the MDA-MB-231 cell line. In 2D a 40% decrease was 
observed in both colony area and staining intensity, equating to a reduction in colony 
number and size in the MDA-MB-231 cell line. In 3D, a 15% reduction in colonies formed 
was observed in the MDA-MB-231 cell line while a 40% reduction was observed in the 
MDA-MB-468 cell line. This reduction in colony formation was much larger in the MDA-
MB-468 cell line than in the MDA-MB-231 cell line. This may be due to the greater 
reduction of GRP78 expression in the MDA-MB-468 cell line, an 8-fold reduction was 
achieved as opposed to the 2-fold reduction observed in the MDA-MB-231 cell line. 
There are several reasons why greater knockdown can be achieved in one cell line over 
another. In terms of the two triple negative breast cancer cell lines, the apparent lesser 
knockdown in the MDA-MB-231 cell line may be down to doubling time. The MDA-MB-
231 cell line has a shorter doubling time (31.1hr) compared to the MDA-MB-468 cell line 
(62.8hr) (Risinger, Dybdal-Hargreaves and Mooberry 2015). Therefore, the shorter 
doubling time of the MDA-MB-231 cell line may have led to GRP78 expression returning 
to innate levels sooner than in the MDA-MB-468 cell line. Other reasons for the greater 
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knockdown achieved may be innately greater levels of GRP78 in the MDA-MB-231 cell 
line observed through qPCR and Western blotting. There was a 1 Ct value difference 
between the cell lines indicating a 2-fold greater expression of GRP78 in the MDA-MB-
231 cell line. This greater expression was also observed at the protein level as shown in 
Figure 3-7 and Figure 3-11. Therefore, while a similar transfection efficacy was achieved 
in both cell lines, the shorter doubling time of the MDA-MB-231 cell line and the innately 
greater expression levels may have led to the apparent lesser GRP78 knockdown. This 
may also have contributed to the greater reduction in colony formation observed in the 
MDA-MB-468 cell line. This reduction in colony formation was consistent with the 
literature; Kuo et al., reduced GRP78 expression through a stable transfection and 
assessed the effect on colony formation in two colon cancer cell lines, HT29 and DLD-1. 
This group observed a reduction in colony forming units in GRP78 knockdown cells, a 
50% reduction in colony formation was detected which was similar to the result shown 
by this current project in the MDA-MB-468 cell line. This group also observed a reduction 
in proliferation post GRP78 knockdown (Kuo et al. 2013). A reduction in colony 
formation due to decreased GRP78 expression has also been observed in renal cell 
carcinoma (Lin et al. 2014a). The method used in this paper was similar to the method 
used in this current body of work, a transient siRNA transfection was used to reduce 
GRP78 expression and then functional effects were assessed. A significant reduction in 
the ability of renal cell carcinoma cells to produce colonies was observed post GRP78 
knockdown (Lin et al. 2014a). This group also observed a reduction in cell growth post 
GRP78 knockdown as well as colony formation at 48hr and 72hr time points (Lin et al. 
2014a). Pathway Studios analysis had indicated a positive role of GRP78 in colony 
formation, Figure 3-5, which would agree with the data observed in this work as a 
reduction in GRP78 expression appeared to induce a reduction in colony forming ability. 
A relationship between colony formation, specifically spheroid formation, and stemness 
has been well established (Gauthaman et al. 2009, Cheng et al. 2013, Li et al. 2015, Li et 
al. 2015b). A connection between GRP78 and stemness has also been reported (Wu et 
al. 2010, Chiu et al. 2013, Heijmans et al. 2013, Cheng et al. 2016b). These reports may 
suggest that the reduction in colony forming ability of the TNBC cells due to reduced 
GRP78 may be linked to stemness. This is an aspect to be investigated further in future 
work, post GRP78 knockdown the stem-like phenotype of the cells may be investigated. 
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GRP78 is known to play a role in cancer progression, many publications have determined 
this (Yao et al. 2015, Zhang et al. 2015, Fu et al. 2014, Lin et al. 2014a, Matsumura et al. 
2014, Raiter, Yerushalmi and Hardy 2014, Kuo et al. 2013, Zhang and Zhang 2010, 
Quinones, Ridder and Pizzo 2008, Yeung et al. 2008). This role in progression was linked 
to the function of GRP78 as an ER stress response protein. GRP78 was elevated in many 
cancers and aids the cancer cells in evading stress-induced apoptosis (Matsumura et al. 
2014, Zhang and Zhang 2010, Quinones, Ridder and Pizzo 2008). The reduction in the 
proliferation and colony forming efficiency in TNBC observed in this work induced by 
reduced GRP78 expression ties in with this knowledge. The lowered expression of GRP78 
reduced the breast cancer cells ability to produce colonies and proliferate. Several 
studies further assessed reduced proliferation and colony formation due to GRP78 
knockdown using flow cytometry (Wang et al. 2015, Ji et al. 2016, Zhou et al. 2016). Due 
to the significant reduction in proliferation observed in the MDA-MB-468 cell line and 
the trend of reduced colony formation due to GRP78 knockdown, an interesting next 
step would be to assess which cycle of cell growth was arrested. The cell growth cycles 
can be easily assessed using the Guava® easyCyte Flow Cytometer available in-house in 
the NICB, with the Guava® Cell Cycle Assay which measures G0/G1, S and G2/M phase 
distributions. This analysis would identify the specific phase of cell growth that GRP78 
knockdown is arresting, inducing the observed reduction in proliferation and colony 
formation. This may determine a role of GRP78 in specific growth cycles of TNBC cells. 
To further investigate the effect of GRP78 on cell growth, analysis of phosphorylation of 
key cell cycle regulatory proteins such as AKT, JNK and ERK1/2 could be performed (Zhou 
et al. 2016). Alterations to phosphorylation of key cell cycle regulators could be assessed 
through Western blotting post GRP78 knockdown. Determining changes of 
phosphorylation of cell cycle regulators may identify the key regulators which GRP78 
knockdown has altered inducing the reduction in proliferation and colony formation. No 
change in anoikis was observed due to reduced GRP78 expression, therefore the original 
hypothesis did not validate. However, knowledge gained regarding the role of GRP78 in 
proliferation and colony formation was novel in terms of triple negative breast cancer 
as very few studies have investigated the role of GRP78 in TNBC. GRP78 may be a viable 
target to interfere and reduce triple negative breast cancer cells’ ability to proliferate 
and colonise in the process of metastasis.
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5. Results – Investigation of the Role 
of the Tumour Microenvironment in 
Pancreatic Cancer  
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5.1. Aim 
 
Investigate the role of the tumour microenvironment in the progression of pancreatic 
cancer using an indirect co-culture model. Pancreatic cancer is one of the most lethal 
cancers worldwide with a 5-year survival rate of only 6%. The poor prognosis and 
survival rate is partially due to the early onset of metastasis, which occurs soon after the 
development of the cancer. Metastasis is the ability of a cell to spread to another 
location in the body, colonising this secondary site with tumour growth. The pancreatic 
tumour microenvironment plays an important role in the progression of the cancer. The 
defined role the stroma plays in pancreatic cancer metastasis has not yet been fully 
elucidated. Aiming to investigate this role of the pancreatic cancer stroma, an indirect 
co-culture model was developed and utilised to determine the role the tumour 
microenvironment plays in the progression of pancreatic cancer.  
 
5.2. Pancreatic Cancer 
 
Pancreatic cancer is one of the most lethal cancers worldwide. The 5-year survival rate 
is approximately 6%, due to late diagnosis by which time usually metastasis has occurred 
(Rucki and Zheng 2014). A hallmark of pancreatic cancer is a high level of stroma in the 
tumours as seen in Figure 1-3, which is due to fibrosis. Fibrosis is defined as an 
accumulation of extracellular matrix (ECM) proteins due to the loss of balance between 
the manufacture and degradation of ECM (Apte, Pirola and Wilson 2012). This fibrosis 
plays a major role in the development and progression of pancreatic cancer.  This fibrosis 
develops due to the stromal cells present in the pancreatic microenvironment. This body 
of work aimed to investigate the role of stromal cells in the development and 
progression of pancreatic cancer. To determine this, the functional effects of indirect 
co-culture of pancreatic cancer cell lines with human primary fibroblasts and pancreatic 
stellate cells were assessed, analysing the impact of cell to cell interactions. The 
functional effects assessed included proliferation, anoikis, invasion and colony 
formation. These functions were investigated due to their important role in the cascade 
of metastasis. 
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5.3.  Panel of pancreatic cancer cell lines 
 
The first step of the project was to establish the phenotypic properties of a panel of 
pancreatic cancer cell lines. Table 5-1 displays the origin and a representative image of 
the cell line in mono culture. 
 
 
Table 5-1. Characteristics of a panel of four pancreatic cancer cell lines 
Cell 
Line 
Morphology Mutational Status Culture 
AsPc-1 
Epithelial cell line which 
produces abundant amounts 
of mucin. Derived from nude 
mouse xenografts initiated 
with cells from an ascites site 
in a female 62-year-old 
patient. Produce abundant 
mucin. 
Mutated: 
KRAS,TP53 
Wildtype: 
CDKN2A/p16, 
SMAD4/DPC4 
 
BxPc-3 
Epithelial cell line which grows 
as tight sheets. Obtained from 
a female 61-year-old patient 
with cancer of the body of the 
pancreas. No metastasis had 
occurred 
Mutated: TP53, 
SMAD4/DPC4 
Wildtype: KRAS, 
CDKN2A/p16 
 
Mia 
PaCa-2 
Epithelial cell line with a 
mesenchymal morphology. 
Developed from a tumour of a 
male 65-year-old patient 
involving the body and tail of 
the pancreas and had 
infiltrated the periaortic area 
Mutated: 
KRAS,TP53, 
CDKN2A/p16, 
SMAD4/DPC4 
 
 
Panc-1 
Epithelial cell line with a 
cuboidal morphology. 
Originated from a tumour of a 
female 56-year-old patient in 
the head of the pancreas 
which invaded the duodenal 
wall 
Mutated: 
KRAS,TP53, 
CDKN2A/p16 
Wildtype: 
SMAD4/DPC4 
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Figure 5-1. Levels of anoikis across a panel of pancreatic cancer cell lines 
 
Characterisation of innate anoikis levels of four pancreatic cancer cells lines, AsPc-1, Mia PaCa-2, Panc-1 
and BxPc-3. Assessment of the metabolic rate of a panel of pancreatic cancer cell lines in suspension 
conditions compared to attached conditions, as described in section 2.3 displayed as percentage anoikis 
i.e. the percentage cells surviving and metabolising in suspension conditions. Error bars represent +/- 
standard deviation between biological replicates, (n=3).  
 
Figure 5-2. Levels of invasion across a panel of pancreatic cancer cell lines 
 
Characterisation of innate invasion levels of four pancreatic cancer cells lines, AsPc-1, Mia PaCa-2, Panc-1 
and BxPc-3. Displayed as average number of invaded cells per field of view, to assess the invasive ability 
of a panel of pancreatic cancer cell lines. Error bars represent +/- standard deviation between biological 
replicates, (n=3).  
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Table 5-2. Relative levels of invasion and anoikis resistance across a panel of four 
pancreatic cancer cell lines 
 
Characteristics Relative Levels 
Invasion BxPc-3 > Panc-1 ≥ Mia PaCa-2 > AsPc-1 
Anoikis Resistance Mia PaCa-2 > Panc-1 > AsPc-1 > BxPc-3 
 
Table 5-2  displays the basal levels of invasion and anoikis resistance across the panel of 
pancreatic cancer cell lines. The relative levels of anoikis resistance were determined 
from the data in Figure 5-1 and the levels of invasion are shown in Figure 5-2. These are 
the levels observed across the cell lines through multiple experiments. The levels of 
invasion observed, are in line with published data from a paper by Deer et al., which 
reviews the phenotype and genotype of commonly used pancreatic cancer cell lines 
(Deer et al. 2010). Interestingly, there does not appear to be an exact correlation 
between invasive capabilities and ability to survive anoikis, the BxPc-3 cell possess the 
highest level of invasion but is the most anoikis sensitive whereas the Mia PaCa-2 cell 
line displays medium to low invasion levels with a high level of anoikis resistance. This 
panel was chosen as these four cell lines represented a wide range of levels in two of 
the cellular functions being assessed in this body of work. 
 
5.4. Functional effects of 48hr indirect co-culture with stromal cell populations 
 
This body of work aimed to investigate the role of stromal cells in the development and 
progression of pancreatic cancer. To determine this the functional effects of indirect co-
culture of pancreatic cancer cell lines with human primary fibroblasts and pancreatic 
stellate cells were assessed, analysing the impact of cell to cell interactions. This work 
involved culturing the panel of pancreatic cancer cell lines with pancreatic stromal cells 
above in a co-culture insert as described in section 2.15 and shown in Figure 5-3. After 
48hr of co-culture the pancreatic cancer cells were detached and assessed for changes 
in levels of survival in suspension i.e. anoikis, proliferation and invasion due to indirect 
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co-culture. These functions were investigated due to their important role in the cascade 
of metastasis.  
 
5.4.1. Functional effects of 48hr indirect co-culture with tumour derived fibroblasts 
(Pt-102) 
 
The patient tumour derived fibroblasts were developed in house. Tumour samples, 
received from St. Vincent’s University Hospital, were enzymatically digested using 
hyaluronidase and collagenase. Following this digestion, the samples were then 
explanted into culture and outgrowth used to develop fibroblasts. The first fibroblast 
line developed, Pt-102, was derived from a poorly differentiated cholangiocarcinoma 
diagnosed in a 61-year-old Irish male. These patient tumour derived fibroblasts were 
used to investigate the role of stromal cells in the development and progression of 
pancreatic cancer. This work involved culturing the panel of pancreatic cancer cell lines 
with the tumour derived fibroblasts (Pt-102) above in a co-culture insert. After 48hr of 
co-culture the pancreatic cancer cells were detached and assessed for changes in levels 
of survival in suspension i.e. anoikis, proliferation and invasion due to indirect co-
culture. 
 
 
Figure 5-3. A schematic of the indirect co-culture model used to investigate the 
pancreatic tumour microenvironment  
 
Schematic of the indirect co-culture model set up. Pancreatic cancer cells are seeded in a 6 well plate with 
the stromal cell population above in a co-culture insert above. The insert contains a polyester membrane 
with 3.0µm pores which allow secretions to pass between the two cell types (Crosson 2014). 
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Figure 5-4. Percentage survival in attached and suspension conditions of Mia PaCa-2 
cells post co-culture 
 
Percentage survival at 24hr in attached and suspension i.e. anoikis conditions, relative to attached mono 
culture of the Mia PaCa-2 cell line following 48hr indirect co-culture with pancreatic tumour derived 
fibroblasts (Pt-102). Error bars represent +/- standard deviation between biological replicates, (n=3). 
 
Figure 5-5. Percentage survival in attached and suspension conditions of Panc-1 cells 
post co-culture 
 
Percentage survival at 24hr, in attached and suspension i.e. anoikis conditions, relative to attached mono 
culture of the Panc-1 cell line following 48hr of indirect co-culture with pancreatic tumour derived 
fibroblasts (Pt-102). Error bars represent +/- standard deviation between biological replicates, (n=3). 
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Following 48hrs exposure to the secondary cell type, in this instance, fibroblasts, the 
pancreatic cancer cells were trypsinised and in seeded into attached and suspension 
conditions for 24hr to assess survival post co-culture  Post co-culture, in suspension 
conditions survival was increased by 20% compared to mono culture cells in Mia PaCa-
2 cells as seen in Figure 5-4. Co-culturing the Mia PaCa-2 cells with tumour derived 
fibroblasts over a 48hr period appears to have increased the cancer cells ability to 
survive in suspension. Figure 5-4 also showed an increase in survival (25%) in attached 
conditions post co-culture compared to mono culture which may indicate an increase in 
growth. The dye used in the anoikis assay, Alamar Blue, measures metabolic activity 
indicating post co-culture, it appears more metabolism was present leading to the 
conclusion that more cells were present. No effect on survival in either attached or 
suspension conditions were observed post co-culture in the Panc-1 cell line, seen in 
Figure 5-5. AsPc-1 and BxPc-3 do not feature in the anoikis results as both these cell lines 
are highly anoikis sensitive it is extremely difficult to get successful data from an anoikis 
assay using these cell lines. The cell lines clump and metabolise the dye very little which 
can lead to negative readings, cells may also become senescent. 
 
Figure 5-6. Percentage proliferation post co-culture across a panel of pancreatic cancer 
cell lines 
 
Percentage proliferation after 7 days’ incubation, following 48hr of indirect co-culture relative to mono 
culture, of AsPc-1, BxPc-3, Mia PaCa-2 and Panc-1 cell lines with pancreatic tumour derived fibroblasts 
(Pt-102). Error bars represent +/- standard deviation between biological replicates, (n=3, * = p value ≤ 
0.05, Mia PaCa-2 p value = 0.03). 
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Proliferation was assessed after 7 days of culture which was preceded by 48hr of co-
culture using an acid phosphatase method described in section 2.11. The hypothesis that 
the increased survival of the Mia PaCa-2 cells observed post co-culture in attached 
conditions (Figure 5-4) was due to increased proliferation, was validated by Figure 5-6. 
This figure shows a significant increase in proliferation in the Mia Pa-Ca-2 cell line post 
co-culture compared to mono culture. The increase in proliferation across three 
biological replicates was calculated as 20% with this result being significant due to a p 
value of 0.03. There was also no effect on proliferation, in Figure 5-6, of the Panc-1 cell 
line relative to mono culture. There was a slight increase in proliferation in the BxPc-3 
cell line post co-culture while a slight decrease in proliferation was observed in the AsPc-
1 cell line, although neither result showed significance. 
 
Figure 5-7. Percentage invasion post co-culture across a panel of pancreatic cancer cell 
lines 
 
Percentage invasion at 24hr post 48hr of indirect co-culture with pancreatic tumour derived fibroblasts 
(Pt-102) relative to mono culture of AsPc-1, BxPc-3, Mia PaCa-2 and Panc-1 cell lines. Error bars represent 
+/- standard deviation between biological replicates, (n=3, ** = p value ≤ 0.01, Mia PaCa-2 p value = 0.01, 
Panc-1 p value = 0.003). 
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Figure 5-8. Representative images of invasion post a) mono culture and b) co-culture 
conditions across a panel of pancreatic cancer cell lines 
 
 
   
   
   
   
Representative images of invasion levels following both A) mono and B) co-culture of AsPc-1, BxPc-3, Mia 
PaCa-2 and Panc-1 cell lines with pancreatic tumour derived fibroblasts (Pt-102). 
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The most notable change in phenotype following co-culture with human tumour derived 
fibroblasts (Pt-102) was an increase in invasive capabilities in three out of the four cell 
lines: BxPc-3, Mia PaCa-2 and Panc-1 shown in Figure 5-7 and Figure 5-8. This increase 
was significant in both the Mia PaCa-2 and Panc-1 cell line with an increase of 100% and 
a p value of 0.01 and an increase of 40% and a p value of 0.01, respectively. BxPc-3 cells 
exhibited a higher level of invasion post co-culture, an increase of 60% but this result 
was not significant. This may be due to the high level of error observed in the invasion 
of the BxPc-3 cell line as these cells invaded as clumps of cells as seen in Figure 5-8. 
Analysing invasion using a cell counting method may be not ideal for this cell line. AsPc-
1, a lowly invasive cell line appeared to become less invasive, a 40% reduction, following 
co-culture with the tumour derived fibroblasts. Figure 5-8 contains pictures of invasion 
levels for all four cell lines post mono culture and co-culture.  
 
5.4.2. Functional effects of conditioned media of Pt-102 
 
It was hypothesised that the significant increase in invasion post co-culture observed in 
both the Mia PaCa-2 and Panc-1 cell lines may be due to secretions being released by 
the tumour derived fibroblasts. To assess this hypothesis an experiment was designed 
to examine if the secretions from the fibroblasts induced the same functional effects. 
This involved using the exact previous co-culture set up with one main difference, 
instead of the fibroblasts being seeded above in a transwell insert conditioned media 
(CM) from the fibroblasts was used as a treatment for the pancreatic cancer cells. In an 
effort to maintain consistency between the two different experiment types several steps 
were taken. This included using media containing FBS in the conditioned media 
treatment, it is usual practice when performing conditioned media experiments to use 
serum-free media. Also, conditioned media practices generally involve concentrating 
the conditioned media. These steps were not used in this experiment as the aim was to 
maintain as much consistency as possible between the co-culture set up and the 
treatment i.e. serum containing media with no concentration of the conditioned media. 
The fibroblasts were cultured for 48hr in a 6 well format using the same cell number 
seeded in the co-culture insert (1x105). Conditioned media was then collected, debris 
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removed through centrifugation before treating the pancreatic cancer cells. The 
pancreatic cancer cells were treated with the CM for 48hr before being removed and 
assessed for functional effects. 
 
Figure 5-9. Percentage survival in attached and suspension conditions of Mia PaCa-2 
cells post conditioned media treatment 
 
Percentage survival relative to attached mono culture, in attached and suspension i.e. anoikis, conditions 
of the Mia PaCa-2 cell line following treatment with conditioned media from the pancreatic tumour 
derived fibroblasts (Pt-102).  Error bars represent +/- standard deviation between biological replicates, 
(n=3). 
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Figure 5-10. Percentage survival in attached and suspension conditions of Panc-1 cells 
post conditioned media treatment  
 
Percentage survival relative to attached mono culture, in attached and suspension i.e. anoikis, conditions 
of the Panc-1 cell line following treatment with conditioned media from the pancreatic tumour derived 
fibroblasts (Pt-102). Error bars represent +/- standard deviation between biological replicates, (n=3, * = p 
value ≤ 0.05). 
 
 
Treatment of Mia PaCa-2 cells with conditioned media from tumour derived fibroblasts 
(Pt-102) resulted in no change in levels of survival while in suspension or attached 
conditions post treatment, as seen in Figure 5-9. A slight increase in survival (5%) was 
observed in the Panc-1 cell line, shown in Figure 5-10, in suspension conditions post CM 
treatment compared to mono culture. While this result shows statistical significance, a 
5% change is not sufficient to be considered biologically significant. A slight increase in 
the Panc-1 cells ability to survive in suspension may have been induced due to CM 
treatment. 
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Figure 5-11. Percentage proliferation in Mia PaCa-2 and Panc-1 cells post conditioned 
media treatment 
 
Percentage proliferation of Mia PaCa-2 and Panc-1 cell lines following treatment with conditioned media 
from the pancreatic tumour derived fibroblasts (Pt-102). Error bars represent +/- standard deviation 
between biological replicates, (n=3). 
 
 
Post CM treatment a small increase in proliferation, ~10%, was observed, seen in Figure 
5-11, in both the Mia PaCa-2 and Panc-1 cell lines, although analysis showed these 
results did not possess statistical significance. This proliferation level was measured 
after 7 days of culture prior to which the pancreatic cancer cells had been treated for 
48hr with Pt-102 fibroblasts CM. 
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Figure 5-12. Percentage invasion of the Panc-1 cell line post treatment with conditioned 
media 
 
Percentage invasion of the Panc-1 cell line post treatment with conditioned media of pancreatic tumour 
derived fibroblasts (Pt-102) relative to mono culture of the Panc-1 cell line. Error bars represent +/- 
standard deviation between biological replicates, (n=2, * = p value ≤ 0.05, p value = 0.05).  
 
 
The most noteworthy phenotypic change post CM is displayed in Figure 5-12, showing a 
50% reduction in invasion of the Panc-1 cell line relative to mono culture. Analysis 
showed this result to be of low significance which may be due to the presence of only 
two biological replicates and error between biological replicates. The pancreatic cancer 
cells were treated with Pt-102 fibroblasts CM for 48hr prior to assessment for changes 
in invasive capabilities over 24hr of culture in the invasion assay set up, described in 
section 2.12. 
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5.4.3. Functional effects of indirect co-culture with tumour derived fibroblasts (Pt-127) 
 
To further investigate the role of stromal cells in the development and progression of 
pancreatic cancer, the functional effects of indirect co-culture of pancreatic cancer cell 
lines with a second batch of human primary fibroblasts derived from a different patient 
(Pt-127), were assessed. While both fibroblast primary cell lines were developed in the 
same way, they have differences, see section 2.1.1.. Both fibroblast populations had 
different pathology, levels of differentiation and invasive capabilities. Due to these 
differences, it was important to assess both stromal populations in the indirect co-
culture model to assess if similar or different phenotypic changes were induced. It was 
highly important to ensure the changes observed were not batch specific and to assess 
differences observed due to different diagnosis or pathology. This work involved 
culturing the panel of pancreatic cancer cell lines with tumour derived fibroblasts above 
in a co-culture insert, as described in section 2.15. After 48hr the panel of pancreatic 
cancer cells were detached and assessed for changes in levels of survival in suspension 
i.e. anoikis, proliferation and invasion due to indirect co-culture. The panel of cell lines 
was reduced from four to two; to include just the Mia PaCa-2 and Panc-1 cell lines as 
these showed the most significant results in previous co-culture experiments using Pt-
102 fibroblasts. These were also the most flexible and adaptable cell lines in all of the 
functions this work assessed. The BxPc-3 and AsPc-1 cell lines were not suitable for 
invasion or anoikis assays. Statistical significance was not shown in any of the phenotypic 
changes induced due to Pt-127 fibroblasts as before three biological replicates were 
performed a change in assay format occurred. This change in assay format occurred due 
to results observed and described in section 5.5, time-course experiment. 
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Figure 5-13. Percentage survival in attached and survival conditions of Mia PaCa-2 cells 
post co-culture with Pt-127 
 
Percentage survival relative to attached mono culture, in attached and suspension i.e. anoikis, conditions 
of the Mia PaCa-2 cell line following indirect co-culture with pancreatic tumour derived fibroblasts (Pt-
127). Error bars represent +/- standard deviation between biological replicates, (n=3).  
 
Figure 5-14. Percentage survival in attached and survival conditions of Panc-1 cells post 
co-culture with Pt-127 
 
Percentage survival relative to attached mono culture, in attached and suspension i.e. anoikis, conditions 
of the Panc-1 cell line following indirect co-culture with pancreatic tumour derived fibroblasts (Pt-127). 
Error bars represent +/- standard deviation between biological replicates, (n=2). 
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Indirect co-culture of pancreatic cancer cell lines with a different batch of fibroblasts, 
derived from patient 127 (Pt-127) yielded the following results. Figure 5-13 displays a 
small decrease in survival of the Mia PaCa-2 cell line in both attached and suspension 
conditions post co-culture. The opposite result was observed in the Panc-1 cell line, 
shown in Figure 5-14 an increase in survival in both attached (13%) and suspension (15%) 
conditions post co-culture. The increase in survival in attached conditions post co-
culture compared to mono culture (13%) may indicate an increase in growth. 
 
Figure 5-15. Percentage proliferation of Mia PaCa-2 and Panc-1 cells post co-culture 
with Pt-127 
 
Percentage proliferation following co-culture relative to mono culture of Mia PaCa-2 and Panc-1 cell lines 
with pancreatic tumour derived fibroblasts (Pt-127). Error bars represent +/- standard deviation between 
biological replicates, (Mia PaCa-2 n=3, Panc-1 n=2). 
 
The hypothesis that the increase in survival of the Panc-1 cells in attached conditions 
observed in Figure 5-14 was due to an increase in growth was confirmed, shown in 
Figure 5-15. This shows a large (115%) increase in proliferation in the Panc-1 cell line and 
it can also be seen that a reduction in proliferation (20%) was observed in Mia PaCa-2 
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cells post co-culture with Pt-127 fibroblasts. Neither result showed statistical 
significance. 
 
Figure 5-16. Percentage invasion of Mia PaCa-2 and Panc-1 cells post co-culture with Pt-
127 
 
Percentage invasion following co-culture of Mia PaCa-2 and Panc-1 cell lines with pancreatic tumour 
derived fibroblasts (Pt-127) relative to mono culture. Error bars represent +/- standard deviation between 
biological replicates, (n=2). 
 
Both cell lines displayed a large increase in invasion post co-culture as seen in Figure 
5-16, 300% and 450% respectively, while large error bars are present the trend was 
visible with each biological replicate. More biological replicates are required to analyse 
if statistical significance is present, it does appear a trend of a large increase in invasion 
was present in both the Mia PaCa-2 and Panc-1 cell lines post co-culture with Pt-127 
fibroblasts. 
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5.4.4. Functional effects of indirect co-culture with pancreatic stellate cells 
 
Another aspect of the pancreatic tumour microenvironment being investigated in this 
work was the role of the pancreatic stellate cell. The indirect co-culture model was used 
with pancreatic stellate cells as the stromal component to assess phenotypic changes 
induced in the pancreatic cancer cells post indirect co-culture. Several different batches 
of human pancreatic stellate cells were donated by Dr. Masamune, based in Tohoku 
University in Sendai, Japan. Statistical significance was not shown in any of the 
phenotypic changes induced due to hPSC24 stellate cells as before three biological 
replicates were performed a change in assay format occurred. This change in assay 
format occurred due to results observed and described in section 5.5, time-course 
experiment.  
 
Figure 5-17. Percentage proliferation of Mia PaCa-2 and Panc-1 cells post co-culture 
with pancreatic stellate cells (hPSC24) 
 
Percentage proliferation following co-culture relative to mono culture, of Mia PaCa-2 and Panc-1 cell lines 
with human pancreatic stellate cells (hPSC24). Error bars represent +/- standard deviation between 
biological replicates, (n=2). 
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Co-culture of the Mia PaCa-2 and Panc-1 cell lines with human pancreatic stellate cells 
(hPSC24) resulted in a 20% reduction in proliferation in both the Mia PaCa-2 and Panc-
1 cell line, Figure 5-17. Analysis showed neither result displayed statistical significance. 
 
 
Figure 5-18. Percentage invasion of Mia PaCa-2 and Panc-1 cells post co-culture with 
pancreatic stellate cells (hPSC24) 
 
Percentage invasion following co-culture relative to mono culture, of Mia PaCa-2 and Panc-1 cell lines 
with human pancreatic stellate cells (hPSC24). Error bars represent +/- standard deviation between 
biological replicates, (Mia PaCa-2 n=1, Panc-1 n=2). 
 
Conversely to the proliferation result in Figure 5-17 both cells lines exhibited a large 
increase in invasion post co-culture with hPSC24 cells, 70% and 50% respectively, shown 
in Figure 5-18. Due to these contrasting phenotypes, it can be deducted that this 
increase in invasion was not due to an increase in proliferation. These results require 
more biological replicates to determine if these effects were statistically significant.  
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5.5. Time-course experiment 
 
In previous co-culture experiments a time-point of 48hr had been used to assess 
functional effects of co-culture. This time-point was chosen based on literature and 
publications on co-culture of stromal cells with pancreatic cancer cells (Takikawa et al. 
2013, Kikuta et al. 2010, Fujita et al. 2009). Co-cultures up until this point had shown 
some but inconsistent effects on proliferation across the panel. Assessment of 
proliferation post co-culture in previous experiments has involved trypsinisation of cells 
post mono and co-culture. The same cell number was then seeded and incubated over 
five days. On the fifth day, an acid phosphatase experiment, see section 2.11, was 
performed to assess proliferation. To assess if this co-culture set up was optimum for 
assessing functional effects a time-course experiment was performed. This involved 
setting up indirect co-cultures of Pt-102 fibroblasts with the Mia PaCa-2 cell line and 
assessing for functional effects on invasion and proliferation through cell counts, after 
24, 48 and 72 hours of co-culture. 
 
Figure 5-19. Cell number of Mia PaCa-2 cells post indirect co-culture with tumour 
derived fibroblasts (Pt-102) at a range of time-points 
 
Cell number of the Mia PaCa-2 cell line following both mono and co-culture of with pancreatic tumour 
derived fibroblasts (Pt-102) at time-points of 24hr, 48hr and 72hr assessed using a haemocytometer, 
(n=1).
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Figure 5-20. Invasion levels of Mia PaCa-2 cells post co-culture with tumour derived 
fibroblasts (Pt-102) at a range of time-points 
 
Average number of invading cells per field of view following co-culture of Mia PaCa-2 cell line with 
pancreatic tumour derived fibroblasts (Pt-102) at time-points of 24hr, 48hr and 72hr, (n=1). 
 
Figure 5-19 shows the cell number of the Mia PaCa-2 cell line following both mono and 
co-culture of with pancreatic tumour derived fibroblasts (Pt-102) at time-points of 24hr, 
48hr and 72hr. While the cell number increases over time due to culture there was an 
increase in cell number post co-culture compared to mono culture at both the 48hr and 
72hr time-points. This increase appeared to continue incrementally over the length of 
the time-course. Figure 5-20 shows the changes in invasion following co-culture of Mia 
PaCa-2 cell line with pancreatic tumour derived fibroblasts (Pt-102) at time-points of 
24hr, 48hr and 72hr. An increase in invasion post co-culture was observed at both the 
24 and 48hr time-point but the effect on invasion post co-culture appeared to have 
tapered off at the 72hr time-point. While the previous co-culture format was efficient 
at examining phenotypic changes in invasion post co-culture it was not sufficient to 
assess the changes the stromal cells induced in the proliferation levels of the pancreatic 
cancer cells. 
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5.6. In-assay indirect co-culture of Panc-1 cells with stromal cells 
 
A hypothesis that an effect on proliferation due to co-culture was present but being 
missed in proliferation experiments was established due to the observation that the cell 
number in samples post co-culture with Pt-102 was consistently higher than mono 
culture samples, this effect can be seen in Figure 5-19. This hypothesis was confirmed 
through Figure 5-19 and Figure 5-20. This was found to be especially true for the Panc-
1 cell line which consistently displayed a higher cell number post co-culture but no effect 
on proliferation was found, as seen in Figure 5-6. Due to this, the Panc-1 cell line was 
used to investigate phenotypic changes in proliferation and colony formation due to the 
presence of tumour derived fibroblasts with an ‘in assay’ co-culture format. In this 
format the two cell populations are indirectly co-cultured in the functional assay set up 
for the duration of the assay as opposed to the previous format. The previous format 
involved only a 48hr co-culture with the cells being trypsinised and re-seeded into 
functional assays. This new, ‘in-assay’ format involved the Panc-1 cells being seeded into 
functional assays (proliferation and colony formation assays) with the stromal cells 
above in a co-culture insert for the entire length of the assay (7 days for proliferation, 
14 days for colony formation). Meaning the cancer and stromal cells were interacting 
throughout the time of the assay, at the end point the effect of co-culture on 
proliferation and colony formation was examined. Colony formation was assessed for 
phenotypic changes post co-culture also as it can also be an indication of changes in 
growth.   
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Figure 5-21. Percentage proliferation of Panc-1 cells post in-assay co-culture with Pt-102 
and hPSC24 
 
Percentage proliferation following 7 days of in-assay co-culture of Panc-1 cell lines with pancreatic tumour 
derived fibroblasts (Pt-102) and human pancreatic stellate cells (hPSC24) relative to mono culture. Error 
bars represent +/- standard deviation between biological replicates, (n=3, * = p value ≤ 0.05, *** = p value 
≤ 0.001, Pt-102 p value = 0.00066, hPSC24 p value = 0.02). 
 
An increase in proliferation of the Panc-1 cells was observed post 7 days of in-assay co-
culture with the tumour derived fibroblasts (Pt-102) and human pancreatic stellate cells 
(hPSC24), shown in Figure 5-21. Proliferation was assessed using the acid phosphatase 
method detailed in section 2.11, with the proliferation of co-cultured cells displayed 
relative to mono culture. The increase in proliferation post co-culture with Pt-102 
fibroblasts across three biological replicates was calculated as 35% with this result being 
highly significant due to a p value of 0.00066. The increase in proliferation post co-
culture with hPSC24 was observed to be 28% with this result being lowly significant due 
to a p value of 0.02. 
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Figure 5-22. Colony formation of Panc-1 cells post in-assay co-culture with Pt-102 
 
Number of colonies and average colony area percentage relative to mono culture of Panc-1 cells observed 
14 days’ post mono and in-assay co-culture with tumour derived fibroblasts (Pt-102). Colonies were 
analysed using MetaMorph software. Error bars represent +/- standard deviation between biological 
replicates, (n=3, * = p value ≤ 0.05, p value = 0.03). 
 
Figure 5-23. Representative image of colony formation of Panc-1 cells post in-assay co-
culture 
 
 
 
 
 
 
 
 
Representative image of colonies of Panc-1 cells observed post mono and in-assay co-culture with tumour 
derived fibroblasts (Pt-102). 
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Post in-assay co-culture with Pt-102 fibroblasts, Panc-1 cells formed a greater number 
of colonies and colonies of a larger size relative to colonies of mono cultured Panc-1 
cells, as seen in Figure 5-22. Analysis (MetaMorph Image Analysis software) of the 
number of colonies did not show a significant p value but a trend of greater number of 
colonies being formed post co-culture appeared to be present, as shown in Figure 5-23 
The average increase in colony size across three biological replicates was 60% larger 
colonies formed post co-culture relative to mono culture with a p value of 0.03. The 
functional effect of hPSC24 on colony formation was being assessed but before three 
biological replicates were achieved, the results in the following sections were observed. 
 
5.7. Determination of the optimum co-culture control 
 
To assess if the increase in proliferation observed in Figure 5-21 was due to the presence 
of the stromal cell populations a range of co-culture variants were assessed. These 
included different media in the insert above with no cells present, the fibroblasts above 
in different media and a later passage number of fibroblasts above. The different media 
types were assessed as the pancreatic cancer cells were grown in DMEM media while 
each of the stromal cell populations were cultured in RPMI media. A later passage 
number of Pt-102 fibroblasts was used to investigated if the activity or influence of the 
fibroblasts diminished after long culture periods, as it was important to be aware that 
these cells are primary i.e. not immortal. 
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Figure 5-24. Proliferation of Panc-1 cells using a range of co-culture variants 
 
Proliferation levels of Panc-1 cells using a range of co-culture variants including RPMI above, DMEM 
above, Pt-102 fibroblasts in RPMI above, Pt-102 fibroblasts in DMEM above and passage 14 Pt-102 
fibroblasts in RPMI above. The mono culture control is Panc-1 cells with no insert above. Error bars 
represent +/- standard deviation between technical replicates, (n=1). 
 
Figure 5-24 shows the effects of all co-culture variants investigated on proliferation in 
the Panc-1 cell line. This data showed that media alone, without stromal cells, above 
Panc-1 cells induced an increase in proliferation. The increase from RPMI alone at 50% 
is double the effect seen in DMEM alone, at 26%. A greater increase in proliferation, 
13%, was observed when Pt-102 fibroblasts were above in RPMI than RPMI alone. There 
appeared to be no difference between DMEM alone and Pt-102 fibroblasts in DMEM 
above. Pt-102 fibroblasts at passage 14 induced a 60% increase in proliferation in Panc-
1 cells relative to mono culture control i.e. no transwell insert above.
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Figure 5-25. Proliferation of Panc-1 cells using volume controls with CM treatment 
 
Proliferation levels of Panc-1 cells using volume controls with conditioned media from tumour derived 
fibroblasts (Pt-102). Mono culture controls contain fresh DMEM media while the CM treatment contains 
50% fresh DMEM with 50% conditioned RPMI media. Error bars represent +/- standard deviation between 
technical replicates, (n=1). 
 
To ensure the effects on proliferation displayed in Figure 5-24 were not due to volume 
differences a volume control CM treatment experiment was performed. This involved 
two volumes, 2mL and 4mL. Previous experimental work used a mono culture control of 
2mL with a co-culture of 4mL. Figure 5-25  displays an increase in proliferation in both 
CM treatments compared to mono culture whether 2mL or 4mL of volume was present. 
As there was no significant difference between the mono culture controls or CM 
treatments of 2mL and 4mL, the volume differences did not appear to be responsible 
for the phenotypic changes observed post co-culture.
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Figure 5-26. Proliferation of Panc-1 cells using a range of co-culture variants with an appropriate control 
 
Proliferation levels of Panc-1 cells using a range of co-culture variants with Panc-1 cells in DMEM with DMEM above as a control. The variants include Pt-102 fibroblasts in 
DMEM above, Panc-1 cells in DMEM above, Panc-1 cells in RPMI with RPMI above, Panc-1 cells in RPMI with Pt-102 fibroblasts in RPMI above, Panc-1 cells in RPMI with Panc-
1 cells in RPMI above, Panc-1 cells in DMEM with RPMI above, Panc-1 cells in RPMI with DMEM above and Panc-1 cells in DMEM with Pt-102 fibroblasts in RPMI above. Error 
bars represent +/- standard deviation between technical replicates, (n=1).
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The previous range of controls, Figure 5-24, displayed that complete DMEM media in a 
co-culture insert above induced an increase in proliferation. This result led to an 
investigation of volume differences. Figure 5-25 portrays that the functional changes 
observed post co-culture were not due to volume differences between mono and co-
culture set ups. Following this, a larger screen of co-culture variants were investigated 
using as the mono culture control, Panc-1 cells in DMEM below a co-culture insert with 
complete DMEM media above, as seen in Figure 5-26. In comparison to this control, it 
appeared fibroblasts above in DMEM had no effect on proliferation of the cancer cells. 
Interestingly, Panc-1 cells in DMEM with Panc-1 cells above in DMEM induced a 20% 
increase in proliferation. Panc-1 cells in RPMI media with RPMI above seemed to 
proliferate faster than Panc-1 cells in DMEM with DMEM above, with an increase of 15% 
found. When Pt-102 fibroblasts were present in RPMI above Panc-1 cells in RPMI this 
effect on proliferation rose to an increase of 70%. When the cell population above was 
Panc-1 cells in RPMI instead of fibroblasts, above Panc-1 cells in RPMI the effect 
increased again to 85%. Surprisingly the greatest effect on proliferation was observed 
when no second cell population was present above but when a mix of media types was 
present. Panc-1 cells in DMEM with RPMI above induced a 90% increase while Panc-1 
cells in RPMI with DMEM above caused a 110% increase in proliferation. Panc-1 cells in 
DMEM with Pt-102 fibroblasts in RPMI above, which had been the co-culture set up 
previously used resulted in a 40% increase in proliferation of the Panc-1 cells. This large 
effect present due to a mix of DMEM and RPMI may be due to the formulations of the 
media types providing a wider range of nutrients or nutrients in greater amounts. A brief 
investigation of the media formulations, identified that almost every nutrient was 
different between the two media types. To identify the root of the effect observed due 
to the mix of media, a large in-depth analysis will be necessary. 
 
5.8. Determination of activation state of tumour derived fibroblasts 
 
The activation state of stromal cells is an area of research gathering a lot of attention as 
discussed in section 1.4.3.2. Whether the stromal cells in the pancreatic tumour 
microenvironment are activated or quiescent has a major impact on the influence the 
155 
 
stromal cells have on the pancreatic cancer cells. There are a wide range of markers 
published to distinguish between activated and quiescent stromal cells, as discussed in 
section 1.4.3.2. Research focusing on the role of stromal cells is now including 
examinations of the activation state of the stromal cell populations. The activation state 
of the tumour derived fibroblasts used in this body of work was examined for the marker 
podoplanin. A published study of podoplanin as an activation marker in CAFs observed 
that CAFs positive for podoplanin expression enhanced the invasive capabilities of the 
pancreatic cancer cells through co-culture compared to CAFs with no podoplanin 
expression (Shindo et al. 2013). I aimed to assess the activation state of the tumour 
derived fibroblasts through podoplanin expression and also assessed if the activation 
state increased due to co-culture with pancreatic cancer cells as the previously 
mentioned study had observed this to be true. 
 
Figure 5-27. Level of podoplanin protein in patient tumour derived fibroblasts (Pt-102) 
 
 
A. Western blot showing podoplanin protein, 17 kDa, levels in patient tumour derived fibroblasts (Pt-102) 
post 72hr co-culture with a panel of pancreatic cancer cell lines above. B. β-actin levels across all five 
samples is included as a loading control. 
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Figure 5-28. Densitometry analysis of podoplanin protein in patient tumour derived 
fibroblasts (Pt-102) 
 
Densitometry analysis of Podoplanin protein levels in patient tumour derived fibroblasts (Pt-102) innately 
and following a 72hr co-culture with a panel of pancreatic cancer cells lines (Panc-1, Mia PaCa-2 and 
SW1990). Protein quantity was analysed using TotalLab Quant software, relative to β-actin used as the 
loading control (n=1). 
 
Assessment of the activation state of Pt-102 tumour derived fibroblasts used Western 
blot analysis of podoplanin expression, as seen in Figure 5-27 and further analysis using 
densitometry, shown in Figure 5-28. It was determined that Pt-102 fibroblasts express 
podoplanin protein indicating that Pt-102 fibroblasts are in an activated state. 
Podoplanin expression was also assessed post co-culture with a panel of pancreatic 
cancer cell lines. This was to assess if the activation state increased due to co-culture 
with pancreatic cancer cells as the previously mentioned study had observed this to be 
true (Shindo et al. 2013). In the present study, this involved a 72hr indirect co-culture 
with the fibroblasts seeded in the well with the second cell population seeded above in 
a transwell insert. Pt-102 fibroblasts with no cells above was used as a control, with a 
second control of Pt-102 fibroblasts seeded above Pt-102 fibroblasts included. This 
control was used to determine if the presence of the pancreatic cancer cells or the 
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tumour derived fibroblasts induced different changes in the activation state of the 
stromal cells. It appears there is an increase in podoplanin protein in Pt-102 fibroblasts 
post co-culture in all conditions, as seen in Figure 5-27. This demonstrates that the 
activity of the tumour derived fibroblasts is further increased due to the presence of a 
second cell population. This increased expression is also induced by the Pt-102 
fibroblasts co-cultured above the Pt-102 fibroblasts. This may indicate that an increase 
in secreted factors, whether from pancreatic cancer cells or the fibroblasts themselves, 
can increase the activity of tumour derived fibroblasts. 
 
5.9. Functional effects of indirect co-culture with tumour derived fibroblasts (Pt-102) 
using the optimum control 
 
Considering the effects observed in Figure 5-26 it was determined that the indirect co-
culture should be performed using a more appropriate control. This control was 
determined to be a transwell insert above the cancer cells containing RPMI, no 
fibroblasts present. This control ensured no effects due to the mix media would be 
observed as the mix of media was present in all conditions. The previous mono culture 
control and the optimum mono culture control are shown in Figure 5-29. The co-culture 
model using the optimum control returned to the method used in section 5.4.1, i.e. co-
culturing the pancreatic cancer cells (Panc-1 and BxPc-3) with the tumour derived 
fibroblasts (Pt-102) above in a co-culture insert for 48hr. The BxPc-3 cell line was 
included in this analysis as no mix of media was present in this co-culture as both the 
BxPc-3 cells and the fibroblasts were grown in RPMI medium, therefore any effects 
observed due to co-culture would not be due to a mix of media. After 48hr the 
pancreatic cancer cells were detached and assessed for changes in levels of survival in 
suspension i.e. anoikis, proliferation, colony formation and invasion due to indirect co-
culture. Positive readings in anoikis assays were achieved in this section due to an 
increase in cell number from previous work, see section 5.4.1, although the BxPc-3 still 
displayed high anoikis sensitivity. Effects observed using this indirect co-culture set up 
should truly show the influence the tumour derived fibroblasts have on the pancreatic 
cancer cells. 
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Figure 5-29. Schematic of the previous mono culture control and the optimum mono 
culture control 
 
In previous co-culture experiments used mono culture set up (A). This contained the pancreatic cancer 
cells in 2mL of the cell specific media. The optimum mono culture control was determined to be (B). This 
consists of pancreatic cancer cells in 2mL of the cell specific media with a transwell insert above containing 
fresh RPMI media, the media specific for the stromal cell populations. 
 
 
Figure 5-30. Percentage survival in attached and suspension conditions of Panc-1 cells 
post co-culture with Pt-102 fibroblasts using the optimum control. 
 
Percentage survival relative to attached mono culture, in attached and suspension i.e. anoikis, conditions 
of the Panc-1 cell line following indirect co-culture with pancreatic tumour derived fibroblasts (Pt-102) 
using the optimum control. Error bars represent +/- standard deviation between biological replicates, 
(n=3, ** = p value ≤ 0.01, p value = 0.01). 
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Figure 5-31. Percentage survival in attached and suspension conditions of BxPc-3 cells 
post co-culture with Pt-102 fibroblasts using the optimum control. 
 
Percentage survival relative to attached mono culture, in attached and suspension i.e. anoikis, conditions 
of the BxPc-3 cell line following indirect co-culture with pancreatic tumour derived fibroblasts (Pt-102) 
using the optimum control. Error bars represent +/- standard deviation between biological replicates, 
(n=3, ** = p value ≤ 0.01, p value = 0.01). 
 
Co-culture of pancreatic cancer cells with tumour derived fibroblasts (Pt-102) using the 
optimum control induced some varied effects in comparison to the results previously 
seen in this work, i.e. section 5.4 and 5.6. To assess survival in suspension, the cells were 
trypsinised after 48hr of co-culture, the cells were then seeded into attached and 
suspension conditions for 24hr at which point survival was assessed. The Panc-1 cell line 
showed an increase in survival in both attached and suspension conditions post co-
culture, as seen in Figure 5-30. Post co-culture Panc-1 cells showed a significant 8% 
increase in survival in suspension conditions in comparison to mono culture in 
suspension. There was a 5% increase in survival in attached conditions post co-culture 
present in Panc-1 cells, this apparent increase in survival may be due to an increase in 
growth. The opposite trend was observed in the BxPc-3 cell line, Figure 5-31 displays a 
decrease in survival post co-culture in both attached and suspension conditions. The 
decrease in suspension conditions was negligible while in attached conditions a 
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significant 14% reduction in survival was displayed. This seeming decrease in survival 
may be due to a reduction in growth post co-culture 
 
Figure 5-32. Percentage proliferation of Panc-1 and BxPc-3 cells post co-culture with Pt-
102 fibroblasts using the optimum control 
 
Percentage proliferation following co-culture relative to mono culture, of Panc-1 and BxPc-3 cell lines with 
pancreatic tumour derived fibroblasts (Pt-102) using the optimum control. Error bars represent +/- 
standard deviation between biological replicates, (n=3, * = p value ≤ 0.05, BxPc-3 p value = 0.04). 
 
The hypothesis that the decreased survival of BxPc-3 cells observed post co-culture in 
attached conditions (Figure 5-31) was due to decreased proliferation, was confirmed by 
the data in Figure 5-32. Both the Panc-1 and BxPc-3 cell line had diminished proliferation 
levels post co-culture, displayed by Figure 5-32. An 8% reduction was present in the 
Panc-1 cell line while a significant 15% decrease in proliferation was seen in the BxPc-3 
cell line post co-culture. Using the optimum control, the tumour derived fibroblasts were 
inhibiting the proliferation of the pancreatic cancer cells through indirect co-culture. 
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Figure 5-33. Colony formation of Panc-1 cells post co-culture with Pt-102 fibroblasts 
using the optimum control 
 
Percentage colony formation displayed as number of colonies and average colony area following co-
culture relative to mono culture, of Panc-1 cells with pancreatic tumour derived fibroblasts (Pt-102) using 
the optimum control. Error bars represent +/- standard deviation between biological replicates, (n=3, *** 
= p value ≤ 0.001, p value = 0.0004). 
 
Figure 5-34. Representative image of colony formation of Panc-1 cells post co-culture 
with Pt-102 fibroblasts using the optimum control 
 
Representative image of colonies of Panc-1 cells observed post indirect co-culture with tumour derived 
fibroblasts (Pt-102) using the optimum control. 
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Figure 5-35. Colony formation of BxPc-3 cells post co-culture with Pt-102 fibroblasts 
using the optimum control 
 
Percentage colony formation displayed as number of colonies and average colony area following co-
culture relative to mono culture, of BxPc-3 cells with pancreatic tumour derived fibroblasts (Pt-102) using 
the optimum control. Error bars represent +/- standard deviation between biological replicates, (n=3, ** 
= p value ≤ 0.01, p value = 0.01). 
 
Figure 5-36. Representative image of colony formation of BxPc-3 cells post co-culture 
with Pt-102 fibroblasts using the optimum control 
 
Representative image of colonies of BxPc-3 cells observed post indirect co-culture with tumour derived 
fibroblasts (Pt-102) using the optimum control. 
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The analysis of colony formation was performed using MetaMorph software, the results 
are displayed as colony number and colony area which represents colony size. Figure 
5-33 displays colony formation of the Panc-1 cell line post co-culture using the optimum 
control with a representative image shown in Figure 5-34. A slight increase in colony 
area was present at 8% but conversely a highly significant 33% reduction in colony 
number was induced post co-culture with a p value of 0.0004. This reduction was also 
seen in the BxPc-3 cell line in Figure 5-35, with a reduction in both colony area and 
colony number observed post co-culture. A 25% decrease in colony area was induced as 
well as a significant 12% reduction in colony number post co-culture in the BxPc-3 cell 
line with a representative image shown in Figure 5-36. 
 
 
Figure 5-37. Percentage invasion of Panc-1 and BxPc-3 cells post co-culture with Pt-102 
fibroblasts using the optimum control 
 
Percentage invasion following co-culture relative to mono culture, of Panc-1 and BxPc-3 cell lines with 
pancreatic tumour derived fibroblasts (Pt-102) using the optimum control. Error bars represent +/- 
standard deviation between biological replicates, (n=3, *** = p value ≤ 0.001, * = p value ≤ 0.05, Panc-1 p 
value = 4.47E-05, BxPc-3 p value = 0.03). 
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Figure 5-38. Representative images of invasion levels of both Panc-1 and BxPc-3 cells 
post mono and co-culture 
Panc-1  
Mono culture 
  
Panc-1 
Co-culture 
BxPc-3  
Mono culture 
  
BxPc-3 
Co-culture 
 
Representative images of invasion following mono culture and co-culture of Panc-1 and BxPc-3 cell lines 
with pancreatic tumour derived fibroblasts (Pt-102) using the optimum control. 
 
 
Post co-culture with Pt-102 fibroblasts using the optimum control both pancreatic 
cancer cell lines displayed a large reduction in invasion relative to mono culture, shown 
in Figure 5-37. A significant 28% decrease was present in the BxPc-3 cell line; the low 
level of significance (p value of 0.03) may be due to the high level of error in the mono 
culture control. Also, the BxPc-3 cell line invades as clumps of cells as seen in Figure 5-38, 
which can lead to errors in counting. In the Panc-1 cell line the level of invasion was 
reduced by a highly significant 40% due to the presence of the tumour derived 
fibroblasts (Pt-102) with a p value of 4.47E-05. These results indicated that indirect co-
culture of the pancreatic cancer cells with tumour derived fibroblasts (Pt-102) using the 
optimum control inhibited the invasive capabilities of the pancreatic cancer cells, this 
trend can be observed in Figure 5-38.
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6. Discussion - Investigation of the 
Role of the Tumour 
Microenvironment in Pancreatic 
Cancer  
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Pancreatic cancer is one of the most lethal cancers worldwide due to late diagnosis by 
which time usually metastasis has occurred (Rucki and Zheng 2014). A hallmark of 
pancreatic cancer is a high level of stroma in the tumours as seen in Figure 1-3, which is 
due to fibrosis also known as desmoplasia. Fibrosis is defined as an accumulation of 
extracellular matrix (ECM) proteins due to the loss of balance between the manufacture 
and degradation of ECM (Apte, Pirola and Wilson 2012). In a healthy pancreas, the 
pancreatic microenvironment is responsible for the fine balance in production and 
degradation of ECM. Reasonably in a malignant situation the pancreatic tumour 
microenvironment is responsible for the loss of this fine balance. As the significance of 
the tumour microenvironment has been realised in recent years the role of fibroblasts 
and PSCs in the progression of pancreatic cancer has become the centre of a great deal 
of pancreatic cancer research.  Both of these cell populations play an important role in 
the pancreatic microenvironment, they are responsible for several things one of which 
is the production of ECM, meaning they are also responsible for the fibrosis present in 
pancreatic cancer. 
 
To investigate the role both fibroblasts and PSCs play in the metastasis and progression 
of pancreatic cancer an indirect co-culture model was developed and optimised. To 
begin a panel of pancreatic cancer cell lines were selected and characterised for the two 
metastatic functions to be investigated post co-culture, meaning anoikis and invasion. 
Based on this characterisation the four cell lines chosen were AsPc-1, BxPc-3, Mia PaCa-
2 and Panc-1. These cell lines displayed a wide range of variety in both levels of anoikis 
and levels of invasion. As can be seen in  
Figure 5-1, the BxPc-3 and AsPc-1 cell lines exhibited the highest levels of anoikis 
meaning these cell lines were highly sensitive to anoikis conditions i.e. suspension. Mia 
PaCa-2 and Panc-1 cells were much less sensitive to anoikis conditions, possessing a high 
level of anoikis resistance. A different trend was observed in invasion levels, shown in 
Figure 5-2. Panc-1 cells possess both a high level of invasion and anoikis resistance with 
AsPc-1 cells being the opposite, displaying low levels of invasion and anoikis resistance. 
The remaining cell lines in the panel appear to have converse characteristics; Mia PaCa-
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2 cell line while being highly anoikis resistant displays a low to medium invasion level, 
observed in Figure 5-2. The BxPc-3 cell line is very sensitive to anoikis conditions and 
possess a high invasive ability. 
 
6.1. Investigations of functional effects post 48hr indirect co-culture with multiple 
stromal cell populations 
 
To investigate the functional impact of cell to cell interactions an indirect co-culture 
model to mimic the pancreatic tumour microenvironment was developed using 
pancreatic cancer cell lines with human derived stromal cells. Through the course of 
developing this model a range of formats were investigated to determine the efficiency 
of each model and the optimum conditions to investigate metastatic phenotypic 
changes. 
 
The first format of the co-culture model involved culturing the pancreatic cancer cell 
lines below a transwell insert which contained the stromal cell population, for a 48hr 
time period. After 48hr the pancreatic cancer cells were detached and assessed for 
changes in levels of survival in suspension i.e. anoikis, proliferation and invasion due to 
indirect co-culture with pancreatic stromal cells. A variety of different stromal cell 
populations were examined for functional effects post co-culture with pancreatic cancer 
cells. Two different batches of human tumour derived fibroblasts were investigated, Pt-
102 and Pt-127, which were fibroblasts developed in house from tumour samples of two 
different pancreatic cancer patients. These fibroblasts were developed in house using a 
combination method of enzymatic digestion and outgrowth. Full details of development 
and differences between the two populations can be found in section 2.1.1. Human 
pancreatic stellate cells were also investigated for functional effects on pancreatic 
cancer cells post co-culture. These stellate cells were kindly donated by Associate 
Professor Masamune in Tohoku University, Sendai, Japan. The metastatic phenotypes 
anoikis i.e. survival in suspension, proliferation and invasion were assessed for changes 
due to the presence of pancreatic stromal cells.  
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The three stromal populations investigated induced a variety of changes in both survival 
and proliferation across the panel of pancreatic cancer cell lines after a 48hr co-culture 
incubation. Phenotypic changes appear to be specific to each batch of stromal cells. The 
effects on survival varied post co-culture with each fibroblast batch and in each cell line 
examined. Post co-culture of the Mia PaCa-2 cell line with Pt-102 fibroblasts induced an 
increase in survival in both attached and suspension conditions shown in Figure 5-4. The 
opposite effect was observed post co-culture with Pt-127 fibroblasts, as seen in Figure 
5-13 these fibroblasts resulted in a decrease in survival of the Mia PaCa-2 cell line in 
both attached and suspension conditions. Both fibroblast populations induced different 
changes in the Panc-1 cell line also. Figure 5-5 shows that no effect on survival in either 
attached or suspension conditions was displayed by the Panc-1 cell line post co-culture 
with Pt-102 fibroblasts. Conversely, Pt-127 fibroblasts caused an increase in survival in 
both attached and suspension conditions post co-culture in the Panc-1 cell line. 
Statistical significance was not present in any of the phenotypic assays using Pt-127 
fibroblasts as while the functional effects due to indirect co-culture with Pt-127 
fibroblasts was being assessed but before three biological replicates were achieved, the 
results in section 5.5 were observed, discussed in section 6.2. While both fibroblast 
primary cell lines were developed in the same way, they have differences, see section 
2.1.1. Both tumours from which the fibroblast populations were derived had different 
pathology, levels of differentiation and invasive capabilities. Therefore, the varied 
phenotypic changes induced through co-culture is may be due to these differences. 
These investigations show that phenotypic changes in survival in suspension conditions 
induced by co-culture with stromal cells are both dependent on the stromal population 
and the pancreatic cancer cell line used. Interestingly, opposing results were observed 
between Pt-102 fibroblasts co-culture and Pt-102 conditioned media treatment. The co-
culture induced an increase in survival in the Mia PaCa-2 cell line with no effect on 
survival observed in the Panc-1 cell line. Conditioned media treatment induced 
contrasting effects, no effect on survival was observed in the Mia PaCa-2 cell line while 
an increase in survival in suspension conditions was induced in the Panc-1 cell line 
through CM treatment. These results are displayed in Figure 5-9 and Figure 5-10 
 169 
 
respectively. There is minimal published data on the effects of co-culture on anoikis and 
there is nothing investigating this in pancreatic cancer. Of the limited data, available one 
study determined that cancer-associated fibroblasts can inhibit anoikis in cancer cells 
therefore making the cancer cells behave in a more anoikis resistant manner. This 
anoikis inhibition was induced due to the elevated levels of insulin-like growth factor-
binding proteins (IGFBPs) secreted by the CAFs, indicating this may have a role in 
inducing anoikis sensitivity (Weigel et al. 2014). This study however was a breast cancer 
investigation and used conditioned media as the co-culture model. While the 
assessment of the effects of stromal cells on survival in suspension post co-culture in 
pancreatic cancer in the present study show varied effects and there is no distinct 
conclusion to be drawn, it is a novel investigation due to the examination of anoikis post 
indirect co-culture in pancreatic cancer. 
 
A similar variation in phenotypic changes was observed in proliferation post co-culture 
with the three different stromal cell populations. Human pancreatic stellate cells 
(hPSC24) induced a reduction in proliferation in both the Mia PaCa-2 and Panc-1 cell line 
post co-culture, displayed in Figure 5-17. Statistical significance was not present in any 
of the phenotypic assays using hPSC24 as while the changes due to indirect co-culture 
with hPSC24 was being assessed but before three biological replicates were achieved, 
the results in section 5.5 were observed, discussed in section 6.2. A reduction in 
proliferation was also observed in the Mia PaCa-2 cell line post co-culture with Pt-127 
fibroblasts, a contrasting result was present in the Panc-1 cell line post co-culture with 
Pt-127 fibroblasts, where the proliferation level doubled post co-culture. Pt-102 
fibroblasts induced an increase in proliferation in two out of four cell lines, an increase 
was observed in BxPc-3 and Mia PaCa-2 cells, with the effect on the Mia PaCa-2 cell line 
being significant and shown in Figure 5-6. Conditioned media from Pt-102 fibroblasts 
also induced an increase in proliferation in the Mia PaCa-2 cell line, interestingly, an 
increase in proliferation was observed in the Panc-1 cell line post CM treatment, seen in 
Figure 5-11. Clearly a difference between the indirect co-culture model and the CM 
treatment resulted in the opposing effects observed on the proliferation of Panc-1 cells. 
An effect may have been missed by the co-culture model or the cross-talk between the 
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two cell populations inhibited the increase in proliferation induced by the CM treatment. 
An increase in proliferation of pancreatic cancer cells post treatment with stromal cell 
CM has been observed in published studies. Hwang et al., investigated the effect of 
human pancreatic stellate cells (PSC) CM on pancreatic tumour progression. This work 
focused on the effect of conditioned media from immortalised pancreatic stellate cells 
on the pancreatic cell lines BxPc-3 and Panc-1. The effect of PSC conditioned media on 
proliferation, migration; invasion, colony formation and cell survival post treatment with 
gemcitabine or radiation therapy were all investigated. An increase in proliferation, 
migration, invasion and colony formation was induced by exposure to PSC conditioned 
media. This exposure also caused an inhibition of apoptosis in cells treated with 
gemcitabine and radiation therapy (Hwang et al. 2008). Another study performed a 
similar CM treatment investigation and found that the proliferation of both the Mia 
PaCa-2 and Panc-1 cell line was significantly increased after 24, 48 and 72hr of stellate 
cell CM treatment (Vonlaufen et al. 2008). These studies appear to validate the effect 
observed in Figure 5-11, treatment of pancreatic cancer cells with stromal cell 
conditioned media induced an increase in proliferation. 
 
Conversely, other studies have found that co-culture of pancreatic cancer cells with 
stromal cells has had no effect on proliferation. A group in Japan who kindly donated 
the pancreatic stellate cells to this project, investigated phenotypic changes induced by 
co-culture with an immortalised pancreatic stellate cell line. This work utilised an 
indirect co-culture method quite similar to the model used in this present study, 
meaning using transwell culture inserts similar to invasion inserts but with a smaller pore 
size. The Japanese study determined that co-culture of PSCs with pancreatic cancer cells 
led to a cancer stem cell-like phenotype. Both colony formation and cell growth in vivo 
were increased due to indirect co-culture along with increased expression of several 
stem cell related genes including ABCG2, Nestin and LIN28 (Hamada et al. 2012). This 
published study also found that co-culture of pancreatic cancer cells with the 
immortalised pancreatic stellate cell population did not affect proliferation in any way. 
Interestingly, of the two pancreatic cell lines used in the Japanese study only one was 
investigated by the present study, AsPc-1 and this present study found a decrease in 
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proliferation was induced post co-culture. The effects of stromal cells post co-culture on 
proliferation of pancreatic cancer cells shows some variation. Many studies show a 
proliferation increase post treatment with stellate cell CM; however, there are few 
publications investigating an indirect co-culture model using transwell inserts, which is 
quite a different co-culture model to CM treatment. This present study has shown that 
converse effects can be observed between the two co-culture models. Also, there are a 
small number of studies which utilise patient tumour derived fibroblasts, in this study 
tumour derived fibroblasts from two different patients were investigated as inducers of 
metastatic phenotypes in pancreatic cancer cell lines. 
 
The most consistent and significant phenotypic change observed post co-culture of 
pancreatic cancer cells with stromal cell populations was an increase in invasive 
capabilities. All three stromal cell populations investigated, Pt-102, Pt-127 and hPSC24 
induced an increase in invasion levels post co-culture relative to mono culture. Pt-102 
fibroblasts induced a more invasive phenotype in three out of four cell lines post co-
culture, seen in Figure 5-7. The Mia PaCa-2 cell line displayed significantly double the 
level of invasion compared to the mono culture control with a significant 40% increase 
induced in the Panc-1 cell line. Considering the effects on proliferation, Figure 5-6, no 
effect in Panc-1 and a 20% increase in Mia PaCa-2, it can be stated that the increase in 
invasion is not due to an increase in proliferation. Pt-127 fibroblasts also induced an 
increase in invasion levels in both the Mia Paca-2 and Panc-1 cell lines post co-culture. 
As seen in Figure 5-16, these increases which are extremely large, 300% and 450% 
respectively, contain a large amount of error which inhibits any statistical significance as 
well as only two biological replicates being present. The increase induced in both cell 
lines is to a greater level than the effect observed on proliferation showing this increase 
in invasion is not due to an increase in proliferation. While a specific conclusion cannot 
be drawn from this result, it can be concluded that a trend of increased invasion is 
observed post culture with Pt-127 fibroblasts. A similar trend is present post co-culture 
with hPSC24, Figure 5-18. Mia PaCa-2 cells possessed a 70% higher level of invasion post 
co-culture with the Panc-1 cell line displaying a 50% increase. As a decrease in 
proliferation was observed post co-culture with hPSC24 this increase in invasion is not 
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due to an effect on proliferation, the increase in invasion may be greater than shown 
considering the reduction on proliferation. Due to the level in variability and need for 
more biological replicates this result on invasion did not show significance but a trend 
of increased invasion induced by hPSCs can be drawn. This conclusion has been observed 
in several published studies. Virtually every publication that has investigated the role of 
stromal cell populations in cancer cell invasion has observed that the invasion 
capabilities of the cancer cells are increased through stromal cell interactions 
(Goicoechea et al. 2014, Shindo et al. 2013, Farrow, Berger and Rowley 2009, Hwang et 
al. 2008). While the increase in invasion post co-culture, is present throughout the 
publications, the method used to assess this change is quite varied across the wide range 
of publications. Several groups use stromal cell CM treatment (Hwang et al. 2008), which 
contrasts with the results seen in Figure 5-12 showing a significant 50% reduction in 
invasion of Panc-1 cells post CM treatment. These opposite effects may be due to 
differences between the methods of the two studies. The Texas group (Hwang et al. 
2008) used concentrated hPSC media while the CM used in this study was not 
concentrated in an attempt to replicate the 48hr co-culture system used in section 5.4.1. 
Hwang et al., also treated the pancreatic cancer cells with CM in the invasion assay set 
up. In the present study, the pancreatic cancer cells were treated for 48hr before 
trypsinisation and seeding into the invasion assay inserts. In some experimental 
investigations, direct co-culture is used to assess phenotypic changes in invasion, as 
opposed to the indirect co-culture method used in this study (Zheng et al. 2015, 
Goicoechea et al. 2014, Farrow, Berger and Rowley 2009). Some investigations utilised 
an indirect co-culture method which involved the cancer cells seeded in the invasion 
insert above with the stromal cells seeded below in the insert in the well, similar to a 
chemoattractant used in invasion (Zheng et al. 2015, Shindo et al. 2013). There is a wide 
range of published methods investigating the influence of stromal cells on pancreatic 
cancer which has led to variation in the effects seen on proliferation, colony formation, 
drug treatment etc. but virtual all investigations report an increase in invasion due to 
stromal cell interactions. The fact that this result is present despite the variation in the 
methods used gives more power to the result overall.  
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6.2. Time-course experiment 
 
The co-culture set up discussed in the previous section, 6.1, involved the pancreatic 
cancer cells incubated in the indirect co-culture model for 48hr before removing from 
the set up and seeding into functional assays to assess phenotypic changes post co-
culture. This previous co-culture set up showed some inconsistent effects on 
proliferation across the panel and stromal cell populations. The time-course experiment, 
seen in Figure 5-19 and Figure 5-20, investigated if this co-culture set up and time-point 
was optimum for assessing functional effects. These results showed that the time-point 
was indeed optimum but led to a hypothesis that an effect on proliferation due to co-
culture was present but being missed using acid phosphatase experiments to assess 
proliferation. This hypothesis was formed due to the observation that the cell number 
in co-culture samples was consistently higher than mono culture samples, this was then 
validated by the result seen in Figure 5-19. In order to optimally assess phenotypic 
changes in both proliferation and colony formation an in-assay co-culture format was 
developed. This differed from the original model in that the two cell populations were 
co-cultured for the duration of the functional assay, as described in section 5.6. It was 
determined that this was a more appropriate model to evaluate phenotypic changes in 
proliferation and colony formation due to the presence of the stromal cells. 
 
6.3. Assessment of in-assay indirect co-culture set up 
 
Due to an observation of increased cell number of pancreatic cancer cells post co-culture 
but no proliferation changes detected using the acid phosphatase assay, an in-assay co-
culture format was developed. This differed from the original model in that the two cell 
populations were co-cultured for the duration of the functional assay as opposed to 
48hr. In detail this in-assay co-culture format involved the pancreatic cancer cells being 
seeded into functional assays (proliferation and colony formation assays) with the 
stromal cells above in a co-culture insert for the entire length of the assay (7 days for 
proliferation, 14 days for colony formation). Meaning the cancer and stromal cells were 
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interacting throughout the time of the assay. It was determined that this was a more 
appropriate model to evaluate phenotypic changes in proliferation due to the 
continually presence of the stromal cells. Colony formation was also assessed for 
phenotypic changes post co-culture also as it can be an indication of changes in growth. 
This alternative format involved the cells being seeded at the required cell densities into 
proliferation and colony formation assays with the stromal cells above in a co-culture 
insert for the entire length of the assay.  
 
Two stromal cell populations were assessed in this in-assay indirect co-culture format, 
Pt-102 and hPSC24, as both these populations previously showed the most consistent 
effects across the panel of pancreatic cancer cell lines. Also, the original hypothesis, that 
an increase in proliferation was present post co-culture but not being assessed 
sufficiently, was developed due to the observation that the cell number in samples post 
co-culture with Pt-102 was consistently higher than mono culture samples. This effect 
was most apparent in the Panc-1 cell line, no effect on proliferation is seen in Figure 5-6 
but the cell number post co-culture was consistently higher. Due to this, the Panc-1 cell 
line was used to develop the in-assay indirect co-culture method. Both stromal cell 
populations, Pt-102 and hPSC24, induced a significant increase in proliferation and 
colony formation in the Panc-1 cell line, shown in Figure 5-21 and Figure 5-22. As 
previously stated a large proportion of co-culture investigations use CM treatment as 
the indirect method. A small number of publications use a similar in-assay indirect co-
culture format (Hamada et al. 2012, Fujita et al. 2009). Interestingly, these groups saw 
contrasting results to the effects observed in this body of work, both observed that in-
assay indirect co-culture had no significant effect on the proliferation of the pancreatic 
cancer cells. While Hamada et al., reported no effect on proliferation this published work 
did state a significant increase in spheroid formation was induced through in-assay co-
culture. A parallel between this result and the increase in colony formation observed in 
Figure 5-22 can be made and may validate the role of pancreatic stromal cells have in 
increasing the colony forming ability of pancreatic cancer cells. The results in section 5.6 
appear to validate the hypothesis that an effect on proliferation due to stromal cell co-
culture is more efficiently assessed using this in-assay co-culture model. The Panc-1 cell 
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line showed no effect on proliferation post Pt-102 co-culture and a decrease in 
proliferation was induced post hPSC24 co-culture. This validation ties in with the 
theoretical idea that the co-culture effects are more efficiently assessed when the 
stromal cell population is present at the end point assessment of the phenotypic change. 
To examine a phenotypic change due to 48hr of co-culture after 5 days (proliferation) or 
14 days (colony formation) post co-culture may be an excessive expectation of the 
power of the co-culture model. 
 
6.4. Determination of the optimum indirect co-culture control 
 
In order to confirm that the increase in proliferation post in-assay co-culture was 
induced by the stromal cell populations, a range of co-culture variants were investigated 
for effects on proliferation of the Panc-1 cell line. These variants included different 
media in the insert above with no cells present, the fibroblasts above in different media 
and a later passage number of fibroblasts above. As this result, Figure 5-24, showed an 
increase in Panc-1 proliferation induced by complete medium above in a co-culture 
insert, it became clear that the mono-culture control previously used needed to be 
optimised. In order to determine the optimum control for the indirect co-culture model 
a larger screen of co-culture variants were investigated, using Panc-1 cells in DMEM 
below a co-culture insert with complete DMEM media above as the mono culture 
control. Figure 5-26 displays some highly surprising and interesting results. The most 
startling result observed was a doubling in the proliferation rate of the Panc-1 cell line 
when a mix of media types, DMEM and RPMI, was present in the co-culture model. A 
brief insight into the formulations of both media types, DMEM and RPMI, revealed that 
virtually every component is different between the two media types. Due to the 
hundreds of variables that could be the cause of the increase in proliferation observed, 
a large investigation would be required to fully elucidate the exact cause. 
 
The increase in proliferation due to a mix of media types was greater than the increase 
induced when the Pt-102 fibroblasts were present in any of the other variants. While 
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this result was only one biological replicate, it led to the determination that the optimum 
control for the indirect co-culture model was a co-culture insert containing RPMI above 
the pancreatic cancer cells. This control ensured no effects due to the mix media were 
observed as the mix of media was present in all conditions. A brief insight into the 
formulations of both media types, DMEM and RPMI, revealed that virtually every single 
component is different between the two media types. Due to the hundreds of variables 
that could be the cause of the increase in proliferation observed, a large investigation 
would be required to fully elucidate the exact cause. A thorough investigation of the 
published data on indirect co-culture models produced inconclusive results on the mono 
culture control used in each publication. Each study states the use of a mono culture 
control but very few are explicit in exactly what this control was. It is hoped that each 
study is using an appropriate control but there is a possibility that some results observed 
may be due to an inappropriate control. Whether that proves to be true or not, it is 
necessary for publications to be hugely more overt and exact in the description of the 
mono culture control. This body of work has shown the momentous importance of 
determining the optimum control while developing an indirect co-culture model. 
 
6.5. Functional effects of indirect co-culture with tumour derived fibroblasts (Pt-102) 
using the optimum control 
 
Based on the results observed in Figure 5-26 the optimum control for this indirect co-
culture method was determined to be a transwell insert above the cancer cells 
containing RPMI, no fibroblasts present. This control ensured no effects due to the mix 
media would be observed as the mix of media was present in all conditions. This format 
returned to the method used in section 5.4.1, i.e. co-culturing the pancreatic cancer cells 
(Panc-1 and BxPc-3) with tumour derived fibroblasts (Pt-102) above in a co-culture insert 
for 48hr. After 48hr the pancreatic cancer cells were detached and assessed for 
phenotypic changes. Using the more appropriate control ensured any changes observed 
were wholly due to the interactions with the patient tumour derived fibroblasts.  
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This interaction with the tumour derived fibroblasts produced interesting results which 
were in contrast to all previous observed results, results observed without the optimum 
control present. Previously results varied but appear to show an increase in 
proliferation, colony formation and invasion post co-culture. Once the optimum control 
was introduced to the model, the opposite trend appears to be induced. The majority of 
the effects observed have negative phenotypes with the exception of a slight increase 
in survival induced in the Panc-1 cell line. A decrease in survival post co-culture in both 
attached and suspension conditions was produced post co-culture in the BxPc-3 cell line. 
The significant decrease in survival in attached conditions is most likely due to a 
decrease in proliferation. This decrease in proliferation was validated in Figure 5-32 
which shows a reduction in proliferation in both the Panc-1 and BxPc-3 cell lines. In 
agreement with this observation, co-culture also produced a significant reduction in 
colony number in both the Panc-1 and the BxPc-3 cell line. As proliferation and colony 
formation share similar characteristics, it was encouraging to observe a reduction was 
produced in both functions through stromal cell interactions.  The final negative 
phenotype observed post co-culture was a significant reduction in invasion levels in both 
the Panc-1 and BxPc-3 cell line as seen in Figure 5-37. This was in complete contrast to 
the trend of an increase in invasion post co-culture with multiple stromal cell 
populations observed in section 5.4.1. To further investigate the inhibition of metastatic 
phenotypes observed in this project, there are several approaches available. A more in-
depth analysis could be performed on the reduced proliferation and colony formation 
post co-culture using flow cytometry to assess which cycle of cell growth was arrested 
(Gundewar et al. 2014, Haqq et al. 2015). The cell growth cycles can be easily assessed 
using the Guava® easyCyte Flow Cytometer available in-house in the NICB, with the 
Guava® Cell Cycle Assay which measures G0/G1, S and G2/M phase distributions. This 
analysis would identify the specific phase of cell growth of the pancreatic cancer cells 
that is being arrested due to the presence of the stromal cells, inducing the observed 
reduction in proliferation and colony formation. To further investigate the reduction in 
invasion levels due to co-culture the levels of MMPs and TIMPs is an interesting aspect 
to analyse. MMPs and TIMPs play a major role in the invasive capabilities of a cell, 
meaning there is most likely a change in either or both present post co-culture indicated 
by the inhibited invasion levels. Alteration to MMP and TIMP levels could be assessed 
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using zymography or at a molecular level using qPCR post co-culture (Tjomsland et al. 
2016). Determining changes of MMPs and TIMPS may identify the key regulators of 
invasion which co-culture has altered inducing the reduction in invasive capabilities of 
the pancreatic cancer cells. 
 
While the inhibition of metastatic phenotypes observed in this study were unexpected, 
there are published studies to confirm these observations (Leake 2014, Rhim et al. 2014, 
Özdemir et al. 2014). Rhim et al., found that suppressing the stroma in pancreatic cancer 
led to more aggressive, vascularised, undifferentiated tumours with increased 
proliferation. This group concluded that the pancreatic tumour stroma can act to 
restrain tumour progression (Rhim et al. 2014). This conclusion was also drawn by 
Özdemir et al., this investigation determined that depletion of the stroma produced 
invasive, undifferentiated tumours with enhanced EMT and hypoxia. This group also 
observed reduced animal survival and a correlation between reduced patient survival 
and reduced myofibroblast presence (Özdemir et al. 2014). Another group produced 
similar results, Lee et al., presented data that suppression of the stroma in pancreatic 
cancer induced accelerated disease progression (Lee et al. 2014). These studies showed 
reducing the stroma induced a more aggressive phenotype which corresponds to the 
phenotypes observed in this present study where the presence of the tumour stroma 
reduced metastatic phenotypes. These phenotypes indicated that the presence of the 
stromal cells appears to restrain and inhibit the development of a more aggressive 
phenotype. A highly important pancreatic cancer clinical trial corroborates these 
findings. The clinical trial published by Olive et al., used hedgehog inhibitors to target 
the stroma with the aim to increase drug perfusion of the tumours and therefore 
stabilise the progression of the disease. This hypothesis was based on studies showing 
the positive effects of targeting the stroma through hedgehog signalling inhibition in 
mouse pancreatic cancer models which showed increased drug delivery and survival 
post hedgehog inhibition (Olive et al. 2009). Unfortunately, and un-expectantly, the 
clinical trial observed no increase in survival through a combination treatment of 
gemcitabine and a hedgehog inhibitor. In fact, the gemcitabine and placebo group 
displayed higher survival in comparison appearing to indicate that disease progression 
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may be induced by stromal ablation (Madden 2012). This startling result brought about 
an immediate halt and termination of the trial. While many in vitro studies have 
portrayed the stroma as a promising target to inhibit pancreatic cancer progression this 
present study found the opposite to be true. Considering this data, recent publications 
and the significant termination of the clinical trial it appears targeting the pancreatic 
cancer stroma may not be the ideal therapeutic approach it once seemed. 
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7. Results – Investigation of the Role 
of miRNA in Metastatic Phenotypes 
in Pancreatic Cancer 
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7.1. Aim 
 
Investigate the role of miRNA expression in the progression of pancreatic cancer using 
sponge knockdown and overexpression vectors. Pancreatic cancer is one of the most 
lethal cancers worldwide with a 5-year survival rate of only 6%. The poor prognosis and 
survival rate is partially due to the early onset of metastasis, which occurs soon after the 
development of the cancer. Metastasis is the ability of a cell to spread to another 
location in the body, colonising this secondary site with tumour growth. miRNA are key 
regulators of gene expression and therefore have an important role in virtually all 
cellular functions including metastasis. There are several methods to alter miRNA 
expression, inducing either up- or downregulation. A novel approach used in this 
investigation, is a sponge knockdown vector to reduce the target miRNAs activity. In 
addition to this approach, overexpression vectors inducing upregulated expression of 
the target miRNA were utilised as well as Pre-miRs and Anti-miRs to induce transient 
alterations in miRNA expression. This body of work aimed to investigate the role miRNA 
expression plays in the progression of pancreatic cancer, specifically in metastatic 
phenotypes. 
 
7.2. Alteration of miRNA expression 
 
Despite an influx of research in pancreatic cancer in recent years very little progress has 
been made and the development of new, more effective therapies is needed. One such 
area which shows promise for these new developments is the area of miRNA in 
pancreatic cancer (Chitkara, Mittal and Mahato 2015). Investigations of miRNA in 
pancreatic cancer have covered several topics from large studies aiming to profile 
pancreatic cancer through both cells and tumour samples, to studies of miRNA as 
biomarkers and the therapeutic potential of miRNA. Many studies have investigated the 
impact miRNA have on pancreatic cancer with some miRNA being involved in 
progression of the disease, some inhibiting its development etc. (Li et al. 2013, Takikawa 
et al. 2013). A range of tools to stably alter miRNA expression had previously been 
developed in house by Alan Costello of the molecular biology group. These tools 
included sponge knockdown and overexpression vectors. Also, available through the 
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molecular biology group was a range of Pre-miRs and Anti-miRs which are commercial 
tools used to transiently alter miRNA expression. Transient alteration of miRNA 
expression is a temporary change where as stable alteration is a permanent alteration. 
The cell line becomes permanently altered, not only due to the change in altered miRNA 
expression but also due to the selection of a subpopulation which have been transfected 
with a plasmid vector. An in-depth description of these tools has been detailed in section 
1.5.5.3. These tools were used to alter miRNA expression in the Panc-1 cell line. 
Functional changes due to altered miRNA expression were assessed in anoikis i.e. 
survival in suspension, proliferation, colony formation and invasion. 
 
7.2.1. Investigation of transiently altered miRNA expression 
 
Assessment of functional changes due to transiently altered miRNA expression were 
examined using a transient transfection. These investigations of increased and 
decreased miRNA expression were performed in the Panc-1 cell line. 48hr after 
transfection, method described in section 2.6.3, functional changes were assessed in 
both proliferation and colony formation. The miRNA investigated using a transient 
approach are displayed . An untransfected control was included in each experiment as 
well as a negative control, either a Pre-miR negative control or Anti-miR negative 
control. These negative controls are random sequences which have been shown to have 
no effect on known miRNA function as described in section 2.6.3. In this body of work 
some phenotypic changes were observed due to transfection using a negative control. 
As a result of this, all functional comparisons were to the untransfected control. The 
miRNA listed in  were chosen for several reasons, the first being an unbiased approach. 
A large, diverse cohort of miRNA Pre-miRs and Anti-miRs were available in-house 
through the molecular biology group. From this cohort three Pre-miR and three Anti-
miR targets were chosen to investigate further, these choices are detailed in the 
following sections. 
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Table 7-1. miRNA investigated in a transient manner 
Pre-miR Anti-miR 
miR-204 miR-224 
miR-224 miR-320a 
miR-320a miR-378 
 
A literature review was performed to determine the level of novelty of these miRNA 
targets and the role, if any, they play in pancreatic cancer. 
 
miR-204 had been shown to be downregulated in pancreatic cancer cell lines and linked 
to the upregulation of Mcl-1 (Chen et al. 2013). Mcl-1 protects cancer cells from cell 
death and contributes to chemoresistance. It had also been shown to be upregulated in 
pancreatic tumour tissues compared to adjacent normal tissue. This same study also 
determined that overexpression of miR-204 using a Pre-miR, reduced expression of Mcl-
1 and subsequently cell viability of the pancreatic cancer cells (Chen et al. 2013). This 
publication indicated that miR-204 acts as a tumour suppressor in pancreatic cancer, 
studies of several different cancer types had also identified a role of miR-204 as a tumour 
suppressor (Imam et al. 2012, Ying et al. 2013, Sacconi et al. 2012). The Mcl-1 study was 
performed in the Mia PaCa-2 and S2-VP10 pancreatic cancer cell lines, the study in this 
body of work used the Panc-1 cell line. The Panc-1 cell line was transiently transfected 
with Pre-miR-204, firstly, to assess if the tumour suppressor role of miR-204 was 
observed in another pancreatic cancer cell line and also as proof of concept to assess if 
the tumour suppressor properties of miR-204 were observed. 
 
There were very few investigations of the role of miR-224 in pancreatic cancer, one that 
does exist identified that miR-224 was significantly upregulated in highly metastatic 
pancreatic cancer cell lines (Mees et al. 2009). This paper appeared to suggest that miR-
224 is an oncogenic miRNA in pancreatic cancer. In relation to other cancer types there 
are conflicting roles of miR-224 reported. In cervical cancer miR-224 showed higher 
expression in tumour vs normal tissues with in vitro transient overexpression inducing 
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increased proliferation, migration and invasion (Huang et al. 2016a). Converse results to 
this were observed in breast cancer. miR-224 was found to have an inverse relationship 
with aggressiveness in a range of breast cancer subtype cell lines (Liu et al. 2016). This 
study also found transient overexpression reduced proliferation and migration as well 
as growth in vivo while transient knockdown induced the opposite effects i.e. increased 
proliferation and migration (Liu et al. 2016). Due to these reports of conflicting aspects 
of miR-224, its role in pancreatic cancer was investigated in two ways, over and reduced 
expression with both being a transient alteration. 
 
There is very little research available to show the function of miR-320a in pancreatic 
cancer. Although the role in pancreatic cancer had been unknown until this point, in 
many other cancers miR-320a had been shown to be a tumour suppressor miRNA such 
as colorectal cancer, glioma, NSCLC (Lei et al. 2016, Tadano et al. 2016, Sun et al. 2015). 
In NSCLC miR-320 expression was found to be significantly downregulated in tumour vs 
normal tissue samples. This study also observed that transient overexpression of miR-
320 induced a decrease in growth, migration and invasion (Lei et al. 2016). An 
investigation of miR-320 in cervical cancer found an inverse relationship between miR-
320 and the anti-apoptotic protein, Mcl-1 in cervical cancer tissues (Zhang et al. 2016). 
Transient overexpression of miR-320 reduced proliferation, migration and invasion 
while increasing apoptosis in cervical cancer cell lines. This is similar to the relationship 
previously mentioned, discussing the role of miR-204 with Mcl-1 in pancreatic cancer 
(Chen et al. 2013). While miR-320 had been shown to function as a tumour suppressor 
in several other cancer types, there was very little investigation in pancreatic cancer. 
Due to this, this study investigated the role of miR-320a in pancreatic cancer using both 
a Pre-miR and Anti-miR separately.  
 
Lastly, miR-378 was chosen to be investigated. It had been found to have minimal 
association to pancreatic cancer, a small number of publications currently exist and 
these had a tenuous link. One such study assessed miRNA in patient sera using miRNA 
microarrays. miR-378 was identified as a circulating miRNA which was significantly 
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elevated in pancreatic cancer sera compared with control groups (Li et al. 2013).  Studies 
into other cancer types had observed a role of miR-378 as a tumour suppressor. An 
investigation into nasopharyngeal carcinoma observed upregulation of miR-378 induced 
an increase in proliferation, migration, invasion and colony formation (Yu et al. 2014). A 
study of stable overexpression of miR-378 in cancer found that overexpression 
enhanced colony formation as well as cell survival (Deng et al. 2013). These findings as 
well as increased drug resistance were observed due to overexpression of miR-378 in 
glioblastoma (Wu et al. 2012). These two studies identified miR-378 as a tumour 
suppressor while one of the few pancreatic cancer studies appeared to suggest miR-378 
as an oncomiR. To investigate this oncomiR role of miR-378 in pancreatic cancer an Anti-
miR was chosen as downregulated expression may exhibit reduced metastatic 
phenotypes. 
 
Figure 7-1. Percentage proliferation of Panc-1 cells post transient transfection with a 
range of Pre-miRs 
 
Percentage proliferation of the Panc-1 cell line following transient overexpression of miRNA 204, 224 and 
320a with a negative control (Pre NC) included. All values are relative to untransfected control (Un). Error 
bars represent +/- standard deviation between biological replicates, (n=3). 
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Figure 7-2. Percentage proliferation of Panc-1 cells post transient transfection with a 
range of Anti-miRs 
 
Percentage proliferation of the Panc-1 cell line following transient knockdown of miRNA 224, 320a and 
378 with a negative control (Anti NC) included. All values are relative to untransfected control (Un). Error 
bars represent +/- standard deviation between biological replicates, (n=3). 
 
The level of proliferation of Panc-1 cells was altered by increased expression of selected 
miRNA. Figure 7-1 displays the changes observed post 48hr transfection with Pre-miRs 
for miR-204, 224 and 320a. Transient overexpression of miR-224 induced a 50% 
reduction in proliferation, a 40% reduction was observed due to overexpression of miR-
320a. While both of these results displayed no significance a trend of reduced 
proliferation was observed and the lack of significance may be due to variability 
between biological replicates. All values are relative to Panc-1 untransfected cells. No 
trend of changes in proliferation were observed due to transient reduction of miRNA 
expression as seen in Figure 7-2. 
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Figure 7-3. Percentage colony formation of Panc-1 cells post transient transfection with 
a range of Pre-miRs 
 
Percentage colony number and colony area of the Panc-1 cell line following transient overexpression of 
miRNA 204, 224 and 320a with a negative control (Pre NC) included. All values are relative to 
untransfected control (Un). Error bars represent +/- standard deviation between biological replicates, 
(n=3, * = p value ≤ 0.05, ** = p value ≤ 0.01, p values = 0.02, 0.01, 0.002, 0.007). 
 
Figure 7-4. Representative image of colony formation of Panc-1 cells following transient 
miRNA overexpression  
 
Representative image of colony formation of the Panc-1 cell line following transient overexpression of 
miRNA 204, 224 and 320a with a negative control (Pre NC) and untransfected control (Un) included.  
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The level of colony formation was effected by both over and reduced expression of 
selected miRNA. The changes observed post 48hr transfection with Pre-miRs for miR-
204, 224 and 320a are shown in Figure 7-3. It displays a significant 40% reduction in 
colony number and a significant 25% reduction in colony area due to transient 
overexpression of Pre-204, p values of 0.02 and 0.01 respectively. Overexpression of 
miR-224 induced a significant 70% reduction in colony number, p value of 0.002. The 
colony size was also reduced by miR-224 overexpression, by a significant 50% with a p 
value of 0.007 as seen in Figure 7-4. A reduction in both colony number and size due to 
increased miR-320a was present but not statistically significant due to error between 
biological replicates. There appears to be a trend of reduced colony number due to a 
40% reduction being present. 
 
 
Figure 7-5. Percentage colony formation of Panc-1 cells post transient transfection with 
a range of Anti-miRs 
 
Percentage colony number of the Panc-1 cell line following transient knockdown of miRNA 224, 320a and 
378 with a negative control (Anti NC) included. All values are relative to untransfected control (Un). Error 
bars represent +/- standard deviation between biological replicates, (n=3, * = p value ≤ 0.05, *** = p value 
≤ 0.001, p values = 0.0009, 0.04, 0.04). 
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Figure 7-6. Representative image of colony formation of Panc-1 cells following transient 
miRNA reduction 
 
Representative image of colony formation of the Panc-1 cell line following transient overexpression of 
miRNA 204, 224 and 320a with a negative control (Anti NC) and untransfected control (Un) included. 
 
Converse to proliferation, a functional effect on colony formation was induced due to 
transfection of Panc-1 cells with Anti-miRs, seen in Figure 7-5. A highly significant 30% 
reduction in colony number resulted from miR-224 reduced expression, p value of 
0.0009. No change in colony size was observed due to miR-224 alteration. Reduced 
expression of miR-320a caused a significant 30% increase in colony size with a p value 
of 0.04. An increase in colony number, 40%, was induced post reduction of miR-378 
expression, p value of 0.04 as seen in .  
 
7.2.2. Development of stable cell lines to alter miRNA expression 
 
A wide range of plasmid vectors to induce miRNA expression changes were available in-
house. These tools included both overexpression and sponge knockdown vectors, a list 
of these are displayed in Table 7-2. All these vectors can be used to generate stable cell 
Untransfected Anti NC 
Anti miR-224 Anti miR-320a Anti miR-378 
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lines. Vectors are transfected into the cells which then undergo a selection process as 
described in 2.6.4 and 2.6.5. This process selects for cells successfully transfected, a 
selection marker is included in the vector. The selection marker used in these vectors 
was Hygromycin B. Hygromycin B is an antibiotic which can be used to select for cells 
which have acquired a plasmid containing Hygromycin resistance. This aims to remove 
untransfected cells from the cell population, thus allowing for a greater examination of 
functional changes due to the expression alteration. The vectors in Table 7-2 are 
inducible vectors, meaning that the action of the vector can be controlled to a certain 
extent. The transcription of the vector is controlled through treatment with an 
inducement agent. Whether a sponge or overexpression vector, the alteration of the 
miRNA expression level should not occur until the inducer is added. Doxycycline Hyclate 
was the inducer for the vectors in Table 7-2. This is an antibiotic which activates 
transcription of the sponge/overexpression miRNA target. Vector maps for both sponge 
knockdown and overexpression are shown in Figure 7-7 and Figure 7-8. 
 
 
Table 7-2. Overexpression and sponge knockdown vectors available for a wide range of 
miRNA 
Overexpression Knockdown 
miR-7 miR-7 miR-409* 
miR-34a miR-23b miR-451 
miR-10a miR-34a miR-455 
miR-206 miR-144 miR-455* 
 miR-204 miR-497 
 miR-338 miR-497* 
 miR-378 miR-505 
 miR-378* miR-505* 
 miR-409  
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Figure 7-7. Vector map of miRNA sponge knockdown of target miRNA  
 
Inducible miRNA sponge vector, TET-NINE-SanDI-HYG. This construct contains a reporter gene, GFP, 
driven by an inducible TRE2 promoter and multiple cloning sites for sponge cloning. A trans-activator, 
rtTA3, which is driven by a PKG promoter, regulates the transcriptional activation of the reporter gene, 
GFP, in the presence of the induction agent Doxycycline. This sponge vector also encodes for the selective 
marker Hygromycin to allow for generation of stable cell lines. 
 
 
 
Figure 7-8. Vector map of miRNA overexpression of target miRNA  
 
miRNA overexpression vector, TET-ON-HYG. This vector encodes for the reporter gene, RFP which is driven 
by a TRE2 promoter with transcription activated by the trans-activator rtTA3. The rtTA3 is co-expressed 
with an eGFP reporter. This sponge vector also encodes for the selective marker Hygromycin to allow for 
generation of stable cell lines. 
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7.2.3. Generation of stably altered cell lines 
 
7.2.3.1. Optimisation of selection agent concentration, Hygromycin B 
 
To generate stable cell lines, the minimum concentration of selection agent required to 
kill untransfected, parental cells needed to be determined. To do this a kill curve was 
used, this involved testing a range of Hygromycin B concentrations, 400µg/mL - 
1200µg/mL, on Panc-1 parental cells.  
 
Figure 7-9. Optimisation of selection agent concentration, Hygromycin B 
 
Percentage cell death of Panc-1 cells using a varying range of selection agent, Hygromycin B 
concentrations. Untransfected (Un) Panc-1 cells act as the control and all values are relative to this. The 
concentrations examined are 400, 600, 800, 1000 and 1200µg/mL, (n=1). 
 
7.2.3.2. Optimisation of transfection reagent concentration, Mirus TransIT X2 and 
vector concentration 
 
To generate stable cell lines, the optimum concentration of transfection reagent and 
plasmid vector required for sufficient transfection efficiency was investigated. To do this 
a range of concentrations for both parameters were examined. Then fluorescence of 
reporter gene GFP was assessed under the microscope to confirm transfection and 
determine transfection efficiency. 
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Table 7-3. Optimisation of transfection reagent concentration, Mirus TransIT X2 and 
vector concentration using miR-505 Sponge KD vector 
Sample Fluorescence only Overlay 
Untransfected 
  
Mirus only 
  
1.5µg in 1µL of 
Mirus 
  
3µg in 3µL of 
Mirus 
  
5µg in 5µL of 
Mirus 
  
5µg in 7.5µL of 
Mirus 
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7.2.3.3. Confirmation of inducement of Panc-1 cells with miR-505 sponge 
 
To confirm these vectors were behaving as inducible vectors i.e. altering expression after 
treatment with Doxycycline, fluorescence was visualised 4 days’ post induction. Without 
inducement, the reporter gene, GFP, should be not expressed meaning no florescence 
should be detected. 
 
Table 7-4. Confirmation of inducement of Panc-1 cells with miR-505 sponge 
Un-induced Induced Induced Overlay 
   
 
The optimum conditions for generation of stable cell lines was determined through 
optimisation. The kill curve shown in Figure 7-9 determined that at a concentration of 
400µg/mL ~80% cell death occurred. This was the minimum concentration in the range 
tested, required to kill untransfected, parental Panc-1 cells. Table 7-3 displays the 
highest level of fluorescence and therefore the highest transfection efficiency was 
produced using 5µg of vector and 7.5ul of Mirus TransIT X2 transfection reagent. To 
confirm these vectors were inducible i.e. altering expression after treatment with 
Doxycycline, fluorescence was visualised 4 days’ post induction. Table 7-4 displays 
minimal fluorescence without Doxycycline treatment ensuring the vector was not 
functioning when induction was not present. Post induction fluorescence was observed 
confirming the vector was functional post induction. 
 
 
 195 
 
 
7.2.4. miRNA target selection and validation of altered miRNA expression 
 
A large cohort of plasmid vectors to induce miRNA expression changes were available 
in-house. These tools included both overexpression and sponge knockdown vectors, a 
list of these are displayed in Table 7-2. The miRNA listed were the beginning of the 
choice of target miRNA using an unbiased approach. From this large cohort miRNA 
targets for overexpression and sponge knockdown were chosen to investigate. The first 
step in target selection was to elucidate the innate, basal expression levels of each 
miRNA member of the cohort across a panel of pancreatic cancer cell lines. Figure 7-10 
shows the basal expression level of the possible target miRNA across the panel with a 
normal cell line, human mammary epithelial cell (HMEC) included. Expression levels are 
displayed as Ct value evaluated through qPCR as described in 2.10.2. Data from qPCR 
analysis indicates the level of expression through Ct values. These values are on a scale 
of 1-40, this is due to the number of cycles ran through the qPCR. In simple terms a high 
Ct value indicates low expression of the target; a low Ct value meaning high expression 
of the target. This is due to the number of cycles it requires for the target to cross the 
threshold, hence the name Cycle Threshold (Ct). This means the more cycles required to 
reach the threshold the less target expression present in the sample. Ct values between 
20-30 Ct are considered reliable data, outside of this range the data can contain 
variability and false readings. These basal levels along with a review of the current 
knowledge of each miRNA, were used to determine which miRNA targets were most 
appropriate for expression alteration using the tools listed in Table 7-2. These choices 
are detailed in the following sections.
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Figure 7-10. Screen of basal miRNA expression across a panel of pancreatic cancer cell lines 
 
Basal expression of a panel of 14 miRNA displayed as Ct value across a panel of pancreatic cancer cell lines (AsPc-1, BxPc-3, Mia PaCa-2 and Panc-1) with HMEC included as a 
normal cell line. The miRNA listed were the beginning of the choice of target miRNA using an unbiased approach. From this large cohort miRNA targets for overexpression 
and sponge knockdown were chosen to investigate further based on the innate basal expression levels.
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There were limited published investigations of the role of miR-7a in pancreatic cancer. 
One study examined the effect of Curcumin which had an anti-tumour activity on 
pancreatic cancer. This treatment caused an increase in miR-7 expression as well as 
suppression of growth, migration and invasion along with an increase in apoptosis 
indicating a tumour suppressor role of miR-7a in pancreatic cancer (Ma et al. 2014a). A 
small number of publications investigated the role of miR-7 in invasion in a range of 
cancer types, such as cervical cancer, gastric cancer, colorectal cancer and melanoma. 
Across this range of diseases miR-7 was very lowly expressed and overexpression 
inhibited migration, invasion and cell growth, identifying miR-7 as a tumour suppressor 
miRNA (Giles et al. 2016, Zeng et al. 2016, Hao et al. 2015, Xie et al. 2014). Similar results 
were also observed in NSCLC (Cao et al. 2016). All of these studies showed miR-7a 
functioning as a tumour suppressor miRNA in a range of diverse cancer types. miR-7a 
showed medium expression, Ct value of ~25, across the panel of cancer cell lines with 
low expression observed in the normal HMEC cell line, seen in Figure 7-10. As a Ct value 
of 28 was observed in the Panc-1 cell line and considering the published cancer studies 
showed miR-7a to play a tumour suppressor role, an overexpression vector for miR-7a 
was deemed most appropriate to investigate if miR-7a acts as a tumour suppressor in 
pancreatic cancer.  
 
Publications had shown miR-34a as a tumour suppressor miRNA that is commonly 
deleted in several cancers including lung, breast, liver and colon. This miRNA was 
involved in the p53 and Wnt/β-catenin pathways and restoration of its expression 
through a transient Pre-miR transfection inhibited tumour growth and progression (Liu 
et al. 2011). It has also been stated that miR-34a is frequently absent in pancreatic 
cancers (Chang et al. 2007). This study showed overexpression of miR-34a induced 
apoptosis through an apoptotic program triggered by the tumour suppressor protein 
p53, evidence indicated miR-34a to be a direct transcriptional target of p53. 
Overexpression of miR-34a was also shown to dramatically inhibit proliferation in Panc-
1 and Mia PaCa-2 cell lines (Ikeda et al. 2012). A Pre-miR for miR-34a known as MRX34 
entered clinical testing in 2013. Unfortunately, as of September 2016, this clinical trial 
was halted due to immune related adverse effects. Downregulation of the target 
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resulted in an increase in cell cycle progression and angiogenesis as well as a decrease 
in apoptosis and DNA repair in pancreatic cancer (Rachagani, Kumar and Batra 2010). 
More evidence of the tumour suppressor function of miR-34a was observed in vivo, 
overexpression of miR-34a inhibited growth and proliferation while increasing apoptosis 
in mice xenografts tissues (Pramanik et al. 2011). Conversely, miR-34a was a part of the 
10 miRNA index discussed below in relation to miR-505, which exhibited higher 
expression in pancreatic cancer patients compared to healthy controls (Schultz et al. 
2014). This paper suggested an oncogenic role for miR-34a but this study was in the 
minority with its suggestion (Ikeda et al. 2012). miR-34a was expressed at varied levels 
across the pancreatic cancer panel shown in Figure 7-10, with the Panc-1 cell line 
displaying medium expression with a Ct value of 25. Considering this either a sponge or 
overexpression vector was appropriate, an overexpression vector was chosen due to the 
fact that miR-34a is frequently absent in pancreatic cancer (Chang et al. 2007).  
 
A small number of publications have shown miR-206 to act as a tumour suppressor 
miRNA in pancreatic cancer. Two publications stated that miR-206 is significantly 
decreased in pancreatic cancer patient tissues in comparison to normal controls (Ju et 
al. 2016, Keklikoglou et al. 2014). These studies observed that overexpression of miR-
206 inhibited progression of pancreatic cancer through decreased growth, migration 
and invasion. Growth in vivo in mice xenografts was reduced as well as proliferation, 
with apoptosis being increased, shown through tissue staining of Ki67 and TUNEL (Ju et 
al. 2016, Keklikoglou et al. 2014). In vitro overexpression in both the Panc-1 and BxPc-3 
cell lines induced significant decreases in cell proliferation, migration and invasion 
(Keklikoglou et al. 2014). These studies showed a tumour suppressor role of miR-206 in 
pancreatic cancer. Due to no/low expression of miR-206 observed across the panel of 
pancreatic cancer cell lines, as seen in Figure 7-10 and the previous publications 
mentioned, an overexpression vector was determined most suitable and may confirm a 
tumour suppressor role of miR-206 on pancreatic cancer. 
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miR-378 has very little link to pancreatic cancer with a patient sera array analysis being 
the only substantial published study. This showed miR-378 as a circulating miRNA which 
was significantly elevated in pancreatic cancer sera compared with control groups (Li et 
al. 2013). There are a small number of publications addressing the role of miR-378 in 
invasion in a range of cancer types. In different cancer types this miRNA appeared to 
play a different role in invasion. For instance, in both glioma and colorectal cancers, miR-
378 overexpression reduced migration, invasion and in colorectal cancer a reduction in 
proliferation was also observed, miR-378 appears to act as an oncomiR in these cancer 
types (Li et al. 2015a, Zhang et al. 2014). However, in liver and non-small cell lung cancer, 
miR-378 overexpression was associated with increased migration and invasion as well 
as increased proliferation in liver cancer and increased angiogenesis in NSCLC, meaning 
it played a role as a tumour suppressor (Ma et al. 2014b, Chen et al. 2012). miR-378 was 
expressed at medium to high levels across the pancreatic cancer panel with a Ct value 
of 26 being present in the Panc-1 cell line, shown in Figure 7-10, therefore, a miRNA 
sponge was deemed the most appropriate for alteration of miR-378 expression.  
 
There is little published data on the role of miR-505 in cancer. The majority of the papers 
which do mention this target are miRNA screens and profiles which reference miR-505 
in a list of differential expression. One of the few functional studies observed that miR-
505 transient overexpression in endometrial cancer reduced proliferation, migration 
and invasion (Chen et al. 2016b). One pancreatic cancer paper exists which addresses 
miR-505, this paper assessed miRNA as biomarkers for pancreatic cancer in blood. miR-
505 was a part of two diagnostic panels used to distinguish patients with pancreatic 
cancer from healthy controls. miR-505 was among a 10 miRNA index which exhibited 
higher expression in pancreatic cancer patients compared to healthy controls (Schultz 
et al. 2014). Low expression of miR-505 was present across the panel of cell lines, with 
Panc-1 displaying a Ct value of 28, seen in Figure 7-10. It was determined to alter miR-
505 expression with a sponge knockdown vector. This was due to no overexpression 
vector being available and due to the level of novelty of miR-505 in pancreatic cancer, 
any assessment of its role in pancreatic cancer was deemed valuable.  
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7.2.5. Confirmation of altered miRNA expression 
 
Figure 7-11 through to Figure 7-15 display the relative quantification of each miRNA 
target. Once stable cell lines had been developed, confirmation of altered miRNA 
expression was required. qPCR was used to investigate the level of, if any, altered miRNA 
expression, qPCR method described in section 2.10.2. Figure 7-11 and Figure 7-12 
display no significant change in fold change in either miR-378 or miR-505 in the stable 
cell lines. In fact, it appears an overexpression is present in miR-505. However, taking 
into account the Ct values displayed in Table 7-5, a 1 Ct value difference is displayed 
between the induced negative control and the induced target miRNA. An increase in Ct 
value indicates a decrease in expression, as described in section 7.2.4, also 1 Ct value 
equates to a 2-fold change (Morey, Ryan and Van Dolah 2006). This reduction in 
expression caused by the sponge knockdown was not found in the qPCR Relative 
Quantification analysis, this was due to changes in the Ct value of the endogenous 
control, Let-7e (data not shown) and also due to expression changes in the negative 
control when induced, seen in Table 7-5. Treatment with the induction agent 
Doxycycline appeared to cause alteration in miRNA expression levels in the negative 
control. There appeared to be no overexpression of miR-7a as seen in Figure 7-13 and 
Table 7-5. The same is true for miR-34a, shown in Figure 7-14, however, the Ct values 
displayed in Table 7-5, show an increase of 1.2 Ct (indicating an increase in expression) 
in miR-34a between the induced negative control and the induced target miRNA. This 
indicates a 2-fold increase in miR-34a expression. This was not found in the qPCR 
Relative Quantification analysis due to changes in the Ct values of the endogenous 
control, Let-7e (data not shown) and also due to expression changes in the negative 
control when induced, seen in Table 7-5. Successful overexpression of miR-206 was 
achieved, displayed in Figure 7-15 as well as Table 7-5. A vast increase of miR-206 
expression was achieved, ~230-fold change. It appeared a reduction in miRNA 
expression of miR-378 and miR-505 was achieved using sponge knockdown and 
overexpression was achieved for miR-34a and miR-206 but more qPCR analysis is 
required to show this conclusively. The change of miRNA expression in the negative 
control post inducement must also be addressed. 
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Figure 7-11. Relative quantification of miR-378 expression post sponge knockdown 
 
Relative quantification of miR-378 expression in the Panc-1 cell line 24hr post induction of sponge 
knockdown relative to the sponge negative control using Let-7e as an endogenous control. 
 
Figure 7-12. Relative quantification of miR-505 expression post sponge knockdown 
 
Relative quantification of miR-505 expression in the Panc-1 cell line post 24hr induction of sponge 
knockdown relative to the sponge negative control using Let-7e as an endogenous control. 
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Figure 7-13. Relative quantification of miR-7a overexpression post transfection 
 
Relative quantification of miR-7a expression in the Panc-1 cell line post 24hr induction of overexpression 
relative to the overexpression negative control using Let-7e as an endogenous control. 
 
Figure 7-14. Relative quantification of miR-34a overexpression post transfection 
 
Relative quantification of miR-34a expression in the Panc-1 cell line post 24hr induction of overexpression 
relative to the overexpression negative control using Let-7e as an endogenous control. 
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Figure 7-15. Relative quantification of miR-206 overexpression post transfection 
 
Relative quantification of miR-206 expression in the Panc-1 cell line post 24hr induction of overexpression 
relative to the overexpression negative control using Let-7e as an endogenous control. 
 
 
Table 7-5. Ct values of each miRNA target, un-induced and induced. 
 
 
 
   
The Ct values of each miRNA target with the negative control included, Ct values in both un-induced (Un) 
and induced (In) conditions are displayed. 
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7.2.6. Functional effects of stable enduring alteration of miRNA expression 
 
Once cell lines with stably altered miRNA expression were generated and confirmed, 
functional changes due to altered miRNA expression were investigated. Functional 
changes due to reduced expression of miR-378 and miR-505 and increased expression 
of miR-7a, miR-34a and miR-206 were assessed in anoikis, proliferation, colony 
formation and invasion. An untransfected control was included in each experiment as 
well as a negative control, either a sponge negative control or an overexpression 
negative control. All functional effects were assessed with inducement i.e. Doxycycline 
present in assay. 
 
Figure 7-16. Percentage survival of induced and un-induced Panc-1 cells 
 
Percentage survival of Panc-1 cells un-induced and induced, in both attached and anoikis i.e. suspension 
conditions relative to attached un-induced as the control. Induction with 1µg/mL of Doxycycline is present 
throughout the assay in the induced samples. Error bars represent +/- standard deviation between 
biological replicates, (n=3). 
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Figure 7-17. Percentage survival of Panc-1 cells post sponge knockdown of miRNA 
expression 
 
Percentage survival of Panc-1 cells in both anoikis i.e. suspension and attached conditions with Panc-1 
induced cells acting as the control. Survival post miRNA expression reduction is displayed by Sponge 
negative control, Spg 378 and Spg 505. Induction with 1µg/mL of Doxycycline is present throughout the 
assay. Error bars represent +/- standard deviation between biological replicates, (n=5). 
 
Figure 7-18. Percentage survival of Panc-1 cells post miRNA overexpression 
 
Percentage survival of Panc-1 cells in both suspension and attached conditions with Panc-1 induced cells 
acting as the control. Survival post miRNA overexpression is displayed by overexpression negative control, 
OV 7a, OV 34a and OV 206. Induction with 1µg/mL of Doxycycline is present throughout the assay. Error 
bars represent +/- standard deviation between biological replicates, (n=5). 
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Treatment of parental Panc-1 cells with doxycycline, the inducer, had no effect on 
survival in either attached or suspension conditions, as seen in Figure 7-16. Neither 
sponge knockdown or overexpression of any target miRNA had any effect on survival in 
either suspension or attached conditions, displayed in Figure 7-17 and Figure 7-18. The 
alteration of miR-7a, 34a, 206, 378 and 505 expression did not show any effect on the 
ability of Panc-1 cells to survive in suspension. 
 
Figure 7-19. Percentage proliferation of induced and un-induced Panc-1 cells 
 
Percentage proliferation of Panc-1 cells un-induced and induced after 7 days’ incubation, relative to un-
induced as the control. Induction with 1µg/mL of Doxycycline is present throughout the assay in the 
induced samples. Error bars represent +/- standard deviation between technical replicates, (n=1). 
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Figure 7-20. Percentage proliferation of Panc-1 cells post sponge knockdown of miRNA 
expression 
 
Percentage proliferation of Panc-1 cells with Panc-1 induced cells acting as the control. Proliferation post 
miRNA expression reduction is displayed by Sponge negative control, Spg 378 and Spg 505. Induction with 
1µg/mL of Doxycycline is present throughout the assay. Error bars represent +/- standard deviation 
between biological replicates, (n=4). 
 
Figure 7-21. Percentage proliferation of Panc-1 cells post miRNA overexpression 
 
Percentage proliferation of Panc-1 cells with Panc-1 induced cells acting as the control. Proliferation post 
miRNA overexpression is displayed by overexpression negative control, OV 7a, OV 34a and OV 206. 
Induction with 1µg/mL of Doxycycline is present throughout the assay. Error bars represent +/- standard 
deviation between biological replicates, (n=4, p value = 0.02). 
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The inducer, Doxycycline, increased proliferation of Panc-1 cells by 10%, seen in Figure 
7-19. Due to this, induced Panc-1 cells were used as the control and all proliferation 
values were calculated relative to this. No effect on proliferation was observed due to 
sponge knockdown alteration of miRNA expression, shown in Figure 7-20. Figure 7-21 
displays proliferation changes due to overexpression of miR-7a, miR-34a and miR-206 
with an untransfected control and overexpression negative control included. 
Interestingly, a 40% increase in proliferation resulted from the OV NC, this change 
validated that induced parental Panc-1 cells were the most appropriate control as the 
negative control vector caused changes in the cell line. A significant 15% reduction in 
proliferation was due to miR-7a overexpression with a p value of 0.02. Overexpression 
of both miR-34 and miR-206 caused an increase in proliferation, 40% and 30%, but these 
changes were not statistically significant. 
 
Figure 7-22. Percentage colony formation of Panc-1 cells post sponge knockdown of 
miRNA expression 
 
Percentage number of colonies and colony area of Panc-1 cells with Panc-1 induced cells acting as the 
control. Colony formation post miRNA expression reduction is displayed by Sponge negative control, Spg 
378 and Spg 505. Induction with 1µg/mL of Doxycycline is present throughout the assay. Error bars 
represent +/- standard deviation between biological replicates, (n=3). 
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Figure 7-23. Representative image of colony formation of Panc-1 post sponge 
knockdown 
 
Representative image of colony formation of the Panc-1 cell line following sponge knockdown of miR-378 
and miR-505. With parental Panc-1 and Sponge negative control included.  
 
Figure 7-24. Percentage colony formation of Panc-1 cells post miRNA overexpression 
 
Percentage number of colonies and colony area of Panc-1 cells with Panc-1 induced cells acting as the 
control. Colony formation post miRNA overexpression is displayed by overexpression negative control, 
OV 7a, OV 34a and OV 206. Induction with 1µg/mL of Doxycycline is present throughout the assay. Error 
bars represent +/- standard deviation between biological replicates, (n=3, *** = p value ≤ 0.001, p value 
= 0.001). 
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Figure 7-25. Representative image of colony formation of Panc-1 cells post miRNA 
overexpression  
 
Representative image of colony formation of the Panc-1 cell line following overexpression of miR-7a, miR-
34a and miR-206. With parental Panc-1 and Overexpression negative control included.  
 
Figure 7-22 displays no significant change in colony formation resulted from miRNA 
sponge knockdown of miR-378 or miR-505. A representative image of colony formation 
post sponge knockdown as well as parental Panc-1 cells treated with the inducer, 
Doxycycline is shown in Figure 7-23. A highly significant decrease in colony number and 
a decrease in colony size resulted from miR-7a overexpression, observed in Figure 7-24. 
The number of colonies was reduced by 70% compared to induced Panc-1 parental cells 
with a p value of 0.001. The reduction in colony size of 25% did not show statistical 
significance. A representative image is seen in Figure 7-25. Overexpression of miR-34a 
and miR-206 had no effect on colony number but caused an increase in colony size, 
although no statistical significance was present. 
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Figure 7-26. Percentage invasion of induced and un-induced Panc-1 cells 
 
Percentage invasion of Panc-1 cells un-induced and induced after 24 hours, relative to un-induced as the 
control. Induction with 1µg/mL of Doxycycline is present throughout the assay in the induced samples. 
Error bars represent +/- standard deviation between biological replicates, (n=3, p value = 0.04). 
 
Figure 7-27. Percentage invasion of Panc-1 cells post sponge knockdown of miRNA 
expression 
 
Percentage invasion of Panc-1 cells with Panc-1 induced cells acting as the control. Invasion post miRNA 
expression reduction is displayed by Sponge negative control, Spg 378 and Spg 505. Induction with 
1µg/mL of Doxycycline is present throughout the assay. Error bars represent +/- standard deviation 
between biological replicates, (n=2, *** = p value ≤ 0.001, Spg 378 p value = 0.0008). 
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Figure 7-28. Percentage invasion of Panc-1 cells post miRNA overexpression 
 
Percentage invasion of Panc-1 cells with Panc-1 induced cells acting as the control. Invasion post miRNA 
overexpression is displayed by overexpression negative control, OV 7a, OV 34a and OV 206. Induction 
with 1µg/mL of Doxycycline is present throughout the assay. Error bars represent +/- standard deviation 
between biological replicates, (n=2). 
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Figure 7-29. Representative images of invasion of Panc-1 cells post miRNA expression 
alteration 
Panc-1 Un-
induced 
  
Panc-1 Induced 
Spg NC Induced 
  
OV NC induced 
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Representative images of invasion of Panc-1 cells un-induced and induced. The effects due to sponge 
knockdown are displayed as Spg NC, miR-378 and miR-505 all induced. The effects due to miRNA 
overexpression are displayed as OV NC, miR-7a, miR-34a and miR-206 all induced. 
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A slightly significant reduction in invasion was caused due to inducement of Panc-1 cells. 
Figure 7-29 displays a 30% reduction in invasion levels post treatment with Doxycycline 
with a p value of 0.04. This may be due to Doxycycline functioning as an inhibitor of 
MMPs. Several studies have shown an inhibitory effect of Doxycycline on MMP function 
(Uitto et al. 1994, Hanemaaijer et al. 1998, Prall et al. 2002). As MMPs play a highly 
important role in invasion, they function to allow the cell to break down the ECM, 
therefore the reduction observed in invasion of the parental Panc-1 cell line post 
induction may be due to the Doxycycline acting as an MMP inhibitor. Due to this, 
induced Panc-1 cells were used as the control and all invasion values were calculated 
relative to this. Sponge NC appeared to induce a 60% increase in invasion, observed in 
Figure 7-27. This change validated that induced parental Panc-1 cells are the most 
appropriate control as the negative control caused changes in the cell line. Sponge 
knockdown of miR-378 resulted in a highly significant increase in the invasive capability 
of Panc-1 cells. Invasion levels increased by 200% with a p value of 0.0008 due to 
reduced expression of miR-378. Figure 7-27 also shows that sponge knockdown of miR-
505 induced a 140% increase in invasion, unfortunately this result did not show 
statistical significance due to large error between biological replicates. While 
significance was not detected a trend of increased invasion post miR-505 knockdown 
was observed. Similar to the Sponge NC, OV NC appears to induce a 130% increase in 
invasion, observed in Figure 7-28. This change validated that induced parental Panc-1 
cells are the most appropriate control as the negative control had a large effect. 
Overexpression of each miRNA, miR-7a, miR-34a and miR-206 all induced an increase in 
invasion, 80%, 150% and 145% respectively, displayed in Figure 7-28. Due to the level of 
error and considering the increase induced by OV NC, these results were not found to 
be significant. Representative images of invasion of Panc-1 cells un-induced and induced 
as well as all sponge knockdown and overexpression miRNA targets can be seen in Figure 
7-29 . 
 
Following the observation of the phenotypic changes due to stably altered miRNA 
expression, survival analysis was also performed. This analysis utilised software and data 
available through the PROGmiR program which yielded a Kaplan-Meier (KM) survival 
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plot. This software analysed approximately 1050 human miRNAs in 33 major cancer 
types and used data from Gene Expression Omnibus (GEO) and The Cancer Genome 
Atlas (TCGA) to analyse the prognostic value of miRNA. These databases provide both 
sequencing/expression data as well as survival data for the clinical samples producing a 
Kaplan-Meier survival analysis yielding a plot, hazard ratio and P value. A significant role 
of miR-7a in pancreatic cancer survival was observed and is shown in Figure 7-30. This 
KM plot displays miR-7 expression in terms of overall survival (OS) of 191 patients over 
a period of 5 years (Goswami and Nakshatri 2012). The KM survival analysis indicated 
that high expression of miR-7 was significantly (p value = 0.0016) associated with greater 
OS in pancreatic cancer patients. The low expression cohort of patients possessed a 
median survival time of 607 days while the high expression cohort displayed a median 
survival time of 702 days. This high expression-greater survival relationship is in 
agreement with the phenotypic changes observed in this body of work which indicated 
miR-7a overexpression inhibited metastatic phenotypes. 
 
Figure 7-30. Kaplan Meier plot showing the relationship of miR-7 expression with 
survival 
 
Kaplan Meier plot of miR-7 expression relative to survival in pancreatic cancer patients. Analysis of miR-7 
expression in terms of overall survival (OS) of patients over a period of 5 years. The KM survival analysis 
indicates that high expression of miR-7 is significantly (p value = 0.0016) associated with greater OS in 
pancreatic cancer patients (n=191, p value = 0.0016) (Goswami and Nakshatri 2012).
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8. Discussion – Investigation of the 
Role of miRNA in Metastatic 
Phenotypes in Pancreatic Cancer  
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8.1. Functional effects of transient alteration of miRNA in Panc-1 cells 
 
Assessment of functional changes due to altered miRNA expression were examined in a 
transient fashion. Investigations of increased and decreased miRNA expression were 
performed in the Panc-1 cell line. 48hr after transfection, method described in section 
2.6.3, functional changes were assessed in both proliferation and colony formation. The 
miRNA investigated using a transient approach are displayed . An untransfected control 
was included in each experiment as well as a negative control, either a Pre-miR negative 
control or Anti-miR negative control which are random sequences which have been 
shown to have no effect on known miRNA function as described in section 2.6.3. In this 
body of work some phenotypic changes were observed due to transfection using a 
negative control, due to this all functional comparisons were to the untransfected 
control. The miRNA listed in  were chosen for several reasons, the first being beginning 
with an unbiased approach. A large cohort of miRNA Pre-miRs and Anti-miRs were 
available in-house, this cohort was the beginning of the choice of target miRNA. From 
this large cohort three Pre-miR and three Anti-miR targets were chosen to investigate 
further, these choices are detailed in section 7.2.1. 
 
Overexpression of miR-204 using a Pre-miR significantly reduced colony number and 
colony size, meaning Panc-1 cells had a reduced ability to form colonies due to increased 
miR-204 expression. A similar result was observed in thyroid cancer, a transient 
overexpression of miR-204 induced reduced proliferation and a significant reduced 
ability to form colonies (Wu et al. 2015). There are several studies investigating miR-204 
in pancreatic cancer. One study observed that miR-204 expression was repressed in 
pancreatic cancer tissues compared to normal tissue. This work also found that transient 
overexpression of miR-204 reduced cell viability i.e. induced cancer cell death (Chen et 
al. 2013). It was also discovered that Pre-204 negatively regulates Mcl-1 which is anti-
apoptotic protein and the reduced cell viability induced by transient overexpression of 
miR-204 was concluded to be due to loss of Mcl-1 expression (Chen et al. 2013). High 
miR-204 expression in patients post gemcitabine treatment possessed a longer survival 
time, 33 months’ vs 16.3 months in patients with low miR-204 expression post 
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treatment (Ohuchida et al. 2011). This work suggested miR-204 as a promising predictive 
marker for chemotherapeutic response in resected patients. As well as possessing a role 
as a predictive marker, miR-204 appears to function as a tumour suppressor in 
pancreatic cancer. The reduction in colony formation observed in this work appears to 
validate the role of miR-204 as a tumour suppressor in pancreatic cancer.  
 
The role of miR-224 in pancreatic cancer was investigated in two ways, over and reduced 
expression with both being a transient alteration. Transient overexpression of miR-224 
caused major reduction in metastatic phenotypes. Proliferation was reduced by 50% 
with colony formation showing a significant 70% reduction in colony number and a 
highly significant 50% reduction in colony size. Conversely reduction of miR-224 
expression resulted in a highly significant 30% reduction in colony number. These results 
in terms of colony formation are in conflict with each other. There are very few 
investigations of the role of miR-224 in pancreatic cancer, one that does exist identified 
that miR-224 is significantly upregulated in highly metastatic pancreatic cancer cell lines 
(Mees et al. 2009). This paper appears to suggest that miR-224 is an oncogenic miRNA 
in pancreatic cancer. In terms of other cancer types there are conflicting roles of miR-
224 reported. In cervical cancer miR-224 shows higher expression in tumour vs normal 
tissues with in vitro transient overexpression inducing an increase in proliferation, 
migration and invasion (Huang et al. 2016a). This is in contrast to this study of pancreatic 
cancer as transient overexpression of miR-224 reduced proliferation and colony 
formation. Phenotypic changes similar to this have been observed in breast cancer. miR-
224 was found to have an inverse relationship with aggressiveness in a range of breast 
cancer subtype cell lines (Liu et al. 2016). This study also found transient overexpression 
reduced proliferation and migration as well as growth in vivo with transient knockdown 
inducing the opposite effects i.e. an increase in proliferation and migration (Liu et al. 
2016). Considering these contrasting publications and the conflicting results observed 
due to transient alteration of miR-224 in this pancreatic cancer study, it was difficult to 
concisely conclude the role miR-224 plays in the progression of pancreatic cancer.  
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A clearer picture was able to be drawn from the results due to altered expression of miR-
320a. Transient overexpression of miR-320a induced a 40% reduction in both 
proliferation and number of colonies formed. These results did not show statistical 
significant but promisingly contrastingly results were observed due to reduced miR-320a 
expression. A significant 30% increase in colony size was observed due to decreased 
miR-320a expression. These results appear to show miR-320a plays a role in the ability 
of pancreatic cancer cells to form colonies meaning miR-320a acts as a tumour 
suppressor in pancreatic cancer. There is very little research available to show the role 
of miR-320a in pancreatic cancer so this may be a novel insight. Although the role in 
pancreatic cancer has been unknown until this point, in many other cancers miR-320a 
has been shown to be a tumour suppressor miRNA such as colorectal cancer, glioma, 
NSCLC (Lei et al. 2016, Tadano et al. 2016, Sun et al. 2015). In NSCLC miR-320 expression 
was found to be significantly downregulated in tumour vs normal tissue samples. This 
study also observed that transient overexpression of miR-320 induced a decrease in 
growth, migration and invasion (Lei et al. 2016). An investigation of miR-320 in cervical 
cancer found an inverse relationship between miR-320 and the anti-apoptotic protein, 
Mcl-1 in cervical cancer tissues (Zhang et al. 2016). Transient overexpression of miR-320 
reduced proliferation, migration and invasion while increasing apoptosis in cervical 
cancer cell lines. This is similar to the relationship previously mentioned, discussing the 
role of miR-204 with Mcl-1 in pancreatic cancer (Chen et al. 2013). As this present 
investigation of miR-320a in pancreatic cancer identified its role as a tumour suppressor 
this function may be carried out through targeting and inhibition of Mcl-1. 
 
The final target investigated in a transient manner was miR-378. Reduced expression of 
miR-378 in Panc-1 cells induced a significant 40% increase in colony number. Decreased 
miR-378 expression appears to increase the ability of Panc-1 cells to form colonies. This 
would imply that miR-378 behaves as a tumour suppressor in pancreatic cancer as 
reduced expression induces a more metastatic phenotype. miR-378 has very little link 
to pancreatic cancer, only one publication currently exists. This study assessed miRNA 
in patient sera using miRNA microarrays. miR-378 was identified as a circulating miRNA 
which was significantly elevated in pancreatic cancer sera compared with control groups 
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(Li et al. 2013).  Studies into other cancer types have also observed a role of miR-378 as 
a tumour suppressor. An investigation into triple negative breast cancer observed 
transient upregulation of miR-378 inhibited migration and invasion (Browne et al. 2016). 
Another study of transient overexpression of miR-378 in cancer found that 
overexpression suppressed migration and invasion and promoted apoptosis in prostate 
cancer (Chen et al. 2016a). While both of these studies used transient overexpression, 
the present pancreatic cancer study used transient downregulation, promisingly both 
approaches identified miR-378 as a tumour suppressor. It appears that miR-378 
functions as a tumour suppressor in pancreatic cancer as well as other cancer types as 
have been published.  
 
8.2. Phenotypic changes of Panc-1 cells with stably altered miRNA expression 
 
A large cohort of plasmid vectors to induce miRNA expression changes were available 
in-house. These tools included both overexpression and sponge knockdown vectors, a 
list of these are displayed in Table 7-2. The miRNA listed were the beginning of the 
choice of target miRNA using an unbiased approach. From this large cohort miRNA 
targets for overexpression and sponge knockdown were chosen to investigate. The first 
step in target selection was to elucidate the innate, basal expression levels of each 
miRNA member of the cohort across a panel of pancreatic cancer cell lines. Figure 7-10 
shows the basal expression level of the possible target miRNA across the panel with a 
normal cell line, HMEC, included. These basal levels along with a review of the current 
knowledge of each miRNA, were used to determine which miRNA targets were most 
appropriate for expression alteration using the tools listed in Table 7-2. These choices 
are detailed in section 7.2.4. 
 
8.2.1. Functional effects of sponge knockdown of miRNA in Panc-1 cells 
 
Sponge knockdown technology has only begun to be used as an investigative tool in the 
last decade with the number of publications being small over a 10-year period. In terms 
of pancreatic cancer there are very little investigations of sponge knockdown 
 221 
 
technology, with only 2 publications being listed (Neault, Mallette and Richard 2016, 
Jung et al. 2015). In this work, sponge knockdown was used to reduce expression of miR-
378 and miR-505. No significant effect was observed post knockdown in anoikis, 
proliferation or colony formation. There is little published data on the role of miR-505 
in cancer. The majority of the papers which do mention this target are miRNA screens 
and profiles which mention miR-505 in the list of differential expression. One of the few 
functional studies observed that miR-505 transient overexpression in endometrial 
cancer reduced proliferation, migration and invasion (Chen et al. 2016b). One pancreatic 
cancer paper exists which mentions miR-505, this paper assessed miRNA as biomarkers 
for pancreatic cancer in blood. miR-505 was a part of two diagnostic panels used to 
distinguish patients with pancreatic cancer from healthy controls. miR-505 was among 
a 10 miRNA index which exhibited higher expression in pancreatic cancer patients 
compared to healthy controls (Schultz et al. 2014). Using a sponge knockdown vector 
for miR-505 in this work no significant change in phenotype was observed, an increase 
in invasion may be present but no statistical significance was detected. This trend of 
increased invasion post sponge knockdown is in line with the results observed in 
endometrial cancer, miR-505 overexpression decreased invasion in that study (Chen et 
al. 2016b). Conversely, in this study miR-505 knockdown may have induced an increase 
in invasion. A significant increase in invasion was observed due to the other sponge 
knockdown target in this body of work, miR-378. A 200% increase in invasion with a p 
value of 0.0008 was induced by knockdown of miR-378 relative to induced parental 
Panc-1 cells. As previously mentioned miR-378 has very little link to pancreatic cancer 
with the patient sera array analysis being the only substantial published study. This 
showed miR-378 as a circulating miRNA which was significantly elevated in pancreatic 
cancer sera compared with control groups (Li et al. 2013). There are a small number of 
publications addressing the role of miR-378 in invasion in a range of cancer types. In 
different cancer types this miRNA appears to play a different role in invasion. For 
instance, in both glioma and colorectal cancers, miR-378 overexpression reduces 
migration, invasion and in colorectal cancer a reduction in proliferation also, miR-378 
appears to act as an oncomiR in these cancer types (Li et al. 2015a, Zhang et al. 2014). 
However, in liver and non-small cell lung cancer, miR-378 overexpression is associated 
with an increase in migration and invasion as well as increased proliferation in liver 
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cancer and increased angiogenesis in NSCLC, meaning it plays a role as a tumour 
suppressor (Ma et al. 2014b, Chen et al. 2012). While no effect on proliferation was 
detected using sponge knockdown in this investigation, a significant increase in invasion 
was observed showing miR-378 may play a similar role as a tumour suppressor in 
pancreatic cancer as previously seen in liver and non-small cell lung cancer.  miR-378 
was unique in this investigation as both transient and stable expression reduction were 
investigated. Both interventions induced different phenotypic changes. Transient 
expression reduction induced a significant increase in colony formation while stable 
expression reduction induced a significant increase in invasion with no effect on colony 
formation. While different phenotypic changes were observed both indicate a role of 
miR-378 as a tumour suppressor in pancreatic cancer, the fact that different forms of 
intervention led to the same conclusion may validate miR-378 as a tumour suppressor 
in pancreatic cancer. The effect of miR-378 on invasion of Panc-1 cells was the most 
significant result observed from the sponge knockdown investigations but the validation 
of sponge knockdown technology in pancreatic cancer is valuable, as is the knowledge 
gained of miR-378 and miR-505, two novel miRNA in pancreatic cancer. 
 
8.2.2. Functional effects of stable miRNA overexpression in Panc-1 cells 
 
The use of stable overexpression of miRNA offers a powerful insight into the role miRNA 
play in disease progression especially as miRNA can act as tumour suppressors in cancer. 
Overexpression of a miRNA target which has a low basal level may restore the tumour 
suppressor function of the target miRNA i.e. metastatic phenotypes may be inhibited or 
reverse due to overexpression of tumour suppressor miRNA. The miRNA targets 
investigated for tumour suppressor role in pancreatic cancer were miR-7a, miR-34a and 
miR-206.  
 
miR-206 overexpression induced no effect in anoikis or colony formation of Panc-1 cells. 
An increase in both proliferation and invasion was observed due to miR-206 
overexpression although these did not show statistical significance due to variability 
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between biological replicates. It was also a concern that the OV NC induced similar 
increases in both these metastatic functions. Considering this, it was difficult to draw a 
specific conclusion from the overexpression of miR-206. Publications have shown miR-
206 to act as a tumour suppressor miRNA. Two publications have stated that miR-206 is 
significantly decreased in pancreatic cancer patient tissues in comparison to normal 
controls (Ju et al. 2016, Keklikoglou et al. 2014). These studies observed that 
overexpression of miR-206 inhibited progression of pancreatic cancer through 
decreased growth, migration and invasion. Growth in vivo in mice xenografts was 
reduced as well as proliferation with apoptosis being increased, shown through tissue 
staining of Ki67 and TUNEL (Ju et al. 2016, Keklikoglou et al. 2014). In vitro 
overexpression in both the Panc-1 and BxPc-3 cell lines induced significant decrease in 
cell proliferation, migration and invasion (Keklikoglou et al. 2014). These studies show a 
tumour suppressor role of miR-206 in pancreatic cancer, unfortunately no conclusion 
could be drawn from miR-206 overexpression in this project but no tumour suppressor 
functions were observed. 
 
Phenotypic changes observed due to miR-34a overexpression were similar to the results 
observed due to miR-206 overexpression. No effect was observed on anoikis or colony 
formation. An increase in both proliferation and invasion was induced due to miR-34a 
overexpression but did not show statistical significance due to error between biological 
replicates. Again, the fact that the OV NC induced similar increases in both these 
metastatic functions is still a concern, making it difficult to draw a specific conclusion 
from the overexpression of miR-34a. Publications have shown miR-34a as a tumour 
suppressor miRNA that is commonly deleted in several cancers including lung, breast, 
liver and colon. This miRNA is involved in the p53 and Wnt/β-catenin pathways and 
restoration of its expression through a transient Pre-miR transfection has been shown 
to inhibit tumour growth and progression (Liu et al. 2011). It has also been shown that 
miR-34a is frequently absent in pancreatic cancers (Chang et al. 2007). This study 
showed overexpression of miR-34a to induce apoptosis through an apoptotic program 
triggered by the tumour suppressor protein p53, with evidence indicating that miR-34a 
is a direct transcriptional target of p53. Overexpression of miR-34a has also been shown 
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to dramatically inhibit proliferation in Panc-1 and Mia PaCa-2 cell lines (Ikeda et al. 
2012). A Pre-miR for miR-34a known as MRX34 entered clinical testing in 2013. 
Unfortunately, as of September 2016, this clinical trial was halted due to immune related 
adverse effects. Downregulation of the target resulted in an increase in cell cycle 
progression and angiogenesis as well as a decrease in apoptosis and DNA repair in 
pancreatic cancer (Rachagani, Kumar and Batra 2010). More evidence of the tumour 
suppressor function of miR-34a was observed in vivo, overexpression of miR-34a 
inhibited growth and proliferation while increasing apoptosis in mice xenografts tissues 
(Pramanik et al. 2011). Conversely, miR-34a was a part of the 10 miRNA index previously 
mentioned in relation to miR-505, which exhibited higher expression in pancreatic 
cancer patients compared to healthy controls (Schultz et al. 2014). This paper suggested 
an oncogenic role for miR-34a but this study is in the minority with its suggestion (Ikeda 
et al. 2012). Unfortunately, no conclusion could be drawn from miR-34a overexpression 
in this project but no tumour suppressor functions were observed. 
 
Overexpression of miR-7a exhibited the most significant change in metastatic 
phenotypes due to miRNA overexpression. Surprisingly, no overexpression of miR-7a 
was detected through qPCR. Due to cells expressing fluorescence, the success of the 
transfection was validated and due to the functional effects induced it was accepted 
that miR-7a overexpression was present but undetected. To further analyse this, qPCR 
will be carried out to detect RFP expression, this will be an indicator of the 
overexpression achieved. The RFP sequence is transcribed from the same promotor as 
the miRNA target indicating that the target miRNA is transcribed along with the reporter 
gene, RFP. As with each of the other target miRNA, no effect on anoikis was observed 
due to altered miRNA expression, but there was one conclusion to be made from the 
investigation into miRNA in anoikis. For all targets, it appears that survival in suspension 
is slightly increased after induction. Meaning that treatment with Doxycycline is allowing 
the pancreatic cancer cells to resist anoikis i.e. death due to suspension. This 
observation has been observed by other groups, inducible fibroblasts displayed positive 
phenotypes such as greater proliferation and survival in suspension with Doxycycline 
present (Fluri et al. 2012). Overexpression of miR-7a induced an increase in invasion but 
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this result was not statistically significant and a trend of increased invasion was not 
observed in each biological replicate. The most significant change in phenotype due to 
overexpression of miR-7a was a significant reduction in proliferation and a highly 
significant reduction in colony formation. Due to the link between proliferation and 
colony formation a reduction in both was promising. A decrease of 80% was induced in 
the number of colonies formed and this result was highly significant, p value of 0.001. A 
significant reduction in colony formation was observed in each biological replicate 
leading to the conclusion that miR-7a plays a highly important role in the ability of 
pancreatic cancer cells to form colonies. It has been widely reported that miR-7a targets 
EGFR, Panc-1 cells have been shown to highly express EGFR and also inhibition of EGFR 
in cancer has been associated with a reduction in colony forming ability (Li et al. 2016, 
Ali et al. 2005). Therefore, inhibition of EGFR through miR-7a overexpression may be 
responsible for the reduction in colony formation observed (Giles et al. 2016, Kefas et 
al. 2008). It is possible that overexpression of miR-7a is inhibiting colony formation of 
Panc-1 cells through downregulation of EGFR.  
 
Following the observation of the phenotypic changes due to stably altered miRNA 
expression, survival analysis was also performed. This analysis utilised software and data 
available through PROGmiR program which yielded a Kaplan-Meier (KM) survival plot. A 
significant role of miR-7a in pancreatic cancer survival was observed and is shown in 
Figure 7-30. This KM plot displays miR-7 expression in terms of OS of 191 patients over 
a period of 5 years (Goswami and Nakshatri 2012). The KM survival analysis indicates 
that high expression of miR-7 is significantly (p value = 0.0016) associated with greater 
OS in pancreatic cancer patients. This high expression-greater survival is in agreement 
with the phenotypic changes observed which indicated miR-7a acts as a tumour 
suppressor in pancreatic cancer and may indicate a possible role of miR-7 as a prognostic 
indicator (Goswami and Nakshatri 2012). 
 
There are limited published investigations of the role of miR-7a in pancreatic cancer. 
One study examined the effect of Curcumin which has an anti-tumour activity on 
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pancreatic cancer. This treatment caused an increase in miR-7 expression as well as 
suppression of growth, migration and invasion along with an increase in apoptosis 
indicating a tumour suppressor role of miR-7a in pancreatic cancer (Ma et al. 2014a). A 
small number of publications investigated the role of miR-7 in invasion in a range of 
cancer types, such as cervical cancer, gastric cancer, colorectal cancer and melanoma. 
Across this range of diseases miR-7 was very lowly expressed and overexpression 
inhibited migration, invasion and cell growth, identifying miR-7 as a tumour suppressor 
miRNA (Giles et al. 2016, Zeng et al. 2016, Hao et al. 2015, Xie et al. 2014). Similar results 
were also observed in NSCLC (Cao et al. 2016).Promisingly, the study investigating miR-
7 in melanoma observed that overexpression of miR-7 significantly reduced the cancer 
cells ability to form colonies in both 2D and 3D with the effect being as drastic as the 
effect found by this project. This appears to confirm that miR-7a plays an important role 
in the ability of cancer cells to form colonies. All of these studies show miR-7a 
functioning as a tumour suppressor miRNA in a range of diverse cancers. Considering 
this, it appears the role of miRNA as a tumour suppressor in pancreatic cancer observed 
through this work is confirmed by these studies. The significant role of miR-7a in colony 
formation and overall as a tumour suppressor in pancreatic cancer is a novel and 
significant finding. 
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9. Concluding Discussion 
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9.1. Concluding Discussion 
 
The aim of this project was to investigate mechanisms of metastasis in triple negative 
breast cancer and pancreatic cancer. Metastasis is the ability of a cell to spread to 
another location in the body which contributes to approximately 90% of cancers 
fatalities (Hu et al. 2016). Both TNBC and pancreatic cancer possess poor prognosis, 
limited therapeutic options and the risk of each becoming metastatic remains a major 
risk and concern. This body of work aimed to investigate metastasis through several 
metastatic phenotypes, specifically anoikis (anchorage independence), colony 
formation, proliferation and invasion. Each of these aspects of metastasis are critical in 
the metastatic cascade. These mechanisms of metastasis were investigated through 
three approaches, the first being microarray profiling to investigate anoikis resistance. 
The second approach analysed the role of the tumour microenvironment using an 
indirect co-culture model. The final approach determined the changes in metastatic 
phenotypes due to altered miRNA expression. Each approach identified unique 
influences on the metastatic capabilities of both TNBC and pancreatic cancer cells.  
 
Through microarray profiling 26 genes were identified as differentially expressed in 
anoikis resistant cell lines. Specifically, GRP78 was identified as a regulator of growth in 
TNBC through proliferation and colony formation, with GRP78 acting as an oncogene. 
GRP78 has long been known as a potential target in cancer treatment but its role as an 
oncogene in TNBC is a novel insight and further research can investigate its potential as 
a therapeutic target in TNBC. The development of an indirect co-culture model allowed 
insight into the complicated role of the tumour microenvironment in pancreatic cancer. 
This investigation led to the observation that the stroma can act to inhibit and restrain 
the progression of pancreatic cancer. The overall conclusion from this model of the 
tumour microenvironment was that the stroma is diverse and complex with a more 
advanced and all-inclusive model needed before distinct conclusions on the role of the 
stroma in pancreatic cancer can be determined. Altering miRNA expression led to the 
identification of a range of tumour suppressor miRNA including miR-7a, miR-204 and 
miR-378. Each induced different changes in metastatic phenotypes including a reduction 
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in proliferation and colony formation and an extreme increase in invasion. A highly novel 
finding was the validity of using sponge knockdown vectors as a valuable research tool 
in pancreatic cancer. miRNA are key regulators of gene expression and therefore can 
give a powerful insight into the mechanisms of metastasis in cancer cells. 
 
Through the three different approaches used, possible effective therapies were 
identified. GRP78 acting as an oncogene in TNBC may be a possible drug target with a 
wide range of inhibitors available such as arctigenin, verrucosidin and metformin (Sun 
et al. 2011, Thomas et al. 2013, Jagannathan et al. 2015). Investigations of GRP78 as a 
druggable target have not advanced to the clinical trial stage as of yet, but there is a 
possibility that GRP78 may provide a more compelling treatment option in TNBC. A 
valuable insight gained is that of the tumour microenvironment, in that targeting the 
pancreatic cancer stroma may not be the ideal therapeutic approach it once seemed. 
Targeting the stroma with the current level of understanding of the role of the tumour 
microenvironment is not a viable therapeutic plan, a much greater knowledge of the 
stroma is required before determining whether targeting the stroma is a beneficial 
strategy. The identification of miR-7a, miR-224 and miR-378 as tumour suppressors in 
pancreatic cancer could lead to the identification of drug targets with the targets of miR-
7a being involved in cell growth and the targets of miR-378 being involved in invasion. 
The emergence of CRISPR technology is also an exciting future aspect, the potential 
targets of miR-7a, miR-224 and miR-378 could be evaluated and eventually targeted in 
pancreatic cancer patients as a potential highly effective therapy. Concluding from this 
body of work, the individual processes of metastasis investigated in this thesis, anoikis, 
proliferation, colony formation and invasion can be greatly influenced by gene 
expression, the tumour microenvironment and miRNA expression. Using these three 
approaches a greater understanding of metastasis has been gained and led to a further 
understanding of the progression of both TNBC and pancreatic cancer, with this greater 
understanding comes a greater possibility of developing effective therapies. 
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10. Conclusions and Future Work 
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10.1. Conclusions 
 
1. Microarray analysis of anoikis resistance in triple negative breast cancer 
• Microarray analysis identified 26 genes as differentially expressed in two 
anoikis resistant TNBC cell lines in suspension compared to attached. The 
microarray data was validated as GRP78 protein was more abundant in 
both anoikis resistant cells lines compared to both anoikis sensitive cell 
lines 
• Transient transfection to reduce GRP78 expression did not affect the 
TNBC cells’ ability to resist anoikis. Therefore, GRP78 did not validate as 
a gene involved in anoikis resistance, the original hypothesis was not 
validated 
• Reduced GRP78 expression significantly inhibited proliferation and 
colony formation in both 2D and 3D. GRP78 has a role in the ability of 
TNBC cells to proliferate and colonise meaning it may be a viable target 
to inhibit triple negative breast cancer cells’ ability to proliferate and 
colonise in the process of metastasis. 
 
2. Investigation of the role of the tumour microenvironment in pancreatic cancer 
• Development of an accurate co-culture model requires optimisation of a 
wide array of parameters. It is extremely important to determine the 
optimum control in the development process. Inappropriate controls can 
lead to misleading information and determining a control as optimum or 
inappropriate can require a lot of vigilant research 
• The type of media used in in-direct co-culture models can be highly 
significant. If a mix of media types is present, this must be tightly 
controlled for and an effect due to this mix of media types should be 
investigated.  
• Publications need to be hugely more overt and exact in the description 
of controls. It is hoped that each study is using an appropriate control but 
there is a possibility that some results published may be due to use of 
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inappropriate controls. This is needed to be sure published data can be 
replicated and confirmed. If different controls are being used in an area 
of research it is extremely difficult to draw conclusions as a scientific 
community. 
• Patient tumour derived fibroblasts act to inhibit the metastatic 
phenotypes of pancreatic cancer cells. Indirect co-culture with Pt-102 
fibroblasts significantly reduced the ability of two pancreatic cancer cells 
to proliferate, form colonies and invade. The tumour microenvironment 
appears to function in a protective manner by inhibiting the metastasis 
of PDAC. Targeting the pancreatic cancer stroma may not be the ideal 
therapeutic approach it once seemed. 
• The role of the tumour microenvironment is complex, there is published 
evidence of the tumour microenvironment both inhibiting and 
progressing pancreatic cancer. It appears the tumour microenvironment 
can play both roles, the next step is to investigate what determines which 
role is being played. Activation of the stromal cell populations may be a 
factor. 
 
 
3. Investigation of the role of miRNA in metastatic phenotypes in pancreatic cancer 
• Alteration of miRNA expression, both transiently and stably inhibited 
metastatic phenotypes of pancreatic cancer 
• Transient alteration of miRNA expression identified three miRNA, miR-
204, miR-320a and miR-378, to be tumour suppressors in pancreatic 
cancer. Overexpression inhibited metastatic phenotypes of proliferation 
and colony formation while reduced expression increased these 
metastatic phenotypes. The role of miR-320a and miR-378 as a tumour 
suppressor in pancreatic cancer is a novel finding. 
• The role of miR-378 as a tumour suppressor was validated further 
through a stable sponge knockdown of miR-378 expression. Generation 
of a cell line which was induced to reduce miR-378 expression had 
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increased invasive capabilities. The use of both transient and stable 
miRNA alteration technologies led to the same conclusion, a role as a 
tumour suppressor although both showed an effect on different 
phenotypes.  
• A highly novel finding of this work is that miRNA expression can be 
altered successfully using sponge knockdown technology in pancreatic 
cancer in vitro. This technology can induce changes in metastatic 
phenotypes. 
• miR-7a was identified as a tumour suppressor miRNA in pancreatic 
cancer as stable overexpression induced a significant reduction in 
proliferation and a highly significant reduction in colony formation in 
PDAC. The role of miR-7 as a tumour suppressor has been published in 
other cancers but this is a novel finding in pancreatic cancer, as is its 
highly significant role in the ability of pancreatic cancer cells to form 
colonies. 
• miRNA transient and stable expression alteration can be successfully 
used to induce significant changes in the metastatic phenotype of 
pancreatic cancer cells. This work led to the identification of miR-204, 
miR-320a, miR-378 and miR-7a as tumour suppressor miRNA in 
pancreatic cancer. The fact that all the miRNA identified were tumour 
suppressors ties into the knowledge that universally miRNA expression is 
downregulated in cancer
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10.2. Future Work 
 
1. Microarray analysis of anoikis resistance in triple negative breast cancer 
• Investigate the specific phase of cell growth that GRP78 knockdown is 
arresting using flow cytometry, specifically the Guava Cell Cycle assays 
using the Guava easyCyte Flow Cytometer. This may determine a role of 
GRP78 in specific phases of the cell cycle of TNBC cells. 
• Analyse phosphorylation of a range of key cell cycle regulatory proteins 
such as AKT, JNK and ERK1/2 using Western blotting post GRP78 
knockdown. Determining changes of phosphorylation of cell cycle 
regulators may identify the key regulators which GRP78 knockdown has 
altered inducing the reduction in proliferation and colony formation. 
• Use stable overexpression of GRP78 to investigate phenotypic changes in 
two anoikis sensitive cell lines. May show a role of GRP78 in anoikis 
resistance. 
 
2. Investigation of the role of the tumour microenvironment in pancreatic cancer 
• Investigate the phenotypic effects of indirect co-culture of PDAC cell 
using the optimum control with multiple batches of pancreatic stellate 
cells and tumour derived fibroblasts from different patients. This could 
show that the phenotypic changes induced were not patient specific thus 
giving greater validity to the results observed. 
• Investigate the specific phase of cell growth that co-culture with the 
stromal cells is arresting using flow cytometry, specifically the Guava Cell 
Cycle assays using the Guava easyCyte Flow Cytometer. This may 
determine the specific phases of the cell cycle which the stromal cells 
inhibit in the pancreatic cancer cells. 
• Further analyse the reduction in invasion levels through determining 
changes in MMP and TIMPs levels post co-culture using zymography and 
qPCR. Determining changes of MMPs and TIMPS may identify the key 
 235 
 
regulators of invasion which co-culture has altered inducing the 
reduction in invasive capabilities of the pancreatic cancer cells. 
• Assess miRNA changes in the pancreatic cancer cells post co-culture. A 
profiling study may identify miRNA expression changes induced due to 
co-culture which then may lead to identification of the miRNA 
responsible for the phenotypic changes observed post co-culture. 
• Develop a direct co-culture model to investigate the tumour 
microenvironment. This would give a different insight to the tumour 
microenvironment as the cells would be in physical contact, cell to cell 
junctions would be formed.  This would require labelling the cell lines, for 
example with GFP. This is required as it is necessary to be able to 
distinguish between the two cell populations in the co-culture model. 
This would allow for a comparison between direct and in-direct co-
culture. 
• Develop a triple co-culture model to investigate the tumour 
microenvironment using PDAC cells, patient derived fibroblasts and 
pancreatic stellate cells. A triple co-culture model could take many form, 
indirect, direct or a mix of both. While the development may be complex 
it would yield a high level of insight into the tumour microenvironment, 
as it is closer to the clinical tumour microenvironment which is a mix of 
different cells interacting to induce phenotypes. 
• Explore the potential of investigating the effects of co-culture on 
metastasis in vivo. The two cell populations could be co-cultured before 
implantation in vivo or both cell types mixed together could be 
implanted, this would be a direct co-culture in vivo. This would allow 
investigation of the role of the tumour microenvironment in an in vivo 
setting. 
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3. Investigation of the role of miRNA in metastatic phenotypes in pancreatic cancer 
• Confirm miR-7a overexpression through analysis of RFP expression using 
qPCR. Assess the mRNA levels of validated targets of miR-7a, if the 
expression of these targets is reduced compared to the parental Panc-1 
cell line this would validate that overexpression of miR-7a was achieved. 
• Develop stably transfected cell lines for miR-7a and miR-378 across the 
panel of pancreatic cancer cell lines. Assess if similar phenotypic changes 
are observed across the panel due to altered miRNA expression. This may 
confirm the roles of these miRNA as tumour suppressors in pancreatic 
cancer, confirming it was not a cell line specific effect. 
• Investigate the panel of miRNA investigated transiently across a panel of 
pancreatic cancer cell lines. This may confirm the roles of miR-204, miR-
320a and miR-378 as tumour suppressors in pancreatic cancer, 
confirming it was not a cell line specific effect. Investigating miR-224 in a 
panel of pancreatic cancer cell lines may identify if this miRNA plays a 
tumour suppressor or oncogenic role in pancreatic cancer as no 
conclusion could be drawn from the effects observed in the Panc-1 cell 
line. 
• Investigate which protein-coding genes are being targeted by the miRNA 
vectors. This could be at a transcriptional and proteomic level and could 
lead to identification of gene targets involved in metastasis. miR-7a has 
been shown to target EGFR, overexpression of miR-7a may have induced 
downregulated expression of EGFR leading to the inhibition of metastatic 
phenotypes. This would also validate overexpression of miR-7a was 
achieved. Similarly, miR-320a has been shown to target Mcl-2. Expression 
of both these targets as well as others could be investigated. 
• Explore the potential of investigating the effects of miR-7a and miR-378 
stably transfected cells on metastasis in vivo. Several studies have 
implanted transfected cells in mice, this would allow for investigation of 
the role of miR-7a and miR-378 in metastatic phenotypes in an in vivo 
setting.     
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